var title_f1_1_1040="Stroke breathing patterns";
var content_f1_1_1040=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F74371&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F74371&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Respiratory patterns associated with neurological injury",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 340px; height: 346px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_1_1040=[""].join("\n");
var outline_f1_1_1040=null;
var title_f1_1_1041="Nevus depigmentosus - abdomen";
var content_f1_1_1041=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F59799&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F59799&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Nevus depigmentosus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFEAbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDItZRtUEjAAyCORV2OXZ93oOMDp9K5WCdsAMCSBkk961bW7ILKZMhsnpjacetea0j3E2dEu8pneqdyuecetTRpGqEsW2/pWJbXqx2yq8SfP8u7Ge/X61o212CrpIysoGQ2ccfSp5UVdl1MMSGKsc8bjio2so54s7g5JwB0AqJLmOVMNnaeQw5Aqa1aHcMsrkZPXr7VShcTnY4rxTYCOVwFCxqOvqa4KGIJqM2BgYzXo3jK+iZHEbA44Ax0rzmMmS7kdT14p01ytmVd8yRoJt7En1qwhLAENwO1V0XHQfj61biXAGcc9RTlMmESxC7EcHHuanUsThfz9agi+UZbqeOegqeHGT83FYts3SJEjcHIwSD0qdEZehx7daahwflzn0FTRjZxna3Tj1qLl2FQFgQ+cDoamSPKgHAOOc9aYq/N1wCanyAR94nsT0pXGKgA6LnAz061MuODg8HpwM0sXzMcY29WyOtOC5GQe/HqfapbGL92RdyjngYoyxJAOMDr2NSIpJzkljz9Kk2ggMVAHUc9aLiFg+Q5Aycd6bhi33cZPGfWpkOQT0bHcjimkDc3yj6ZwadwJF7ADaOrCndHUKo5OeRyKQEcAg7QB7kGnqgC4CgHHpyKVwHxr14ADdiKlUDt6Y+ao0UoOM5xk561Oe/U89ugHc0AIoBi2qoIzk7RkmlUZAwuSh6EGlGA+89+Mlf/AK/FPYqF5Iz3fHJz7VQiF49rcKCRxjBAApsrhcjHLdSDn8aseWCP9ZlmGACCcj8uajeMD5myDn7uz+tO4ivIDtLHjHSqsmBx8pPTjoKuShwhwOD2PNQOMqM7jgdSKYiBThCScqeOgPNNChzu2gg9No6Uro6sCTx0yBStleoKuSehyaEDK3lrk5GMZIHtUUi8FgQRwBjqKsNjPLDGc4IqGVRhgQcA5JHamBXkCBRvUMRjtTSoDMFxk9AQD+tSN0Ak6e1NCAM3XOOBincLDQOzCMH0IFRiNcsCqc85wKe2chgASfXkVFhsrwpB7UhjSgJwUjHPdaheNV3fIOeMYBqftkDGD2qIlg3mYA54Hv70AV2VDkhAMcdKhdFOdyrnoBirT5yCBk57VFIPlPqaAKkiJnCqvT+6OaYyKB/q1wR6CrB6dck+3So2Xng5HtRcRCVjwBsX/vkVXuYEccImR32irTjrxx2qJz264p3sS1cZZ3SxuBIqAjj7o5rcttQt3j2vHED67BXPuoYdBVcxYHysQfrTauJTcdzqftFsrfciz1+6KHvLbYQIos9fuD/CuQlVx/y0b86qYlkuo4hK4UnJwaFSv1CVfyOruL225HlQH6xj/CoRLby8JZQsfXyR/hRZWSjnGTV6L5RhQNwrNuxqot7lGO82oMMGJGKt22oBBhiPYd6tnw7a+UX2lOOMNXKauv2KQiF2J7A819Dismq0IubaaPDw+bU6r5bM6sXalkO7Hc56U97wZJVkG4bSK4ePULkryBipf7RlAwVP4V5Doz7HpRxMDt4dbEIKb+OnWo5tZV1KqOD1APWuHku5ZegIoVZiFzIeT2o9m1uHt4vY2NZv0lG2I7uwGaz7aHYo9c5NLDAqMG6t6mrC4A5wBSemiEm5O7JET071aVdq5GB+NQR/McAcdDVjjcB096yZtEk+9jHHarEa7DgZPsKrpk4HHrVuLOzIyM+hqWWiZCQBgDpzUqPhD8q/nyajQFgBtH0qxFGChJTIHpUFD0xgsMZPbrU8ce1eeAe+M4pqDj5euelSRjJC4Prx61Nyh8CkKeCR7inqpDZXr39qeikHgkjPHHU0mwI5wc59OKQxxLDKtnOelO3N/wAs8ce9LtOflDbcYGaeqdODgdB1NAhQpI5Cggdh1pUUh/uN681MoHAwT260iISSFYEemTRcB4XIAXGWx1xxUowQykqQcHAXP61H5a4O/oOgzUgiO4qVJA5wPX1oAYqsTgAA5znpn6CpFQ4AKkqe3Xn1pVPPzH5mGD8vX/PrQDgjZjI464xRcGOCySttUEMT0yOakbd5nXAHI3HjimjHJbGWOfvdvQ04q6t83Gexz+ZPeqTJsNBKgbmUA5AwTTC5PzM+SOMc4NOy2zJdm4OFApG81eWfafvD5Bj8aYBLhgW2jAPvVN+CQSvJ+mPrVwZYqRGBzgFev5VBtUyhCV7llbj+dMRWcbNj5wemc5z+BpkilfutwckEr+lWpY2U8kIoGOPmGDVaRSCVDrvzjpRcCuUC5+ZkxyQeefpTJFzztDE8DHB/GpH3AE5B9s9KY54ynJPb0oQyHrhuFIP1x7fSmyBc5UjOOT2NPIYK/Ged3HaoQxLZf5gR24oCxEwxzzn36CmSHf2+YHmrEwDYOM47Z6VWkJJBAyPXpQBG4yBzgD3pJSDw4yfQ8U187wd2T/d7496Y+4fNnPtimA1hySM5prDIABPSlDAA4zn+VMbC8AkEdfegRHg55x7VEcZ681KWzuwRj+VRNy3QH6UxDMgZIPIqKRcjk9KkOBnI/KoJDngUCZGSMGoJGHcdBUzEYqCT2qkZsgkOQSelV4CBfxk8AjAqWUcGqk+cBh1BzW0UYydtTs7clYFYEYPan7sHnI71i6ZeiSIDOOMc1oeaQMZyDWbpnTGpdXOj1K5WG02ADOK881ZvMusda6PXborFhvvGuSyXctkk5r7TNq+ipo+Oy+nrzj0Uk8DilI5xUkY4pShJ44+tfPzVj14MaExjip1XoKRR8oqZEHBwc1ySOuBJEBnnpT2UE+ncCiNCoORgin7PXPJ5xWLOiI+AHBBwM8E1OqYP40zbg9OfWpjlCAcYPQVm0aokC4PpnnjvViFcqBngelQAgMATjn9KmjG5xgjrkZHWoaLTLUQIBJwRnGfWrCgbuGHAzUMQYHOAST0xxVlVLqO3PGBWbNESrEdo5BPSpgSrdW4OPSmRjnAz0zj0qztJ44Uepxk1LGJGyk/OpY/X+VSqAw5ByT3pmwnoWBPvxUijnbjJ6Y9aQxwDKh3HOO+KkB3MCWx+oFRrGzMxBbI/DNTxr9wbSpHPHP40gFkXCgqSVPXjikXkDaHz1wR1qTAL9WJYenelTLNkEHHbNAAyHjA6kAjHT8acgJJI5IPYHApyjHAXJ/u84pQSwDKAOcnjj+dMBcqgDh8P67SPyp6EA5wrY46Hp601y2TtUcEc7fz+lPVo+Bv6E4H+NCAedhJUktg9160qOhkwWOc8dgadIkgARVyFPXaP1NJljMRsOxDjfgYH4d6pCZC4C7ickZyo3Dr701s8h0O3GflIO0GrJQSNvH3cfeIGB+lQywYw5RCuOfl6+4oERMrgh8SIpP3gDx78UkpwCFkZgeCOpP5inozEjhlbqTyVx70zIJbY6jB4ySufzp3HYj25jydhOOcjH06VCxO5jtPy9fmq0NxPowHIOD+VMdHYjOBwcv2/n0oTCxS24YMckHoTzUEqKnUq4Hc81ZyxVQ2ePTsfpVeQsRg7Wx3zRcLFd143KffKnvUII2ktwPUD+lTumAwfAI5BWonXDg85P+c0BYryfeOASvqO1RyIcDOAOvNTsGBPYN2Peo3GVBAHPHPTP9KoRXwR8o7c4xmoJVOc4OO3tVohCBgbmIx+FRzH5wAMHpTQitxgZb9KYcAA8cetSyZDDgccYqJzlT796YiFlBB4znnIqEEqeCQalJwnHIqFzzkjn1pksaTk5zURGFJI5pxPp2NMZ+cEUybkZHNRPyD+dTNhvwqNu30pksqSjINU5cgYNXJQRkVUlHfHFaxMJlbc8Z3RsQe9WYdW2DEuQfWqsx2r71UfGCa3UU9znc3HY6rWrksxX1rKjGCTmn3UrT3JJ+lKowcZGK9bFVPa1XI82hDkgkWEAAHNPwGqMFs9OPanqpzyTXDUZ2QRIF5wBVlQdoOBxUcaAAsSamjxwCRu7VzSOqGg5Txj05qQAdDwD0GaTcFXoFDcE1KhHm54GOvFZSRtEekf70r3AAFTPFiTbuBVeBj1pIuvqQM1ct0VPLJUbR83XrUNGiZC2UkwAo2DHHNWY1wqqDyOTTEzJLuAwD1AqdAzE/KcA9M4xWbNETodx7AAdMZqWIHJGMH+lQpwFwCCw6etSRAZDZCnpismi0WeRkDPJyRT42GMPnGc4HeogeTzls9cdKsbCCuQnJzxz+dQ0WiUMAoYbSO3NOQjaeCcdBimoq/ebJGOM8U/ZtPfJGARUlCLhlUMWIPUYwasALgAAYH95utMIK4JKHnkDIxT1QbM7gM9ieh/KgQbtyjoW9hTgWYH5QOpwq4xTCOAcsp3evBqWPHy4I25yTnNMCbA2glSp7EYFOEORjbjJ6letNiYZ+bGD+B471MmCCx4GeMsCfypXGKFXbhQSOM9gT706JcuDvGOgyKYjhiBjlR3AqQMN/zAb/cjihMdhPKAO0qEGME4I/8A10qg/MSBt+9z/n9KlUOxTaVDY4UDmlVSyBmVWIbG7pigViFIl8tuEfnvn9CKNgBbygcYIJJOB7VK2Dt9+SMD+VTJbO8ZdTwScArycUNjSM+JeQh3DPoetKxLOxY7iPlG4gbff/61WvLcRsX3ZdQAoHenJbPJG4J5A9DS5w5TNOUX7uWH8Q/nTJgASEyOwwMVoyWZhAyWC9epAx71RmJG4An5hgEdfwpqSBxKhYt8nmAn361WmQcAKVA/nV2bcpP+1yeKpuuCMruX06Z/H19qYrFcoEABJ6kkVC6MMLkNjnIHB/GrD7iflwV68HmoicnC4J64AqrisVGyykYyOuCOaZu2A5Dc8jPpViQnJbHHU46Ae9QPnkE/hVLUTIDyM8AA9T1qBmyflz14GKmcsz42gjk4AqA4XjcCB0+tUiGMnOB0Oe/FQMfl6VPISvABGRnI71XYhhwOAaYiFwSuByOpqvI2QT04qw3fbk+pqvJg/wCFUiGRE9PT+dN7dacOnv6GkH4VRI1uBjvUcnbFSEA5AqNsYPGKBFaVuDxVWQ8Yq1JzVSRa1ijGbKk3vVR6tyjnvVZlzXTBXOOozTj/ADzU6rnkjiq0DY61OME85rqk9DmitSdSeM8YqePB9/aqm8ZwKsRZJGOAeK55M6oIthsrkrxSjBxtHNMYgcA7iOmOlKpOc7c/SsWzeJYVc4AGQBxmpojjOMAEYJqCInnI5qwMEisWzaJOv3QACAamXAGWOV6KMdqrcFs9CB9anU5UHPXgc1DZokTxMBgqw4OcD+lWYZN5II3Enpj9aroqtjI685zVmHaABtz7j09aybNUh6A42sTxkeuKsRIR1U5Pc9RUCKBkbjnrz3q8sfyc9doyAeT71m2WkOjXZ/FuJ7t0qUA4OwADPJPU0hVF6HaB3NWUXJKY/DFZtlpCQptxyQO4NTxgAcYIYcmmhR7c8de9O3F/lO0+n/16koZIMkBiuAcAeoqZI8JwARzwTgGkJT73QDpx/SnMqsuf4iBu47elMRHEW2lkGe2KmUbiA5CkH6U0HHL4b2Bx9KmhyCAFGMZB559hTAIwc5+cDPbv9alVNuQzYB6kL8wNEIG453HJ6L601sKBkkDoeAM0ikTKf7x3d/u5wenNTQWkkjKAJMLluVxk+9QxsquoJDLt6gY/CrttfKoVX6sclv6UnfoBahsdwAnDGUdyccflVmK0hjAyF5zwcZ+tJ9siG3ewGTkMM5HsKUPFLKDGRyx+UVm2yrIU2sYlztLNjsOcVMFwDuxnoQBgCpwAoJyBL2AHWkCh8cgEc8jr7VDY0iFo0bGPvY69e9M8sF8kjaR94etWCAo68DgHpkUzYRnA2+wHH41NyrFJlVl25Cr/ALP+FU1tooI/mIIHzE9K15lBThfl9uMfQ1k6kfLtcn+L8Kab2FYwdRKGZlhIAIxx39qyLjcGLEkjPIA4q/cDdu35AI64zVOWHEnzDkcqM9q6o6GbGYJPQAk49jTWQfOSBjqeakwqZHIHrjioZCBGGCA5456imIgKdTk7z1zzVd1wuVGffpU7g7OpJ9uAKgkOSdx+VuDVollZiVLEZwPzpjE4POc89OtOkyc7iR2/CmFWYZznPp2q0QyGXr15HFMkJIwwwo4OP5VLLyVBJwe3Woz6AcCqJZXZfzPUVXcHOO44xircnUrjkH8qrSDK8fnTIZWfAP0po6/pQckHnjtTTkdaoi4p6+lROeD3p7dTiomJHHGKaRLZC5yDnrVaQ5HvU8jfKcVXc8c1tFGM2VpP1quVqxL70wCuukrs4qrJYRlRmpQfmIqOI/KKeBk5605MmKHDlh65q2jZAC1XiXJ561ZXGAMYrCR0RJ0OD1xipYwASScioEzgYGas8dOgFZs2iTqBux7VNCV29ORVcDC524yPTtU8A5yM4xgcVmzWJYiX7xA79TUqKrNgHgjIB7U2PbjDYI6jH9amjA45Gexx0rJs2iSQp+93ZOcYGR6VciTcp68jJzUCqS3KkEdv71W4skFnyG7gelZSNUSRrhwzHtn5atR4BODyDyD3FVwdzALlQecjg1ZhGAM/MOzHjms2aImiUEAEDBJ4PUVYjRgAcjA4PFRxr83GcAfTj+tToByB0x2rNspD1C+WM45PPTr9KWTG84wMdCetOUEorLtI6k9MGlxgNnk9Tz1/ClcdhgX51YAYxnC+vrUoRmGNxGPbt/8ArpFzkgNnpx/ntRJhjk4+pOAfWncVhufv988dM1KjZBIGDjk7aiOSMjHBGcHvT1xtVGJbHck8/WqAlQ4KFF7j5j3/AFoBZ2wVywOOBx+dKiqSCASzdSe2O1PZQAXXg5+YKcZoGEeSm1TjIPOTgUKoSM7iSM4yOD/hTpGf92odiR2I6f8A1qekLM22Mgrx/D15z+FF7BYWAGR0SMjkZyR2rYs7JQWYMuQfuoei0y2t2RWYOmwjp61ctkEKSMFZWzkHPAHpWMpX2LRaRY/LBCAEHGMcD3qfazxEBlbawzj0Hp7VHA3yljjkYwDyT6/SmlmLM+fnH8JzWLZSQwqwVyjZI5yelBG0jDDPO7kipJWYNuYEEg9OQKrouAcMMHnaOKBjZAWxuwG9Ae/WsbWpAiPh8OOxHBq1qPmODsBRSOP9mucuWeSXIcZxgbuP19auCvqJlVlyxCsN3oT+WKhkOC+0jGD371ZJGAflweRkVVlTgbWb2GMjNbpmbK7bexK57E5FRL82Q+MHgD3qd8qy7QCT1I9KrunQN1wfyqhMY3CYDAHOCOtVZ1ODuII/iINTyJvQHnk9aidSu4MByflPb8apEsqyK2TzkYAGeoFQt8oJAJH0qeQvvO5Q3r71A4IPXHNaIhkfDHJGB1zURY7sAYxyDn9asEYXOPaqzY34bIQdxVozZHNh+M84/E1UfO0jj6VbkHAx36VBMBuJ7nsBxTJZVbJJyB1xTWPJBxUj/dOO/eoWORVIhjW4znpUMnXOamJzUZAI57VaRm2V5OTmq8p4qeXOcVXkPr1rWKMZsrydOaEwWFK/WiMZcY9a9DCq80cNd2TEQkdKnXpnHJNV14PFWFPA9awkXEmycDgVKhJODUKHP0qZM9OlZM2iWYRyOP1qY5yR3qGPIPUcVYiwclhyelZs2iS5JAHVRVmIEgIT8o6HNVgT8uMc1YRh8gHBHNZSZtFFmPpjBz6A1NGp3+pPfPNRxud3GDxyD6elWVAPQY9cdvrWMmbxRJGGxgDB96uQZYBuhGD/APqqGLsVHJ6E1YWPHLYAHXBrNs0SJo0wTuwuOSBVhdu7kYz3PYYquC3ysytkEcCrEfBAPAHOc9fSs2WixG5xkqCu7HXFSqxYHaMr+h9qiyWbKhT2PfH4VIA+4jbySOh/lU2KJgx4OVyOpHPFTmRgMcDjJ56VXUN8wxk9QPSrCRZyzksAOn+etTYZLEisQQp3MMY7VFIpbJI57j0qeIqA7BSDjJpCC207zjqM8fj7UICJYsYIQ/KOTn1qVYwp2s/OM4A/SgoGP3M4/PFPX5wQAFPTJ6HHpVBYcFwrbm+ZcHOP0x60hXevy5HcAn+dSqodwdp2qeh5p+1AcNyCRkY6d8UDGRQ75lHAAGAMdP8ACtuzs/JUnO5MYznGf/re9ZwYhQPL2serjir1rHM8mV3BMHBHVqzkUi0llux8xPttNSR20kTspfCkd1PX3p0aAgAyEEcEkn86mV8SgkswAxgjg/WsmyhTG6MQFXaBkHGPm7//AK6jJLNnGGzw2SMe5qfcfmKMrHpgj7tBQ7+AB8owCKm4yHDE7cIR1JXqf8ajaPIx8oYdTjvViYHPGQuc9aiZyMFgSM457UhmdeQu67GYAew5+lcrdo4kZco2044U8/T3rrb2cQI2AC2ejcGuXmJ6yjGW545Ge9bU7kMoSFt27Ax2Az+dRyq6qOcDAwQ1WJF2YPYk4PdqjkZyhAGeeoHUVqQU5VcDAA3dyRxge9QSAjhsc8DHarkjZzszwRx0/Ko2HVVbdjgbqYigQ6sSTjHbsfYio5WJBAAz3OOPwq04dcjKnHPSoJcgFcAsPSrRLK0ueCQMduelQSgBDnG7noatyjCkDkHkHFU3G09M8YOOKtEMYfugFRjvz1qr5Z3bSR/jVliFXOST0quw56jPbHarRDISp2gMRnOPpUMoGRzk9Me9Tk5B4JGOc9qiYA9OP8apEMruB1FQvzg+vtU0oPPB6VXbnPqapGbI+vFMPCjmpG598UxyMVqjJlZ+uaqy/eqzJjmqsvI461rExmQufeptOTzblF9TUDcnmtPw7Hvvk47162XQ5qqR5mMlaDZlLnv0qZM+p+lRJ16VOg4ya85nVEljPNTRnn0PSqyDB61ZXpms2bRLMZz9atRn5TtOOKqRYyMHHrVqPjBzgEcnFZs3iTryR0JxU4B2jJBxUS7NuePcCp4jux69qxkzaJLAWVMgfeI5xVuNXO0jJPQioEJA46DqBVuP5W3BuG5AHTNZM3RYjUlsqSce1WFJOGG3OKhiGBuOPYHvVjaOMKSc5A7AVkzRFiBWZhzuB5zirEAIAHccdOfrUMQwe5PoevpVjpgsTxxx29qhlk0ZHy7gd2Pm/lUx29BkZP4fnUSA8Dpnge/tUoTbjIHuM9akokRQAMYHHXtVhSSPmyGI4HTJ9aihyMhn77TkcYq3uVR9zaOw6/5+lIEQc4ZuQcdPxp2FBXk7vqPxFSEDbktknGT0x7im/LuXzM5zwxGOKaAcWAGeh6HufrS5UMqhRk9Ae3+FKnGWx8gwMnvTyEic44HIzwaEAsQYDduyQMFicVKMEY24UHAAGev8qAmAFOVCjvQgcMwCDaB6fzp2AtWTwpNtdAQWwSzcA+wrXt50UDax44IUDkZ9K5/y2ZQV7DJPXHtVm0jadlyu0L1XkZFTKPcpM1Jb+OJ2CqMZ/DFVJtRkdgIh1HQ4IXPbNTx2MHmEbwcgE98H8e1Sw2UOS2B97IXqT7Vl7qKIbW7kZ9sqFQT24496uvdggkHD5IyT1HepTlI1QhfmXJBGMelc5qxy+CAGAwDu4B96lRux3NOa6UFhkrgHp61mSaizKw/eKuODVNmbbnJDADvyahDPtHTk/Q4q1BILkk88kkJ3HzACcEHBqowZghCsxIKtxnbzxU7fcwSevJx1/CoypIbnDAZyO3096pabCZX8tMbVOd3Hr+VQSBicEEqOAd2O1WihO4qxB7knk+/1qnKG5KjORjjqfeqiyWiGSPaQ7MWb8s1E+7bjAAA69ck1O+Pvq2SnOAOBTQCW3IDxk9eeev4VaJZTffn5c8D8z3FQ7cHcnQnBz3P+NW1UBSH+YDB645z1/wAahcAk4Gcg8AcYpollWbBXC5BBzVWRAhz1wemMirbKDuC8k+nXNV5Bu5JYHPBA7VomQytJ8q5X06/Wqjjjb71ekPDLkHOAcjmq8yhZGUpgjjA6VaIZWYDYc55HI7GoG4Uj+HPWrEgx0wOcVFMAo5x16UyWVmB79Mc+9VjjPt1HvVg9ODkd6jbrxjHbPYVaM2QOADx19qgk9KsMCTjjj8Krv6CtImTK0h6jrVWUEHmrbjOfeqsmT1reBzzZXbium8FQB7sOw4FcxJ7V3XgaEYyRX0GTwvUv2PFzGVoWOGj61OvHWoVqZV4wa8NnpRJVGO2AalTA45qJQAKepyf6VmzaJaQ4x7VaTGf16VTjIarceSB39qzZtAuRksSOw7+tWEGGBAAz3zVeMAHAHFW4m+bcME+prFnREmGc7u351ai4w2QKqqoOcsQSeT/hV4AjJGVZeCT0FZSN4kkWWPQjHNW41GDyAV657VBDjKrnJPXHWrESbyckAH5cms2Wi1GFB2uDnHGDUy8ZIPXrUUI5xnB9MVPGmc7RlQOWNZstEqFvM3oQSTwCOn41LGG3khgcDrjoKakQI+VSM9VJ6VOqg4JBGB6ZIqblIXIC4U55OPepl5cHac55J5pildwOQVOMdyalDlVwApBPApDJAQVA4GPTjNGF3cYxjof6UoGFDNnPQCnLhV79MZ60IBYyu4IWGVwVPt3qSMROSNpAbrxyPwqNcxnAJJAxgc9amQEhATuIJODxj2z3qhDoUGM7CT0/+uKcsSkIFZzzg9aesfGCcjJ4HPNSRAhFAClcn5SO/r70XsBCP3YCgFtxOAT0/wAK0rK5jQ4cEcdzgA+9VSApYJgE8Md2fwyaACQwHyq397qfQD3otcC/NfRozQhcgHJ9uPUVXW/ZJ8yEovBwOQR/jVR0B53JkAHaG5/Dtmoy6qeWBGSPkHJ9qhpXLRcnvZpNyoRl/l56/rWfNGwLAoGfruOc4qdZQ+ApHIzxiopDuIXLgnOGA/T6UrWGQFUJdRhhgkf4VA7hTkgjOOvNSlVIwo3A9QPSo2B3YyQehAPBAp3Cwwk8knknpjgU11DKCdoI+Y+xp79AQfmz2HIH+FREDjgHB4BxgmloA52VgGJBHJ57/wCFVmbG1Oc5+U+lOYjOSXdTzjo2fT2pkrd8ZK9Mjg+1CBkMoG3KqA2ex6/561HMcK/l5IGCC3pUzAngHJJwABjdVYtkng9eB7+laIhkbgMpCYA9Tjr9ah++M5xz0JqRtvCPgDGc44IqCQDI65x1aqJIwF5Yblbtj+tV5lBbcCQPc1ZZsnBXOF7d6ru5CEFs4PAP+fSqRDIZF3AYBbAwcHkVSlGSSMsScEj+VXJshFIwS3Uj+VVZPvfN8pDcc1aIZUk3LjJIU5P5VC+QMEYz19qssewGSx3YFVZxkngLk1aIZA5G8jGATzUUnQEjv+lSspBJ7ZwSaY42kkdOwqkZsjfAX5uTVV8DNTyH5ce3SqzDINaxMpEEnPIqrNznvVqXA5FVJBya6IHNUIMbnUe9ei+FtsFnuPHGa89gG65QV2TXQttMCqfnYdK+pyhKNOUzwMwfNJROJjJB6ZqdXGORio+i+9Pjxgk9q+ZZ7ESXIPtUkYbnj6UwHIxUyAEHntWbNUTQg45ODVmLOScjAqCMcVZhB68YNZs6IlqItjFWVOCARxjPNVohlAT3q7AeedpA9DmsJHREnQbTlV3DIGT1/AVbiBIOVww4FRL945GAAADVwN2B6ngn0/xrNmqHZXAz16HnpipkyFAbJPA69e9MUkMr49/rVhOfmzyOeB149fX2rORoixEpGBgk9AOuBVuNeOCAF6H1qBFzjK5AHP0qdGxnGcnAGBxWbNETI3G3qWJznvUiFSdu7B29zgYqJCSykAnIPy4xx14pyBSmG5B7Hsakos4DHY4IU+nr7VNsIYIcYJ69AfrUcXGFHzbRg54qU73BLfwjGBg/hSuFiZQTHls7+QBQB83ygYyOD2oPyqC2RxnJOc1JHtVcpnpzmlcdhkaHJLnoc8cDPpVgZXuCW5xnrUQIB+X5eO5I5qUbQC2dp5BVRzTuBKEDEA7iAdw44qUYCtncWHfPGKRJFWNclXYYzyenvUiAbgAmYzz15zVCEjYfOvA3LuIxnPv9KbPGkRG5w5YZODnP5UmCxk527RkY9O9LKqBFDR5bP3VOfxY/0oBEO0bd21R2XPp/hS4CtuC9/lGRkH/Gn5jwuArMTkbc4xjn9aj8sMjZBZvvEnis9ixjOsUhkQ4LZVfrULPHkBjhyeck469/Sp96be2CA2w8Yz+oqCQZyrLzk5GMn04pgI8ihQeRt6HFRM/zqSCMDAAHU+/vUrLsG37yjhRnGT9KZKVLl85Oc4H86BETDPmAsc4BPHTmoCoLHBOWJDc8H2qcMA2A2cHofSq5O7JGDnsOMn0oGNPytuVuORjOSKhOQRuAJ649akDfKSvJGDg+tMk3AtkYJ5INAhjLwSRxkYFRSZVmyMrxwex7092GFU59ST0qGVz06t1AHce9MRA6EY9jyAagmJ2YGSTwFxzUzFk4w2fT0FMYq27DZIHOapEsg24wML6cdSKqzMSxDLuweAe/4Vbd8uAc9OO3Wq8y4OV2nIPP+NaIzZTeNsZB4J55qtN1wR8uMVcYhVYhvmU5AHJIqs7A5ABxt71oiGVzk+2O/wDWq7sCw77h3qxITtwFx6ZqC4C5Xv8ApVIzkyowKt7Zz9aa4+bJ5XqcdqlOAcEY781CW3PlRirRmyF8n244NV5Djr+lWHPBx9309KrSfdwK0iZSK8vPJqpKe/WrMnX0qnMecV000ctRhbNicMe1a9sWuphnO2sJclwBXV+G7YySIK+nyy8ocvQ8LGtKVzmkBI5NOUbSQBmo0PPNTDoQOa+aZ7CHoe9ToBg8c1XX5QBU8fuazZqiyg4GD+dW4+3eqqr0+lW4u2Dis5HRAsocKcg4P6Vcg+Y9Bgc5AxxVVeAAduOnWrMbfKDjA6GsWdES2clc44zjb6e9WEJAwAAR61XQnJPDDpg96sxsUbcV6Ad/88VlI1RPFguAA249QOhqdGZeg3ZOMeh9ajh+SQAtjPUEcGrG0Bhz6dOnvmsmaont5Qr45HHJPUfSrSZZwrcBc54z0/rVdE3AiQLtA7HrU8cW5lZSV6cCoZaLcceRhT8xwwA6VMu5WbdgBR90elV4oyELR8jHDE9T6f8A16ljXg8HgcEcZFSUWI2Ma/dUZ52jkY/xqZCMocA4PO3vUMUXzjb8qZHBP+eanwwxzgjt3H4UmNErKGYHBGcgj+tCY+Y4IYjGDTZGkZsZHB/zzTEBDAnOScY9PcUkBPyNoY546dSPbNShQ2NxBOMk/wCFMCEDALbj79SPWiOILMrkcfwjsT9e9NATI8aSDcfmJwxIBP1qVHQIRklQTyOCT79/wqO2V1QDyxnf839MVIGUcgAM2QSRVXuKw18cKJC23rn+VPaQEFMhFyGBQdvTHrUmAIyIygV+RgdKjVlZkSORdwGTu424680bCRWlfZKdypErHcQo9fWhJVAzvJUDHPc1KgR412AMRkDcRge/51E4VlZyOE9sj8ah6loGdZFYHlu5C8g+lRsWIGMqxP1xTnwygnpjAJGKj8sOuIwQw9Dg0DF25wd+fl+83YZqN8F+OR1PT9DQ6DBBY+WeBn196gMbttyWVTk4BwB6VXQkJF3OwOPvYD9BTGGV3H7wypXGSBUhLZyM5C9OnNRS5WQl2Xa3QYzUjGPk7VxtZBnjjrVeQFmBIIPQbRjI7mrMgby8RtnGPxqJwWjOCAVPX+lFxFKTIXD5YFjg5/SmMQFOMnnHTkfl/KnuRvxuHHUjkf8A66iUtkbTz0+hqkJkTnK5O7Pqf4vrUbZZclgAfXpUgYnIQFSAQTjnNRrhwDhiD1561aRDZFIv3twJC4BBHT6VFIwO5SPbgfpU5K/MAS3tVeTZkZBC+tUiWVZUPHBBXv6VXkcEls9TkgVZnBYNlh83Bxz+VVl4aUFfmIAUVojNlaTkHAwecH2qBwGn+ToRx/WpZFIOevOCPWorjBPJJ469MVaM2VsgAgemM018cYBB9KkKjjPUcHFMGCCODiqIK02Xc8DPoO9VpgBwKtNjGCeo4qnJ1xWkTKZXfpVOQenerb55Gaqyn0rqpnJUGW4zLXbeFQeGHSuJhOHPvXe+FYybcY719VlXwHgY/wCI4FRzwMVPH044qBWxxU0ZzXyrPbRIR7VIn3sH9aYnX61NGOee/FQzWJYiI7np0q1Fgdec/liqSr8w4981ah6Hvis2jeDLyKpI3HpxircKEbc4IHUZ61Vg24+YDPXNXIc7gcEnGAfSsZHREsRfNg4GAcdMVcjKg5YcHIOO9V4VC7TjcOgB9fWrUOSwXnPQ4/iNZM2QRYB64PbjtWjAVkxhgM9CT1qoAMEuDs9O2auRbGUqVJzgkYrJmqZYHAA4HTI6kn/CpoV+dQQABknHcelRRgFR8wAPH0A61MuCEAfgjaCRnJqGWi3HhVIf6gA4NTxyo7YkOCfl6dPwqvExy3KnjBp6HDc5Of4sen60rDuW1HRWOVJHUc05TwpyDg8npUSnkfNtGAfx9qd/dyRnP3QOntSY0TSOdxDDJJ5pY+GwScjqAOlR54HGR1wTnFSMFXczsc5+YVNhj2lzwMYBwMcc/WlU5+8chTyM9OaryEFFBKlvY8de1BIDAoQxYblHUE/WmgL6yMzBhu+bIIPT8P8AGmzJwrLuAQZbdjqfXFIr4L4O7A4z3PcUwyFEfCFW9xx+dMRYjdNuWTzEJywORmmsysqqGzzwMY4pqeUwIIBbYMHr+vrSNkkCTnHo36/WhjQq7gcs74YYGO/tSqTuzu564Kg4pqqqHlAoPfrj3qRyVICgZBI35zUsYzoMbmIHU7c5/Ggrnl15z7dKVflGWYhRgNuP9KVwQ/K8E8Kcf59KBsqsgZQqqSF+bg4I9/pTAoOCu085JHSpCTlsKMnhv8c0ShQg24YLwMcZzQxEeAuD5nB5IIyc+lRMFON3Uk8U9lRRlAo+bAPbPpSOI/lPBbOG7kc0kMhJUg4OeMAiqshTPytk9+OgqeXaWyoLDJ6VAXXdjhccZxnmgRXmTqVT933zwarAfNtLEgnjsM1Zkcc7gccjIGcVTx0Byy9RjtVkivzHw3zE4J9ar7dy8kKSR+GPWpHDHBAbpnk0xmOMbcEjk4qkSyOTjBYAqDtxjqKryEYG4cdSB2qxgsDgAjGBuPeq82d2cncMA4x1rVGTZBLjgDOcYGDVdycgM4bHU4qaXHVs5Bycev0qJwGdtoOBywB61okZtlQKVX/a7j1zUcidc5xjofWpiSxUe2MH19ail+YjJIyOnSqJZWcFWC8ZHb1+tRshVvfrz3qVlBxnoTgH1pJMEEkgE8U0QylOevHHaqj8n6d6uy8mqb5JrWJjMrSnvjmqUo561dlGTVOYYb2rogclQiT/AFg+td5obslkgTrXCwrmZAPWvQtIhPlRLjAxX1WUp8jPBx7XMeeLgfWpFyMEdajQjNS8DjtXyzPbRMmOMnFTocnnmoB93jrViM4HcVDNYkyLuHpg4NWolwcHjHaq8fGOR9KtxLyM/dHP4VmzeJZgBxn+8eD6VchILEY+XoQKpxqCeARntVuNQTuAOB6fyrKWp0RLcJOOfXaT2q0g2MQpO7jA9PaoIfLVyTk59O4/pVoHLK7cHGTj/D1rJmsSYBQrc8k9MVbicFVAG4L/ABDrioIgpBfbyDyKmjDbgEUbRnOe4rJmqLS4IYDgDjA71JsBXKEgf3T0FQLlNu8AKeQR2q1F8wBz8u3qDyo7VmWiSKIFBu+9jr6VPEvyLgcj5Qe1JbqUQnpjgg9SakVOSSDtP3uelK5RJFhSoABD4BPTFPEnAA3cE+/NRqF+YZ7557exqUgjaqfdBzz60hikfLhfvEZxnFNXG4NL91ehxwaUbmXCncM5Hp9aD91sEkgcjrzUlA0m35gRgdjkY+lSOxEe0AZ4AJPBGaTa5U5X6BTyKMsyjKgZ5zxyKaESZOSeQpBwDg5/KnozcbtpVwBgj+X+NRI0bHocH7wAHGP61JDMMYKMpGRtzj8qtK5LZMpxwkeNwwwHQGpFC+WIyTIfbPFM42hiuVA4Df4inBYTCdu0beDwePpSaGJt2SHEbbhnOcnJpBuZT5hQr6MeTxSliCAI3Ibod2OfX/61K/mbChztHXHGc+tTYpMbFGWfEaIecnjgVGFx8spZQTyV5xz7UrKDuTziWXgc0wOypld4wvPOcZPbFCQNjGRSzyBgzA/MW6ntxTpCqEqFXaQDleMD/PekJ2Y3IShGdwPSmeZvUHIY9ArDjA6c0AN4Utvf6Htj6VHuXDBcbscDPX6UrkqMyKDjgAL296ifO0e2cjPP40rBcb5oLHHUZGf8KiJKHCAZP45odQuCFbao+hPrimFlBPdgMA5/lTsK5BPlgQQcdMgZ5/wFVZM4+Ylh3x6+/tVqRgQCAD9eRioCrLhjgg/KM9/erRDIXYgkgg5HPtTGO9QM5OCSOmB/WiWQcAA7s/fU9P8A61NUhuX44yR159KpIlsilbMQ2qOfb+lVCwKbgCwPHJ4NWWyvzKRntjjNVZVKxMMYTPJx1rVGbKpf5QrHv1pcOWYkjLdcHGafIvLblA3DIz/CKhYE4G7OOnvWiMmRSlAh+UgkkA56AVEclFPcjj2qxcAf3Q3v61G4LxnacZ4piKsuFbAGVHAzULg5IByV6Z71NJwpPfOP/r1FNj5gee+R61USJFTGCxNVpT/9arExwSAeOpFVmGQcY9q0RjIrS9cCqkqg5xVxvuknqOM1UmOAa3gc0xtqP3yj3r03Q0DQx7uMCvMrY4nT0zXqOjEfYUYdcV9blD/dM+ezBe+jyiLGfWpl67TjjpUEeatLjHPXFfJs91D06475qdQR3AqFegxyDU0ZycfjWbNYlmHnHAq3GNxGM49aqRDjoMVZjbDDPAz2rOR0QLsJG4bmO/PAq5FkuFwdo5BB/wA81QUZYNj7pzx1q7CTtxkA9/Y1kzeJdt1ALKcAY7Hn8KsBCy9fnAyAO2PU1WhAzkAE46g1biUnIP3Sck84P5Vm7GqLke6MAYJwP85NWVBY4OAevvUSrkYJOG7d/r9KsRqz9WOfpyPf3rKRrEeEDJswSvrn/PFSwp8rKpyFGR/tfSkRZAWLHIycEf4U+JlRwN+BjONvOfepLRZixt25xgYOTxViP7uMqe3Xk1AhVl2sME8g8cY7VIccEnqO386zLJVwuT78FqUBRtGcY4HcVG7nBB3bv4SP50K2VVjgsBznrSY0KRsyFbkYIIOMClLAjBOMHr60MykscNuHOB3/AAqMAOSN5JHXtSGT7d+cvhiMnnHHtTxwVcDeRwBnofeq4xkDvnGetTZJBG1lHfIB5piJo14BBXbjGB1+tGzOMkkgEEjPSmxOdsfBCgEkEc/n61IuWAbhjjkEYGKdxEkXlqg+QgZJIBxge1KxiaLb82Cc4J6UkaMEVvMI9Nq5yfxprBlQsGI+o/zxTAfvAKjJI7AqQDn0pwKlcKNoHUnnPvTEiWUxrvJwvGB3/OnbFVv3oJx2A5HsD3pMY1di53ScHgAelR5BT5GH97A/rTTGHf5cqy5OD0/AUyUvFtDvlPVWxj8PSmIizh9pGxOPXrTj8jYBBIGMA5+gz2pJFZgQ0n3gPmBwDUDqqqd27ceoB6D3qSh8rgANkbgeDn86iaZQxbgL3Ge9PlVVb5lyCcZP86qyYDgovGeQecinYQssg3Fjk8nB7Cq5nDA7T279/anksFzjocbMYqNslgW25xjOOtOxLZGznftXlicDjGR6fSom8pyd4YZOQcelSY3jcW3Y6Z7D60xjhSrZOOvPOPTNUiWQEkMF6p27kGmklSflIwcdeakk6DIVQfQ8/Wq7vhwWJHHU1aIYyVmGCBnGQcnNVZSORjcE7k9qlkKg7WJPpn+dV3BXcBjJGefT1rRIzbI+cA4GB75ppxjKjn345ppcgow288ZNGdx2HHPI7nHpVohjHA/hzxkADtTckqQeCRgc96kkO7cRjJGGwO3qKifAfcWDZHyn37ZpiKz5VVOQwIwcVC+fmBPHGTUjhgpKjjHWoJWOORgYxiqSIZVl5yeh6VWckDjtVmQgLgfXFVpD3H41qjCRWlPHPWqkvOauSAZJqpNxkitYs55IihbbIv1r0LRb5FsFBPIFedZ+YVv6TclRtbkHoK+kyepvE8PMo2tIwU4GalXpk1AOtTLjJz1r51nsIsR4x+FToMYB6Gq8QAyKtJhsZ7VmzWJPDwcA8fpVqHPA7VUjz1xVmMnOc9+tZs6IFq3z68Hr61ciPJHVsdx2qpECCAM8jpnvV6IblUEZb0FZSOiJZh+6CcjBJJHX6VdiyRncc4G0ZxVCIY+6eCc9evNWogWw24EHsB3rJmqL8UgIIJwB61at5N3Q/hnHH+e1Z65Y4B5HGcVZhTEfmbPmX5MfrWZojTVGZlXABznjnPpU8boG2oFIB5DdvSqsBbCqeB2Pt/jVi2C795U57lR1HrUNFosdHyfujjB69P1p8mDGrcHngjjHtUe9RgKhwR1xwaQkb9zA7SODjvUlCh8YBIyec8HFO3lgSxxn05FV2mxn5iTk5DYHP0oSTA4I3f7Jx+FDQ0StKxwY8gEdBS+auw5JUnrkfpVeVwqllwB025pGmwhyG3qR0pWAvEMOQxIxnrj8KkVlyOcnOOP0qmZd6ld3GMlR/D+NSAkt3JI69cUrAWknGwoXBJOSCKmD7lQo5BwcBeoqmcoi7Rk9/epLdlbJGfUHPemgLqD58AH0AZiD/wDWpN2HG0YC8DDcgHrzUcLFT0IbJP3+CfxpwmUOVDshAzndkZp2AcgcqVAwhOc9fpSSxyeWu+QhBxjI604hJiMtJkdhz+NQEx4JwHI6fLzSAnEcacr97s2/n8vWq8yjGU3c4zuORn2pzIvyjd8w5wR+tNXY4KhSM9Bg+tO9gsQsAAq5b72SMg80xm3ByCCc9vWp5g2G+TaTwMH9TULK2GwOoHI9allEbK7RljICVbG4dT7Y9KhkfaArKzjHIp8hfcd4BwMYPemNyiktyPbmncmxHK2wKzAHjj0z6Go2Qs+WXKDnGecVMyj7qjjGf97FRlgApDEKTwapEshJbZhmBBB5HP8A+uoWIZcr91uOf1p8mARglT6jjFQSMcAk8nORnk/SqRLIZCyhlfaD/dz+X4VBkiQ9RIGxx1+gp0pDIdoA78dfxFRsOS2VUn04q0QyN9inbkKMkDaP1xUDkCMNzk8fT3pXbKE8nGcHHTNVpg2DnhRyMnoO9aRRnJjiclkHAYjAamltrfKDtHfP4U0sygAZ8xcd88UwSkfwjgc1RJK7lQDtGVXpUZAAOTw3IOO9Sb8AN2HU/WoZiQMEHavA/HvVIkjkXHTrkj2zVW5znPHPOPerUxCkKDxjg4qjITt6g56e1WkZyZVk9Mcjiq7k4OKmcHdzz3qJupHSrRlIhbAU+lVZMEfWrMnQ56VWm4UVpFmMiox5963dFjLzrkcVhMMsB2zXVaBhXQ4ziveyhXk2eNmGyRyQOTzxUqjn2qBD6jmp4uTzXhs9NE8TZHvVqInHYjrVVVx0/KrUY24z3qWaxLKkEZzzVmFuOPun34qqg6c1YjB6+nf2rJnREuwnODxkZPFXIgVI3ZG5cjHeqMQwRwck9qswszcFTxnnNZs3iXQqiJ1yCe/bFT2KCONUG7aOAT6VBGAwGCWYngAdatR4wpbcqcgD1I9qybNUi4u1X2gZB6n/ABq5GwCghGPHAH171Vt5fmwxAz0BH5VZhZAAVJPcgnIqGaIsoxyMLw/JzV22MfQjOPwqoHynBwTxjOMVYhPQbuOoGOMe9Zs0RY2gMVyGbPp1oY7kOM9MccGhWygIC7jgY4PFN3ZbBHIOOTn86kYwbv7ucD+dNcKkZ2EDHvkijzF4XK4BK/jUc0xZC5OMjoO+KdhXK5dgSOQevPehJCzNhAR6g/571XmnAyRt9ODwKrifD/Kee5zj86fKO5qRTDaM8DuOvH+NWRPGSB82cdsn8MVnQS7lLOADuJ9jVm3GTgEt396loaNCObgLyuR74/GpUmw23DMG9gOcVUhYlCDuUZwc1bQnCE8qBjIUHNIZOZZFBwgwOu40zfJlQIwQx7tj8KbJsAZUdc4HbGaLaRS4LSqHCkA7c4NMRJKXwT1bPTdnFHmSvvwiAAY4OOc96kD7CxK7R0C7e/r9KQAKCRIjD7xBwCff/CgYrSyDAcx4x0Bz/wDqqORnZsbgo6ZHPH0qZomA2lRsHO7sR71WZwuHBbAGTgkGpsMC8gUhWUYzzioXZmADv3wOKlRiU3KM5XGD6npTGQOOpDDg4OPm+lTYZA+ANzEv2qFjiQ5PDdAf881NIqvHgZDdSPaqTLlsiQKT2z0qkibjnKY4VjnvnINQOAjscY7g9/8ACnMxRgBj0Pr+FQM+05+UjHIqkiWx0v3OmCvO0jvVZtkgZRjnoO4/GnvLk4VgGBxnOPxqu6qqbsbjzx3+taJGbIWKmUFxnnJzxn2zTZHC5Yn6e1KcA7ipOOwI69zULM0mSMjggnPU1aRDY0sWHGzAAyCefrUEg2OQu5TjKGpgnAwTtPBJphHzZl6EcZ5B7CtEjNsikcfu8Jlhxnp161FH5ZJG7knAB71NtAKj5sgEkj1oCxsORwowMHGaaE2RgAHCtnsc8c1FcNhsjlMcf41MVCkFgpx+tQSJ0GDjqR6VZBBK2VGeg6EdaquPmwQcEdTVp8jO4j0+lVZOTkkgY+X3qkQyBlJz/s9fpVeTjpzx1qw5OTjjtzVd+AAeKozkQuQcAdKq3HIwKssOvNVpG49xVxMpFKQ7SCBzW3ot8I5Fz0rClb5+OtWkUogPc16eCxLoO/Q8zFUlVViovI/rU0fWoIzwKmjbGPSvPZ2ItpjuelWF+96YqCLkc8mrKDB/rUM2iTIMHOMVag+U+oPr6VXjGRjvViFT0HP1rNm8CygAKnn8DVmPb0+9noTVaMccHKn361bi7kkDtWLOiJbhyfTbgHOP88VoRRhRgAE+meoqlbgHGRtOME//AFqurExSMx4x0+tZyNYlgJ0bnJxgjqB7VbjUBkHlkk+1RW6/KV6njbn0q6NqqCoOMjPPU1DZaHIMgKUyrnO3r+dTrGpGEYYPB25GabGGKHBxnjOMY9aUOwY7eQB1zgYpFXJI4lHysQwwcZ7/AP1/enhFyCEUjHLHp+VNjkKZBAxj7+Oh9sU2SR2UgrtUevBGfSi1wuI4j3scZYccnt7GqcsiIrlFAPpionkwzDzAuO/p+FVLq8iiVvm8xlA5/hrRQuQ5W3IrubP3WGOi5X9Kz4bkLJlSeDnOKivdUWN1jnikTHQHr9TVeO4SWVjFhB/dbn8TVODS1IVRN2R0FpKcZViG6EEZxWlFIcbQASPTv9Kw7SYl2CgEKvzZ9PpW3aMQRhgFPT3PpWElY3i7l+MKu0/NsAOAOePf3qzbgbR5hkbg8Fu1RwnIYFAvH3T3PtVuJd+OE+bHOcYxUXLsOMZVTuX5+g+TJxihoiMeWqnAHU5we/NNPLkEHIzhgetThGGegBGAQM8gUbggDMF4TrwMnn9aFBKhMBW64+n4c0jKFA2NjOeC3INSMrgF0QZzz82COKNw2GScx52Zdjkr6D/GoZCQwGwlj0APfFOc7hnODnmmFwAqKzK4bpuOPrSsMTMkqdAPQCoZgDtc5+UHAxUzZ+XIO0HrnrUMxKIuMFc9uv4+tIdysSGJGwkH/axjPeq74TLDBx13dz7VKAASSMLnGB1NROiDgn5W5zjpTsTcrliOSxwQOc80gPvwByQM4+lPK7B8vIGRn1+lRMANuCMHjPpVolkbhiuGUr6Y7VDIHCt6kchamdgVY4HzA/N6j6VXcsFOzrwAcdfcVcUZyZWkwOuAUGeR0PtUUjZVDj5yMnBwOtTzEbyMkNjPTOaryhckseV5IXpWqM2IzhxgqNuc46AGo3UDGDkg/LzyKVixLM2TkZPTIpqsDwRlG68Y2n2NUiGAOMEYbIOfpURIBJySQOD0GacWO4cZx1z3puSV5BPXg0xWGnJPJ+Yj86jk5Y5PGRwO+KlOFQrgAjgknoarTDCgg5wRz700SyJuSWGCc8DuKrykFcdx0qwzBmYjjB5qvI2HH932q0QyBtuM9B/I1XfnAODU8pU7jjFV5CMcdqaIkROME1RnO3NXZ2+XI7VRYGV9o6HvWsUc83ZEKR5heRu3IqGxuvOJRzx2NWdSfybVkU89Kw7GTbIecc10baHDe7L6cDmrCAHn9KgUcZAzU0RwMVizpiWoMjkHgVeXAI71SgILCraEnjHNZs3iWougIPPrVlF+cD8KqxnBX+73q5Ec4Bz09ahm8SSLBbBHy9yatQgHg9R1NVoxjb0+TpVyPG0kkbc4GD0NZM3RbUk7CPlHTHr9a0LZwQMNmUHj2xWVDwFVyWP9a0bYblHTn5Qcds1nJGsS+ny4x16kdjVuFjlfMYEHoMcj3qhbpuhU5O09Bnt61dgUqqgEpj8SR6VnsWTgyFNjqODnGeo/zipldk4ZHbPQkZzUKcyF2kIyMFQvBPbNSeb8hVXQDpgHbigYsjgMAMEkj95txiqdzcCJXKhhgHouamkk2OAFztH8PzD2xWVeTq4Y5Y9enAFVFXYpOyKV7dlVJcA84C5BJ+tQ2Qm/c3Ew37iV2f3FwTwPXA60zy1aXdkMPfjNTXsp/s4+VjzFmCqVzgcYA+mM11K2xySu9Run6Wst9Fe6jNvi+VzAAcvgfLz3Hqax9QRbfUD5YIjlYlQDwvNdoWgXSzOZA7gmIRv95ucDjsOOlcbrUBhe0Ug7WUlT+NW9VYztZ3RqabJv2ZYFlPI65rp7MnYoAxjn0/CuT0zAkBIGQPvAda6S0zkhiCw4IH+NcFTc9CGxtRvlASc88e1X7dQysylSRzgnpWRahtoJT5Mbd3c+vFacEjeWARgfQdKyZoh7AMxJBJBP3Tjj61OodwCyMNzYz6fQClVkSQqfmwckpkY46U4SptUFsEjqTjd74oARopM9gTwGZc7Rj2qPDAsoK8AYGzH45pFkHlY83vgADpQxRRhjwDuIDE5HpTsAkowNrOsnTkcEU13weGBOOQV7mkJkLblIJx909hn+dRPgkFQf9o9jnv7UNDFdszZxjjHC8CqkigH5g2D0HrU0jEbgmcHPJHQZ71DJIAAEJ+UA7Sc59aSAY2SpXBcjgem4+lVJWIC7skjAzk4HtU7uPMYhQCPlBHPNVZnG9lUNx0BHJPvVJXERyOxJUswx0wRj2JqI5VskkoBwPSnuwJ2rnrz7H0qGV8Alj+HaqRDCSUHgAbiOcioFf5x6gZJHTnvS85xlGJbuCRUJUA/KN2P88VpEhkUvyzKRjHTP9aaXLbUOM5JxikkYvc9VAJzt+tRM2WJOTg44HaqRDDHcAdeFHU0wkgqI8BR6j9aVyCfu5K9McA1ExD5Clhg5HtVIhinIbG9hle475pp57sOMgH09advwMYyOpx1zUMh65GCBTAFb94DgDIxUDNgFCMjPfsakk5BxnbgHceoNQM2HGDuxyaaJYxiVcnI5qJhkE9DT2OAetRSE7f61aM2yq5561Wkf05qaU8HPNRCMyKW6KOpq4xuYTmlqyEgvwOvrTnKW8RH8frUdzdRW67UyWPpWbNcM+cmuiK5ThqTcyrqlyWzk1lRH5xVu/BOCaoq2DmqMzp54yh3jG09vSoUxn60+1nSSPy5DgHileIxgDt2NRJGtOXRk0R56/jV2LjgDms+I/MM9KuQmsZHXBl9OvpVmIj/geePaqcTe+asK2Oo5rNnREuRsB2zz0NWYgcHcpAUcjuaqREZAPGepNWIWzk7/AJgQR61kzZF9CvHrjBq3bt8hXcFYYP1+lZqHLEMBnoO1WoW+fDEYB+XmoZqjVgcgYIGwdwOlXUkIPHyIBwM9KykLB8r82flw3rV7epUKxBB5yP5VDRaZo5KMD85HByOcfpSOVU4O8MOm5RzVZNuQFbqc43Yx7VIdki7EyQCeec+9Fh3ILuQKgyPm7BjxWXcyng9h2A6Vp3W1cbI8BhhQQB+JrJuWy2JOgyODmqWgmVEQGUnlznoDVpkmaOZD5So4JIYkDPb8fQ1XJ2QMijAPcc4/+vU8EaXFoyySGOSL95GoPDYrZMwkjOu4LpbSdpTIpQZYMMj/ADzWO+8zR7n3475J/nW3f6r/AKJdKXJmfKc993t7Vi2wy/zZIA5q72i0Yu8pI6DTSqNtUDkdD2rp7JdqkjjjAGO3euW05WDYB687h0I/wrobORlKfIvmZ2r6fXmuOep3Q0RsIG2oVC4C8grwDV2BioXcU5HBPPeqNuy/LkkMc9Rj8/WrqPjJBVV5Bxjken0rOxoWoxtwYyQw5ADc/WnRxHbhQrA8EkYH5/401FyAOA2AVOef/wBdS4VVVypwOdqjrj3oAa20kOy47qAMZqvJtkkbaojHOQc9ulWixb5euegIAPrwKik3GMuwyzfKw4O1T/WmhFcqC2GceWvRsH070yRT95FYcdBz+VK4YOAGG4cn0I9PSnEgMDyCO6Hp9KGNEGcLlmxn361BKVyVVSAxwMkdamkYKzZYfNx16+vFVpXBIH3xzg54z9KmwEEzBigwF44C9OvWobh+WyfmxksOePY+tPZlA35BUnBG7n6YqucsADjGeAT92rRI18KwJbOeOnb1qKZSrFQcsuOV6D6UskmS2AQvAHsB6VAzEqRkCTO3rxnvVJEtgysdyqNzD5iO+BUUhUDcoXJPrikZtwZmyxzyB1pHOcZ2uBnOOoFaIhkYLM2VIxncGA5zTGIUNgnI4wP1olbaQowVxknHY1Ax+Ugdc5GTgYqyGI2QCvGAcbh3pNwWNSyjp0/xoDkLwMkjAP8AWo2YFc9SOBTIHx5AAKguOc1XLdSc475pWGdw5ORjPvRlSAWxtztNMBk2fvcMCcVXJyCc8jHSnuR1U5GcY9BUEsig7R0HXAzTSIlJLcbIxDnHXvVeaXnrk+1NnmwX3/LjjOazpr9lcqgHPfHSt40+5xVMQtolmeSOPlznHUCsu81FnykfyqB2qKQtJksfvdqgKYzkdK2StsckpOTuyNiXXcxJNP2KVyTSLgkYP1okYAFQaZJWul3x8dBWWOGxWpM2IyOKz4UMs20CgRoIQFyxrSsZDJHm4U+V2fbWRuB2jvnH1rpbOUeSIpY13Y6D07fhQgZXdMMCjbgR16VLET6fWny2jQo3lZaJuoAyR9Ki6AMM7emfWolE6KVS+jL0bjIzyDViNvfJ96pI6k5z9atK4zxjmsGjtiy5E2Rz34xVlCCMjr1IqhGQcenpVqIjuSM96yaN4suxkhemfx6Gpo2wOpBA5461TTOG6dM4I61PG5+XPfpzUs1RpQkNgqMP/OtGCQP90AHdkEcCsaBiVHHHJyK0ImIA2jKHAznr/hUNFo04kDSdCSDnHr7irSkCMlyASScpwT9aow8sAxXCjIB7/Qe1XIGxwMDIwCvOallJEciBosoisRxnoCaxruIqSWGT/s9K6L5Gj+ZcnJ7/AMvU1n3MZIJI79R/D/hQhmDNlctGeo6GqFxevGdqRgufU8Ctm9hU8KTyMA59KzJrUh84zz0rZNHPJMxhEXcvI5kdjksau2ludwwevari2uMHBx7dqu28IRMsAGxmpnO5UKdieyjBUL2z1rZiUbwpJ+9wRzj3qlaKN+7GGHQAYBrTt0Zd2DyBwCOorE3LVqS2Q+Q2P/11aj6qFG0E5JCjPHfFVYQQw3ZG1SQx6kd8VaSZGVTuTjseMD/PepsO5bX5SQr7C3zAhsg1KZlcgr8x5wQcH6mqjSYTsDnop/Snq7FWICYPy4HAz6UWAc7sX2wlOepB6D60hbaNzDlTgDjr/hTJACA6EMWXHzHAz+FVwXB5CMcgDf296dguTiRlkULFsLH5ff3AqKZ1znkHknHGah8xSM8EjjPX/P4U2VwqjaCMcEsO/wDhUsYyclhtC7gRx61CyqcsH3KBgMOOfpU0uSAMnHVfc1BKQqnoXJ/hH3aBlSXYxDE45JOe9NIVZSeTuXqPWiYkjcecHAwODUchAJI+9nb79qokSQlgOcegH61Xl/1g2jnuM1K7lpB2JOM+nrioZzhgqliM/e6nFWiGRNIsboCTtBznrUTyZVguNygswB4NBxnjJPTOePyqtKAWKqSBjpnPSrRmxwKsMkdRySevsajaQgY9OKRz129zng0yYHcPuj0xVkMCflO7jn8hTWO1kB79SBx7UMyowYt77ie/1qs90g4Qs4BxnHQ1UU3sRKcYrUnZsKn5Y96hnuVjKqSMVn3d+sbsHw4A6DpWdc3jOpXO3A/IfSto0erOOpiukS/c3oRl+YAEZI7kVnzX77V2HDs2QR1FVPndskDkc01goGRyeAM/p/jWyilsckqkp7sdJK7F2YcNwM9qikyg244J6092BY8Fs44/z60x5AnB5PUY71RmR5UnBBHOabKpz6D1pDJk5YYPvTAxbJIzjjFADxxyB0qq75JzU7ttXAIz3qkzFjigAl+eMnFFggUFgMtThkIRVjTMIGIGSaaAoWhzdqDzjpXTRDZcyIvQHAPcc0UUREy5po8y5SFydhcr17VBeQpbX8aR/dlBLA9ue1FFDBCMoWYheB6fhUi5VQwJBNFFYT3O+k9EW4//AK1XIhknJPc0UVkzqiWIF3OqknGQKkjOX2kAjmiis2bRLUZ2Jlf4uvvzWiqAPwTRRWcjWJcQdV7Dj60oldHjUNncM5PWiioLQ7z3AiBw2c5z3p7uxVR2Kgn3zRRR0DqQzIpG4jLZ25qsYlKKTmiimhMVVAjDDjB7UqRKJI15IOTiiikykXLRAx5LcNtHPatVVG4enp2ooqRsswxLIHZskryOfWpJEVjGSM7uD7fSiikJD3jWOVVjG0EdvrSsgwCSST1z35NFFUAYIdgGYDgYFU7gkMe4U55/KiikNASSmSec7fw9KikG2RQOQ65INFFSUMZv3kyjAwgIIqBwUzgnof8A9VFFAkQXACjOAfkBwelU5OGKAnG3J96KKrsJkJHzY7EkU378YkPDM2OKKK0RmyCYYY4z6VAwHlZHGGx+YooqkQxshJYZPY/pVS6kKx5AAJooq1uZS2My5lkYPvdn2vtG7sKzJ5pNoUMQGOSKKK7Y7Hjzbb1IUGTz3wfzOKRgNzjA+VSR+HSiiqIGMMMq9QOP0zUQYqmQeSR+vWiigRFMxQ7lPzFev44qEucbu5Gc0UUARg8D25p8jFBgd+tFFIGUySz80/FFFAyNuCQKmsGIjcjrzRRTQj//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This 6-year-old boy was noted to have a well-demarcated hypopigmented patch on the abdomen at birth. The lesion is consistent with nevus depigmentosus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy; Mary Tonsager, Dermatlas; file://www.dermatlas.org.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_1_1041=[""].join("\n");
var outline_f1_1_1041=null;
var title_f1_1_1042="Fetal spine limb body wall defect";
var content_f1_1_1042=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F55474&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F55474&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    First trimester vaginal scan of fetus with limb-body wall complex",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 399px; height: 256px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Note that the spine is twisted out of the plane of the image at the left side. Arrow points to herniated abdominal contents.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Wendy Shaffer, RDMS and Joshua A. Copel, MD, Yale University School of Medicine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_1_1042=[""].join("\n");
var outline_f1_1_1042=null;
var title_f1_1_1043="Primary CNS lymphoma MRI II";
var content_f1_1_1043=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F60130&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F60130&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Magnetic resonance imaging of primary central nervous system lymphoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 407px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Panel A shows a gadolinium-enhanced cranial magnetic resonance image (MRI) of an immunocompetent patient with a homogeneously enhancing, single periventricular mass (yellow arrow). Pathologic examination revealed this to be a diffuse large B-cell non-Hodgkin lymphoma. Panel B is a MRI of the same patient after four cycles (2 months) of high-dose methotrexate, showing resolution of the mass lesion.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Batchelor, T, Carson, K, O'Neill, A, et al. Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: A report of NABTT 96-07. J Clin Oncol 2003; 21:1044. Copyright &copy; 2003 American Society of Clinical Oncology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_1_1043=[""].join("\n");
var outline_f1_1_1043=null;
var title_f1_1_1044="Ciprofloxacin and dexamethasone: Patient drug information";
var content_f1_1_1044=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Ciprofloxacin and dexamethasone: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/13/16595?source=see_link\">",
"     see \"Ciprofloxacin and dexamethasone: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/11/37042?source=see_link\">",
"     see \"Ciprofloxacin and dexamethasone: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F151783\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Ciprodex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F854897\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Ciprodex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10024885\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691827",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat ear infections.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10024884\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701811",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to ciprofloxacin, dexamethasone, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10024889\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10024890\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Ear discomfort.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10024892\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10024887\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694912",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For the ear only.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696236",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Warm suspension in hands 1 to 2 minutes before putting drops in ear.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695632",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shake suspension well before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695296",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Lie on your side with problem ear up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705870",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Pull the outer ear outward and upward.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695238",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put drops in ear without touching dropper to ear. Stay on side for 1 minute.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10024888\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10024893\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10024894\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10851 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-C9EBEEE8B0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_1_1044=[""].join("\n");
var outline_f1_1_1044=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151783\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F854897\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024885\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024884\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024889\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024890\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024892\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024887\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024888\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024893\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024894\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?16/13/16595?source=related_link\">",
"      Ciprofloxacin and dexamethasone: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/11/37042?source=related_link\">",
"      Ciprofloxacin and dexamethasone: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_1_1045="Triamterene: Pediatric drug information";
var content_f1_1_1045=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Triamterene: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?42/60/43973?source=see_link\">",
"    see \"Triamterene: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?41/33/42516?source=see_link\">",
"    see \"Triamterene: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708892\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F230700\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Dyrenium&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1062701\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antihypertensive Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Diuretic, Potassium Sparing",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1062694\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?42/60/43973?source=see_link\">",
"      see \"Triamterene: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children: 1-2 mg/kg/day in 1-2 divided doses; maximum dose: 3-4 mg/kg/day and not to exceed 300 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults: 100-300 mg/day in 1-2 divided doses; usual dosage range (JNC 7): 50-100 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in renal impairment:",
"     </b>",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Avoid use",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in hepatic impairment:",
"     </b>",
"     Dose reduction is recommended in patients with cirrhosis",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F230682\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dyrenium&reg;: 50 mg, 100 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F230666\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1062705\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Administer with food to avoid GI upset",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1062704\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Used alone or in combination with other diuretics to treat edema and hypertension; decreases potassium excretion caused by kaliuretic diuretics",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F230730\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Triamterene may be confused with trimipramine",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Dyrenium&reg; may be confused with Pyridium&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F230728\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Bradycardia, CHF, edema, hypotension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, fatigue, headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Constipation, nausea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Dyspnea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Dehydration, gynecomastia, impotence, metabolic acidosis, postmenopausal bleeding",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1062709\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to triamterene or any component; severe renal or hepatic impairment, hyperkalemia; patients receiving other potassium-sparing diuretics",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1062693\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with impaired hepatic or renal function, history of renal calculi, diabetes mellitus; patients receiving other potassium-sparing diuretics or potassium supplements may cause uric acid elevations; use with caution in patients with gouty arthritis",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F5940404\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hyperkalemia (serum potassium &ge;5.5 mEq/L) can occur; patients at risk include those with renal impairment, diabetes, the elderly, and the severely ill",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Serum potassium levels must be monitored at frequent intervals especially when dosages are changed or with any illness that may cause renal dysfunction. Hypersensitivity reactions have been reported; monitor for possible occurrence of blood dyscrasias, liver damage, or other idiosyncratic reactions.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300169\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F230675\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Potassium-Sparing Diuretics may enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ammonium Chloride: Potassium-Sparing Diuretics may enhance the adverse/toxic effect of Ammonium Chloride. Specifically the risk of systemic acidosis.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: May enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Canagliflozin: May enhance the hyperkalemic effect of Potassium-Sparing Diuretics. Canagliflozin may enhance the hypotensive effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Potassium-Sparing Diuretics may diminish the therapeutic effect of Cardiac Glycosides. In particular, the inotropic effects of digoxin appear to be diminished. Potassium-Sparing Diuretics may increase the serum concentration of Cardiac Glycosides. This particular effect may be unique to Spironolactone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Potassium-Sparing Diuretics may enhance the hyperkalemic effect of CycloSPORINE (Systemic).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dofetilide: Triamterene may increase the serum concentration of Dofetilide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Drospirenone: May enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: May enhance the hyperkalemic effect of Potassium-Sparing Diuretics. Management: This combination is contraindicated in patients receiving eplerenone for treatment of hypertension.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Indomethacin: May enhance the nephrotoxic effect of Triamterene. Management: Consider alternatives to concomitant treatment with triamterene and indomethacin.  If the combination cannot be avoided, monitor for development of renal failure.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May diminish the antihypertensive effect of Potassium-Sparing Diuretics. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Salts: May enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Potassium-Sparing Diuretics may diminish the therapeutic effect of QuiNIDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: Diuretics may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with diuretics, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, hydrate adequately and monitor fluid and renal status.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Systemic): Potassium-Sparing Diuretics may enhance the hyperkalemic effect of Tacrolimus (Systemic).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: May enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1062711\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid salt substitutes and diets with increased potassium",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F230677\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F230690\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No data available. Generally, use of diuretics during pregnancy is avoided due to risk of decreased placental perfusion.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1062700\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Electrolytes (sodium, potassium, magnesium, HCO",
"     <sub>",
"      3",
"     </sub>",
"     , chloride), CBC, BUN, creatinine, platelets",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1062692\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Interferes with potassium/sodium exchange (active transport) in the distal tubule, cortical collecting tubule and collecting duct by inhibiting sodium, potassium-ATPase; decreases calcium excretion; increases magnesium loss",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1062707\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Diuresis occurs within 2-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 7-9 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Maximum therapeutic effect may not occur until after several days of therapy",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1062708\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Unreliably absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic conjugation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: 100-150 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: 21% excreted unchanged in urine",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1062699\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?41/33/42516?source=see_link\">",
"      see \"Triamterene: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause dry mouth. May cause photosensitivity reactions (eg, exposure to sunlight may cause severe sunburn, skin rash, redness, or itching); avoid exposure to sunlight and artificial light sources (sunlamps, tanning booth/bed); wear protective clothing, wide-brimmed hats, sunglasses, and lip sunscreen (SPF &ge;15); use a sunscreen [broad-spectrum sunscreen or physical sunscreen (preferred) or sunblock with SPF &ge;15]; contact physician if reaction occurs.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1062710\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Abrupt discontinuation of therapy may result in rebound kaliuresis; taper off gradually",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Chobanian AV, Bakris GL, Black HR, et al, \"The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report.,\"",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(19):2560-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/1/1045/abstract-text/12748199/pubmed\" id=\"12748199\" target=\"_blank\">",
"        12748199",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents, \"The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2004, 114(2 Suppl):555-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/1/1045/abstract-text/15286277/pubmed\" id=\"15286277\" target=\"_blank\">",
"        15286277",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      van der Vorst MM, Kist JE, van der Heijden AJ, et al, \"Diuretics in Pediatrics: Current Knowledge and Future Prospects,\"",
"      <i>",
"       Paediatr Drugs",
"      </i>",
"      , 2006, 8(4):245-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/1/1045/abstract-text/16898855/pubmed\" id=\"16898855\" target=\"_blank\">",
"        16898855",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12859 Version 29.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.131.240.2-23F828356C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_1_1045=[""].join("\n");
var outline_f1_1_1045=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708892\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230700\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062701\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062694\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230682\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230666\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062705\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062704\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230730\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230728\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062709\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062693\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5940404\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300169\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230675\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062711\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230677\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230690\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062700\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062692\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062707\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062708\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062699\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062710\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12859\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12859|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?42/60/43973?source=related_link\">",
"      Triamterene: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?41/33/42516?source=related_link\">",
"      Triamterene: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_1_1046="Superior flap";
var content_f1_1_1046=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F58295&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F58295&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 512px\">",
"   <div class=\"ttl\">",
"    Superior flap creation in thyroid surgery",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 492px; height: 413px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Creating superior flap - Kelly clamps on dermis, countertraction with assistant's finger, and electrocautery, also demonstrating anterior jugular veins.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Clark O. Fine needle aspiration biopsy of the thyroid: Thyroid lobectomy and subtotal and total thyroidectomy. In: Mastery of Surgery, Fischer JE, Bland KI, Callery MP (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_1_1046=[""].join("\n");
var outline_f1_1_1046=null;
var title_f1_1_1047="Mefloquine: Pediatric drug information";
var content_f1_1_1047=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Mefloquine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?17/21/17751?source=see_link\">",
"    see \"Mefloquine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?30/38/31333?source=see_link\">",
"    see \"Mefloquine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F192228\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Mefloquine&reg;;",
"     </li>",
"     <li>",
"      Lariam&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1023592\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antimalarial Agent",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1023626\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?17/21/17751?source=see_link\">",
"      see \"Mefloquine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral (dose is expressed in terms of mefloquine hydrochloride):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children: &ge;6 months and &gt;5 kg:",
"     <b>",
"      Note:",
"     </b>",
"     Experience with dosing patients &lt;20 kg is limited.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Malaria treatment (mild-to-moderate infection):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Manufacturer&rsquo;s labeling: 20-25 mg/kg/day in 2 divided doses, taken 6-8 hours apart (maximum total dose: 1250 mg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Unlabeled dosing (CDC, 2011): 15 mg/kg followed 6-12 hours later by 10 mg/kg/dose. If clinical improvement is not seen within 48-72 hours, an alternative therapy should be used for retreatment (maximum total dose: 1250 mg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Malaria, uncomplicated, chloroquine-resistant",
"      <i>",
"       P. vivax",
"      </i>",
"      malaria treatment:",
"     </b>",
"     Oral: 15 mg/kg followed 6-12 hours later by 10 mg/kg/dose (maximum total dose: 1250 mg) with concomitant primaquine (CDC, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Malaria chemoprophylaxis:",
"     </b>",
"     5 mg/kg/dose once weekly (maximum dose: 250 mg) starting 1 week (CDC, 2012: &ge;2 weeks) before arrival in the area with endemic infection, continuing weekly during travel, and for 4 weeks after leaving endemic area.",
"     <b>",
"      Note:",
"     </b>",
"     Prophylaxis may begin 2-3 weeks prior to travel to ensure tolerance if patient is on multiple medications.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Labeled dosing for prophylaxis:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     20-30 kg:",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     of 250 mg tablet (125 mg) once weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     30-45 kg:",
"     <sup>",
"      3",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     of 250 mg tablet (187.5 mg) once weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &gt;45 kg: 1 tablet (250 mg) once weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Unlabeled dosing (CDC) for prophylaxis:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &le;9 kg: 5 mg/kg/dose once weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     10-19 kg:",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     of 250 mg tablet (62.5 mg) once weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     20-30 kg:",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     of 250 mg tablet (125 mg) once weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     31-45 kg:",
"     <sup>",
"      3",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     of a 250 mg tablet (187.5 mg) once weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &ge;46 kg: 1 tablet (250 mg) once weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Malaria treatment (mild to moderate infection):",
"     </b>",
"     1250 mg as a single dose",
"     <b>",
"      or",
"     </b>",
"     750 mg followed 6-12 hours later by 500 mg (CDC, 2011). If clinical improvement is not seen within 48-72 hours, an alternative therapy should be used for retreatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Malaria prophylaxis:",
"     </b>",
"     250 mg once weekly on the same day each week, starting 1 week (CDC, 2012: &ge;2 weeks) before arrival in endemic area, continuing weekly during travel, and for 4 weeks after leaving endemic area.",
"     <b>",
"      Note:",
"     </b>",
"     Prophylaxis may begin 2-3 weeks prior to travel to ensure tolerance in patients on multiple medications.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in renal impairment:",
"     </b>",
"     No dosage adjustment needed in patients with renal impairment or on dialysis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in hepatic impairment:",
"     </b>",
"     Half-life may be prolonged and plasma levels may be higher. Specific dosing adjustments are not available.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F192203\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hydrochloride: 250 mg [equivalent to mefloquine base 228 mg]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F192187\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874703\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088616.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088616.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1023633\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Administer with food and an ample amount of water, at least 8 oz of water for adults. If vomiting occurs within 30 minutes after a dose, repeat dose. If vomiting occurs within 30-60 minutes after a dose, an additional half-dose should be administered. If vomiting recurs, monitor closely and consider alternative treatment. Administering mefloquine on a full stomach may minimize nausea and vomiting. For patients unable to swallow tablets or unable to tolerate its bitter taste, crush tablets and mix with a small amount of water, milk, applesauce, chocolate syrup, jelly, or food immediately before administration.  Pulverized dose of mefloquine can be enclosed in a gelatin capsule to mask bitter taste.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1023614\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at room temperature.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1023593\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of acute malarial infections and prevention of malaria due to",
"     <i>",
"      Plasmodium vivax",
"     </i>",
"     and",
"     <i>",
"      Plasmodium flaciparum",
"     </i>",
"     (including chloroquine-resistant strains) (FDA approved in ages &ge;6 months and adults)",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F192272\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Chills, dizziness, fatigue, fever, headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, appetite decreased, diarrhea, nausea,  vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Myalgia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Abnormal dreams, abnormal T waves, ataxia, aggressive behavior, agitation, anxiety, arrhythmia, arthralgia, AV block, cardiac arrest (with concomitant use of propranolol), chest pain, conduction abnormalities (transient), confusion, depression, diaphoresis increased, dyspepsia, dyspnea, edema, encephalopathy, erythema, erythema multiforme, exanthema, flushing, forgetfulness, hallucinations, hearing impairment, hematocrit decreased, hyper-/hypotension, insomnia, irregular pulse, leukocytosis, leukopenia, liver function tests increased, loss of balance, malaise, mood changes, muscle cramps/weakness, palpitation, panic attacks, paranoia, paresthesia, pneumonitis (allergic etiology), psychosis, QT prolongation, restlessness, somnolence, Stevens-Johnson syndrome, suicidal ideation and behavior (causal relationship not established), tachycardia, thrombocytopenia, tremor, urticaria, vertigo, visual disturbances",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1023598\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to mefloquine, related compounds such as quinine and quinidine, or any component; history of convulsions or psychiatric disorder (including active or recent history of depression, generalized anxiety disorder, psychosis, or schizophrenia)",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F4470411\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with a previous history of depression (see Contraindications regarding psychiatric illness, including active/recent depression). Use with caution in patients with significant cardiac disease; EKG changes have been reported. If mefloquine is to be used for a prolonged period, periodic evaluations including liver function tests and ophthalmic examinations should be performed. Use caution in activities requiring mental alertness and fine motor coordination such as driving or operating machinery. Hypersensitivity reactions ranging from mild skin reactions to anaphylaxis have occurred. Agranulocytosis and aplastic anemia have been reported with use.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1023599\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Mefloquine may cause a range of psychiatric symptoms (anxiety, paranoia, depression, hallucinations and psychosis). Rare cases of suicidal ideation and suicide have been reported (no causal relationship established). The appearance of psychiatric symptoms such as acute anxiety, depression, restlessness, or confusion may be considered a prodrome to more serious events. When used as prophylaxis, substitute an alternative medication. Discontinue if unexplained neuropsychiatric disturbances occur. Dizziness, loss of balance, and other CNS disorders have been reported; due to long half-life, effects may persist long after mefloquine has been discontinued.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     In cases of life-threatening, serious, or overwhelming malaria infections due to",
"     <i>",
"      Plasmodium falciparum",
"     </i>",
"     , patients should be treated with an intravenous malarial drug. Mefloquine may be given orally to complete the course. Not recommended for the treatment of malaria acquired in Southeast Asia due to drug resistance.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F192262\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2D6 (weak), CYP3A4 (weak), P-glycoprotein",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F192196\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoquinolines (Antimalarial): May enhance the adverse/toxic effect of Mefloquine. Specifically, the risk for QTc-prolongation and the risk for convulsions may be increased. Mefloquine may increase the serum concentration of Aminoquinolines (Antimalarial). Management: Avoid concurrent use, and delay administration of mefloquine until at least 12 hours after the last dose of an aminoquinoline antimalarial when possible.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticonvulsants: Mefloquine may diminish the therapeutic effect of Anticonvulsants. Mefloquine may decrease the serum concentration of Anticonvulsants.  Management: Mefloquine is contraindicated for malaria prophylaxis in persons with a history of convulsions.  Monitor anticonvulsant concentrations and treatment response closely with concurrent use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): Antimalarial Agents may increase the serum concentration of Antipsychotic Agents (Phenothiazines).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Artemether: May enhance the adverse/toxic effect of Antimalarial Agents. Management: Artemether/Lumefantrine (combination product) should not be used with other antimalarials unless there is no other treatment option.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g., brain) may also be increased.  Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a p-glycoprotein inhibitor.  In those with normal renal and hepatic function, reduce colchicine dose as directed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: P-glycoprotein/ABCB1 Inhibitors may increase serum concentrations of the active metabolite(s) of Dabigatran Etexilate.  Management: Dabigatran dose reductions may be needed.  Specific recommendations vary considerably according to US vs Canadian labeling, specific P-gp inhibitor, renal function, and indication for dabigatran treatment.  Refer to full monograph or dabigatran labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dapsone (Systemic): Antimalarial Agents may enhance the adverse/toxic effect of Dapsone (Systemic). Specifically, concomitant use of antimalarial agents with dapsone may increase the risk of hemolytic reactions. Dapsone (Systemic) may enhance the adverse/toxic effect of Antimalarial Agents. Specifically, concomitant use of dapsone with antimalarial agents may increase the risk for hemolytic reactions.  Management: Closely monitor patients for signs/symptoms of hemolytic reactions with concomitant use of dapsone and antimalarial agents, particularly in patients deficient in glucose-6-phosphate dehydrogenase (G6PD), methemoglobin reductase, or with hemoglobin M.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dapsone (Topical): Antimalarial Agents may enhance the adverse/toxic effect of Dapsone (Topical). Specifically, the risk of hemolytic reactions may be increased.  Management: Closely monitor for signs/symptoms of hemolytic reactions with concomitant use of topical dapsone and antimalarial agents. Patients with glucose-6-phosphate dehydrogenase deficiency may be at particularly high risk for adverse hematologic effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Everolimus.  Management: Everolimus dose reductions are required for patients being treated for subependymal giant cell astrocytoma or renal cell carcinoma.  See prescribing information for specific dose adjustment and monitoring recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Halofantrine: Mefloquine may enhance the QTc-prolonging effect of Halofantrine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lumefantrine: Antimalarial Agents may enhance the adverse/toxic effect of Lumefantrine.  Management: Artemether/Lumefantrine (combination product) should not be used with other antimalarials unless there is no other treatment option.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Substrates: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prucalopride: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Prucalopride.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: May enhance the adverse/toxic effect of Mefloquine. Specifically, the risk for QTc-prolongation and the risk for convulsions may be increased. Management: Avoid concurrent use, and delay administration of mefloquine until at least 12 hours after the last dose of quinidine when possible.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNINE: May enhance the adverse/toxic effect of Mefloquine. Specifically, the risk for QTc-prolongation and the risk for convulsions may be increased. Mefloquine may increase the serum concentration of QuiNINE. Management: Avoid concurrent use, and delay administration of mefloquine until at least 12 hours after the last dose of quinine when possible.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Silodosin: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Silodosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topotecan: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Topotecan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1023613\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food increases bioavailability of mefloquine by &sim;40%.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F192198\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F192212\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Mefloquine crosses the placenta and is teratogenic in animals. Malaria infection in pregnant women may be more severe than in nonpregnant women. Clinical experience with mefloquine has not shown teratogenic or embryotoxic effects in humans; use with caution during pregnancy if travel to endemic areas cannot be postponed. Nonpregnant women of childbearing potential are advised to use contraception and avoid pregnancy during malaria prophylaxis and for 3 months thereafter. In case of an unplanned pregnancy, treatment with mefloquine is not considered a reason for pregnancy termination. CDC treatment guidelines are available for the use of mefloquine in the treatment of malaria during pregnancy (CDC, 2011).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1023635\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Sequential blood smears for percent parasitemia; periodic hepatic function tests, ophthalmologic exam",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1023616\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Mefloquine which is structurally similar to quinine, destroys the asexual blood forms of",
"     <i>",
"      Plasmodium falciparum, P. vivax, P. malariae, P. ovale",
"     </i>",
"     ; interferes with the malaria parasite&rsquo;s ability to metabolize and utilize erythrocyte hemoglobin; produces swelling of the parasitic food vacuoles",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1023618\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Slowly absorbed; more complete absorption when administered as a suspension compared with tablets",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Distributes into tissues, erythrocytes, urine, CSF",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     V",
"     <sub>",
"      d",
"     </sub>",
"     :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children 6-24 months of age: 11.95 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children 5-12 years: 8.84 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults: 19 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~98%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic; main metabolite is inactive",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 9.8-10.7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 21-22 days (range: 13-33 days)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: ~17 hours (range: 6-24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Primarily bile and feces; urine (9% of total dose as unchanged drug, 4% of total dose as primary metabolite)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: Not removed by hemodialysis",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1023639\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?30/38/31333?source=see_link\">",
"      see \"Mefloquine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not take mefloquine on an empty stomach. May cause dizziness or drowsiness and impair ability to perform activities requiring mental alertness or physical coordination. Advise women of childbearing potential to use effective contraceptive measures during malaria prophylaxis and for 3 months after the last dose. Report any symptoms of anxiety, confusion, depression, or restlessness.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F4472066\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Information on recommendations for travelers can be accessed by contacting the Centers for Disease Control and Prevention (CDC) Malaria Hotline (770-488-7788) or visit the CDC website:",
"     <a href=\"file://www.cdc.gov/travel/diseases.htm#malaria\" target=\"_blank\">",
"      file://www.cdc.gov/travel/diseases.htm#malaria",
"     </a>",
"     .",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2009, 58(RR-11):1-166. Available at",
"      <a href=\"file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf%20\" target=\"_blank\">",
"       file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/1/1047/abstract-text/19730409/pubmed\" id=\"19730409\" target=\"_blank\">",
"        19730409",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Guidelines for Treatment of Malaria in the United States,&rdquo; Treatment Table Update, September 23, 2011. Available at",
"      <a href=\"file://www.cdc.gov/malaria/pdf/treatmenttable.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/malaria/pdf/treatmenttable.pdf",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention,",
"      <i>",
"       CDC Health Information for International Travel 2012",
"      </i>",
"      , New York: Oxford University Press, 2012. available at",
"      <a href=\"file://wwwnc.cdc.gov/travel/page/yellowbook-2012-home.htm\" target=\"_blank\">",
"       file://wwwnc.cdc.gov/travel/page/yellowbook-2012-home.htm",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention, &ldquo;Treatment of Malaria (Guidelines for Clinicians).&rdquo; Available at",
"      <a href=\"file://www.cdc.gov/malaria/pdf/clinicalguidance.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/malaria/pdf/clinicalguidance.pdf",
"      </a>",
"      .",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dubos F, Delattre P, Demer M, et al, &ldquo;Safety of Mefloquine in Infants With Acute Falciparum Malaria,&rdquo;",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 2004, 23(7):679-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/1/1047/abstract-text/15247612/pubmed\" id=\"15247612\" target=\"_blank\">",
"        15247612",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fryauff DJ, Owusu-agyei S, Utz G, et al, &ldquo;Mefloquine Treatment for Uncomplicated Falciparum Malaria in Young Children 6-24 months of Age in Northern Ghana,&rdquo;",
"      <i>",
"       Am J Trop Med Hyg",
"      </i>",
"      , 2007, 76 (2):224-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/1/1047/abstract-text/17297028/pubmed\" id=\"17297028\" target=\"_blank\">",
"        17297028",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      <i>",
"       Red Book: 2009 Report of the Committee on Infectious Diseases",
"      </i>",
"      , \"Drugs for Parasitic Infections,\" 28th ed, Pickering LK, ed, Elk Grove Village, IL: American Academy of Pediatrics, 2009, 783-816. Available at file://aapredbook.aappublications.org/cgi/content/full/2009/1/4.10",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13029 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-61.234.146.186-42B5A9483A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_1_1047=[""].join("\n");
var outline_f1_1_1047=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192228\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1023592\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1023626\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192203\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192187\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874703\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1023633\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1023614\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1023593\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192272\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1023598\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4470411\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1023599\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192262\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192196\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1023613\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192198\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192212\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1023635\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1023616\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1023618\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1023639\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4472066\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13029\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13029|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?17/21/17751?source=related_link\">",
"      Mefloquine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?30/38/31333?source=related_link\">",
"      Mefloquine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_1_1048="Diagnosis of hepatitis C virus infection in patients on dialysis";
var content_f1_1_1048=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnosis of hepatitis C virus infection in patients on dialysis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/1/1048/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/1/1048/contributors\">",
"     Svetlozar Natov, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/1/1048/contributors\">",
"     Brian JG Pereira, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/1/1048/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/1/1048/contributors\">",
"     Jeffrey S Berns, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/1/1048/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/1/1048/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/1/1048/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/1/1048/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 1989, the hepatitis C virus (HCV) was cloned, and identified as the major cause of parenterally transmitted non-A, non-B hepatitis (NANBH) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1048/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The transmission of HCV by transfusion of blood products and by sharing of needles among intravenous drug abusers has been unequivocally demonstrated. Horizontal transmission by sexual",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    household exposure and vertical transmission from mother to fetus have also been reported. Tests are now available that detect antibodies to multiple HCV antigens (anti-HCV), and the presence and titer of HCV RNA [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1048/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The basic biology of hepatitis C virus, the limitations and types of methods used to detect the presence of the virus, and the clinical course of infected patients, with an emphasis on issues relevant to the patient with end-stage renal disease, are reviewed here. Issues relating to HCV infection in patients on maintenance dialysis or receiving a renal transplant are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/24/31114?source=see_link\">",
"     \"Hepatitis C virus infection in patients on maintenance dialysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31289?source=see_link\">",
"     \"Hepatitis C virus infection and renal transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     STRUCTURE OF HCV GENOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hepatitis C virus is a small 40 to 60 nm virus with a lipid envelope and a single-stranded RNA viral genome comprising approximately 9500 nucleotides [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1048/abstract/1,4\">",
"     1,4",
"    </a>",
"    ]. The N-terminus encodes the basic nucleocapsid (C) followed by two glycoprotein domains, the envelope (E1) and second",
"    <span class=\"nowrap\">",
"     envelope/non-structural-1",
"    </span>",
"    <span class=\"nowrap\">",
"     (E2/NS1)",
"    </span>",
"    regions. Downstream to this region are the non-structural genes NS2, NS3, NS4, and NS5 respectively.",
"   </p>",
"   <p>",
"    Several HCV genotypes have been identified and significant genetic heterogeneity has been observed over the entire viral genome. The regions encoding the E1 and",
"    <span class=\"nowrap\">",
"     E2/NS1",
"    </span>",
"    are the most variable sequences of the viral genome, while the 5' non-coding region (5'NCR) represents the most conserved one.",
"   </p>",
"   <p>",
"    A universal system for the nomenclature of hepatitis C viral genotypes has defined six major groups (1 to 6), designated as HCV types [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1048/abstract/5\">",
"     5",
"    </a>",
"    ]. Each major type consists of one or more closely related variants, designated as subtypes and named a, b, c, etc in order of discovery. Finally, each subtype includes individual isolates. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/5/29780?source=see_link\">",
"     \"Characteristics of the hepatitis C virus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TESTS FOR HCV RNA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The detection of HCV RNA by reverse transcriptase polymerase chain reaction (PCR) has been used as the \"",
"    <strong>",
"     gold standard",
"    </strong>",
"    \" to identify current HCV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1048/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41849?source=see_link\">",
"     \"Screening for and diagnosis of chronic hepatitis C virus infection\"",
"    </a>",
"    .) In patients with post-transfusion non-A, non-B hepatitis (NANBH) due to HCV, high levels of HCV RNA in the circulation can be detected by PCR within one week of exposure and prior to the appearance of anti-HCV antibodies or elevations in ALT levels [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1048/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. There are two types of PCR assays presently available &ndash; qualitative and quantitative.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Qualitative polymerase chain reaction assay",
"    </span>",
"    &nbsp;&mdash;&nbsp;The qualitative PCR assays report results as the presence or absence of HCV RNA. These assays are considered the most sensitive tests for the diagnosis of HCV infection. However, they are not intended to be used as screening tests for detection of HCV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1048/abstract/9\">",
"     9",
"    </a>",
"    ]. The reliability of these tests might be limited by false positive and negative results.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     False negatives",
"    </span>",
"    &nbsp;&mdash;&nbsp;Imperfect handling",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    storage of blood samples can lead to failure to detect HCV RNA in up to 40 percent of samples [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1048/abstract/10\">",
"     10",
"    </a>",
"    ]. Whole blood anticoagulated with EDTA or with mixed anticoagulants (CPDA-1 and EDTA) may be stored at up to 25 degrees C (room temperature) for up to five days without any significant loss in plasma HCV RNA level [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1048/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     False positives",
"    </span>",
"    &nbsp;&mdash;&nbsp;PCR can detect very low levels of HCV RNA [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1048/abstract/12,13\">",
"     12,13",
"    </a>",
"    ], and rigorous measures are required to prevent false positive results from even minor contamination [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1048/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Quantitative assays for HCV RNA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Quantitation of HCV RNA titers, ie, defining the number of HCV RNA copies per milliliter of serum, can be done with the use of quantitative reverse transcriptase PCR (RT-PCR) assays or branched-chain DNA (bDNA) assays.",
"   </p>",
"   <p>",
"    Several quantitative HCV RNA assays are commercially available. One study found that the lower limit of detection for a currently used bDNA assay is 200,000 RNA genome",
"    <span class=\"nowrap\">",
"     equivalents/mL,",
"    </span>",
"    while the limit of detection of the RT-PCR method is fewer than 100 RNA genome",
"    <span class=\"nowrap\">",
"     equivalents/mL.",
"    </span>",
"    Thus, the quantitative RT-PCR assay is theoretically three orders of magnitude more sensitive than the bDNA assay [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1048/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Significant shortcomings of the quantitative RT-PCR assays are their labor-intensive performance, lack of standardization, and wide variations in sensitivity and specificity. By comparison, the bDNA assays are automated, simpler to perform, and more reproducible, but less sensitive than the quantitative PCR tests.",
"   </p>",
"   <p>",
"    In clinical practice, quantitative tests for HCV RNA should not serve as an initial diagnostic tool for HCV infection, but should be reserved for pretreatment evaluation and monitoring patient response to anti-viral treatments. Because of the great variability in sensitivity and lack of standardization across assays and laboratories, when a patient is tested repeatedly, particularly during monitoring the response to anti-viral therapy, it is critical to use the same test and the same laboratory where previous testing was performed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Tests for genotypes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most commonly used system for classification and nomenclature of HCV genotypes is based upon nucleotide sequence comparisons of the NS5 region [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1048/abstract/5\">",
"     5",
"    </a>",
"    ]. Although numerous tests can be used for HCV genotyping, the nucleic acid sequencing of the NS5 region is generally considered to be the gold standard.",
"   </p>",
"   <p>",
"    Other practical methods that can be used to identify HCV genotypes include PCR using subtype specific primers, restriction fragment length polymorphism (RFLP) analysis, cleavage fragment length polymorphism (CFLP) technology and line probe assay [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1048/abstract/13\">",
"     13",
"    </a>",
"    ]. In addition, an enzyme-linked immunosorbent assay (ELISA) that detects antibodies to serotype-specific immunodominant epitopes from the NS4 region of the HCV genome, as well as novel recombinant immunoblot assays have been developed [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1048/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HCV genotyping is mostly used as a tool for research or epidemiological investigations tracing the source of infection. HCV genotype testing is unnecessary for the diagnosis of HCV infection, but may eventually be useful in clinical practice to assist in tailoring anti-viral therapy to the individual patient's HCV genotype.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     TESTS FOR ANTIBODY TO HCV",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tests for antibodies to HCV (anti-HCV) are the mainstay of the clinical diagnosis of HCV infection, because of the above noted technical difficulties in detecting HCV RNA. Enzyme linked immunosorbent assays (ELISA) and recombinant immunoblot assays (RIBA) have been used to detect non-neutralizing antibodies. ELISA detects antibody to a specific HCV antigen (first generation tests) or to a combination of antigens (second and third generation tests) in a standard ELISA plate. In contrast, the RIBA detects antibodies to one or more HCV antigens on a strip that is read visually. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41849?source=see_link\">",
"     \"Screening for and diagnosis of chronic hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While ELISAs have been used as screening tests [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1048/abstract/16\">",
"     16",
"    </a>",
"    ], RIBAs have been considered confirmatory tests by virtue of their increased specificity. The second generation tests can detect seroconversion as early as four weeks after exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1048/abstract/17\">",
"     17",
"    </a>",
"    ]. The third generation anti-HCV tests, which are currently largely in use, have shown better performance than the previous two generations of anti-HCV tests [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1048/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. In addition, the window period has been further reduced, and is estimated at a mean of 70 days [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1048/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Currently, the detection of anti-HCV antibodies should be done with the use of third generation ELISA [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1048/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     TESTS FOR HEPATITIS C CORE ANTIGEN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tests have been developed to detect the presence of viral antigenemia using a monoclonal antibody to the HCV core antigen (HCVcAg) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1048/abstract/22-25\">",
"     22-25",
"    </a>",
"    ]. A commercial ELISA test for \"free\" HCVcAg is available in some countries [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1048/abstract/25\">",
"     25",
"    </a>",
"    ]. Other tests that detect \"total\" HCVcAg, both free and complexed with anti-HCV antibody, are presently undergoing evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1048/abstract/24,25\">",
"     24,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Preliminary results indicate that assays for HCVcAg have excellent correlation with virologic tests for HCV RNA and make possible to detect HCV infection prior to anti-HCV seroconversion, confirm anti-HCV positive status, assess patient infectivity, depict those anti-HCV patients who are most likely to be viremic, and monitor the dynamics of the infection as well as the therapeutic response in individuals receiving anti-viral treatments [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1048/abstract/23-25\">",
"     23-25",
"    </a>",
"    ]. The HCVcAg assays, similar to the HCV RNA assays, detect HCV infection between 40 and 50 days earlier than the current third generation anti-HCV tests [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1048/abstract/26\">",
"     26",
"    </a>",
"    ]. In addition, HCVcAg is a stable substance in contrast to HCV RNA, and extra precautions for handling and storage of blood specimens are expected to prove unnecessary [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1048/abstract/22\">",
"     22",
"    </a>",
"    ]. Overall, these tests seem to be a viable alternative to HCV RNA testing and are likely to find a large clinical application.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DIFFICULTIES IN INTERPRETING HCV TESTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two combinations of anti-HCV and HCV RNA results among patients exposed to the hepatitis C virus can produce difficulties in the interpretation of test results: the anti-HCV positive and HCV RNA negative patient, and the anti-HCV negative and HCV RNA positive patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     The anti-HCV positive and HCV RNA negative patient",
"    </span>",
"    &nbsp;&mdash;&nbsp;The anti-HCV tests that are currently licensed for clinical use detect non-neutralizing antibodies to recombinant HCV antigens. As a result, the presence of anti-HCV does not necessarily imply the presence of HCV RNA in the serum. As an example, HCV RNA has been detected in only 52 to 93 percent of dialysis patients who are anti-HCV positive. However, preliminary evidence suggests that the presence of IgM anti-HCV may serve as a complementary marker of virus replication [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1048/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several possibilities could account for the presence of anti-HCV in the absence of HCV RNA [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1048/abstract/28-31\">",
"     28-31",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      HCV may be sequestered at sites other than the blood stream, such as the liver or peripheral blood mononuclear cells.",
"     </li>",
"     <li>",
"      Viremia could be intermittent. HCV RNA may therefore not be present in the plasma at the time of testing. In one study, 35 percent of HCV-infected dialysis patients demonstrated fluctuating pattern of viremia with virus-free intervals [",
"      <a class=\"abstract\" href=\"UTD.htm?1/1/1048/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The number of copies of HCV RNA may be below the limit of detection.",
"     </li>",
"     <li>",
"      Antibody to HCV may persist even after the viral RNA has disappeared, representing patients who had been infected with the virus, but no longer harbor it.",
"     </li>",
"     <li>",
"      Anti-HCV may have been passively acquired from blood transfusions. In this situation, anti-HCV would disappear over the next few weeks in keeping with the half-life of IgG.",
"     </li>",
"     <li>",
"      False positive results can occur due to nonspecific reactions, a problem which has been largely resolved with the use of ELISA in combination with RIBA.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We consider patients who are anti-HCV positive to be infected unless the result is a false positive.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     The anti-HCV negative and HCV RNA positive patient",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although more than 90 percent of non-immunosuppressed individuals with HCV infection test positive for anti-HCV [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1048/abstract/33\">",
"     33",
"    </a>",
"    ], some patients are anti-HCV negative despite being positive for HCV RNA. Possible explanations for this result include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The anti-HCV test may not be sensitive enough to detect existing anti-HCV antibody. This may result from either a low titer of antibody or because the antigen used in the assay system cannot detect the serum antibody response to the particular genotype.",
"     </li>",
"     <li>",
"      Various diseases, conditions, or pharmacologic immunosuppression could suppress or modify the anti-HCV response [",
"      <a class=\"abstract\" href=\"UTD.htm?1/1/1048/abstract/28,29,34-36\">",
"       28,29,34-36",
"      </a>",
"      ]. As an example, among dialysis patients, only 83 percent of those who are HCV RNA-positive test positive for anti-HCV and 2.5 to 12 percent of those who are anti-HCV negative by first or second generation ELISA test positive for HCV RNA [",
"      <a class=\"abstract\" href=\"UTD.htm?1/1/1048/abstract/28,29\">",
"       28,29",
"      </a>",
"      ]. In one study, in an area endemic of HCV infection (Saudi Arabia), 28 percent of the hemodialysis patients who were anti-HCV negative by third generation ELISA tested positive for HCV RNA [",
"      <a class=\"abstract\" href=\"UTD.htm?1/1/1048/abstract/34\">",
"       34",
"      </a>",
"      ]. Similarly, among HCV RNA positive transplant recipients, anti-HCV was detected by ELISA1, ELISA2 and RIBA2 in 35, 70, and 52 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?1/1/1048/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The patient may be in the \"window\" period between infection and anti-HCV seroconversion.",
"     </li>",
"     <li>",
"      After anti-HCV antibody has persisted for a certain period of time, it can disappear despite the persistence of HCV RNA.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to the above possibilities, HCV RNA has been detected in the peripheral blood mononuclear cells from hemodialysis patients without anti-HCV or HCV RNA in the serum. The HCV RNA in these cells could therefore serve as a viral reservoir and further frustrate efforts to identify HCV infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     KDIGO GUIDELINES FOR HCV TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Kidney Disease: Improving Global Outcomes (KDIGO) clinical practice guidelines for hepatitis C in chronic kidney disease were published in 2008 [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1048/abstract/21\">",
"     21",
"    </a>",
"    ]. They recommend the following for HCV testing in patients on maintenance hemodialysis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      With the initiation of hemodialysis or transfer from another hemodialysis facility, testing with ELISA (and, if positive, followed by PCR) should be considered if the new hemodialysis facility has a low prevalence of HCV.",
"     </li>",
"     <li>",
"      With the initiation of hemodialysis or transfer from another hemodialysis facility, testing with PCR should be considered if the new hemodialysis facility has a high prevalence of HCV.",
"     </li>",
"     <li>",
"      Repeat testing with ELISA should be performed in patients who are negative for HCV.",
"     </li>",
"     <li>",
"      PCR should be performed in patients with unexplained abnormal aminotransferase levels.",
"     </li>",
"     <li>",
"      In the setting of possible nosocomial infection, PCR should be performed in all patients who may have been exposed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    KDIGO guidelines also recommend tailoring HCV testing to the prevalence of HCV infection in the specific dialysis unit, region, or country, and the patient's risk factors for acquiring HCV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1048/abstract/21\">",
"     21",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients in dialysis units with a high prevalence of HCV should be tested once for HCV RNA, as it is likely that many of the ELISA-negative patients can be HCV RNA-positive.",
"     </li>",
"     <li>",
"      ELISA-negative patients who are likely to be at high risk for acquiring HCV infection should be tested for HCV RNA.",
"     </li>",
"     <li>",
"      Incident dialysis patients, who are highly likely to be infected with HCV, should be tested for HCV RNA on admission to the unit.",
"     </li>",
"     <li>",
"      Patients in dialysis units with low prevalence of HCV or from low-prevalence regions or countries, as well as patients who are at low risk of acquiring HCV, should be tested with ELISA.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     CLINICAL COURSE OF HCV INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients with post-transfusion hepatitis C, HCV RNA is detected in the serum within one to three weeks after exposure, followed several weeks later by elevated serum alanine aminotransferase levels (ALT) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1048/abstract/7\">",
"     7",
"    </a>",
"    ]. Among such patients, 50 percent have self-limited disease and 50 percent have persistently elevated serum ALT levels. Of those who undergo liver biopsy, 60 percent have chronic active hepatitis and 10 to 20 percent cirrhosis. Some of these patients also develop hepatocellular carcinoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/38/25194?source=see_link\">",
"     \"Epidemiology and etiologic associations of hepatocellular carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Little is known concerning the natural history of acute and chronic HCV infection in patients undergoing maintenance dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1048/abstract/37\">",
"     37",
"    </a>",
"    ]. This is due in part to an unrecognized onset of infection and the slow progression of hepatitis C viral disease; the latter may not have the time to become clinically apparent among those on maintenance dialysis because of the overall shortened life-expectancy. A prospective study of 19 dialysis patients with acute infection found that, at a median follow-up of three years, nearly 80 percent remained viremic [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1048/abstract/38\">",
"     38",
"    </a>",
"    ]. Overall, approximately 60 percent had increased transaminase levels and positive HCV RNA, with five patients exhibiting chronic active hepatitis on liver biopsy. Four patients (21 percent) cleared the viral infection.",
"   </p>",
"   <p>",
"    The time required to develop liver complications from HCV can be prolonged. Two studies, for example, found that in patients with post-transfusion NANBH, the mean interval from the time of transfusion to the diagnosis of liver disease was 10 to 13.7 years for the patients with chronic hepatitis, 18.4 years for those with chronic active hepatitis, 20.6 to 21.2 years for those with cirrhosis, and 28.3 to 29 years for those with hepatocellular carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1048/abstract/39,40\">",
"     39,40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The relationship between hepatitis C virus infection and survival in dialysis patients is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/24/31114?source=see_link\">",
"     \"Hepatitis C virus infection in patients on maintenance dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Relationship among serum ALT, HCV infection, and liver disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, the greater the elevation in serum ALT, the higher the probability of histologic evidence of the liver disease in HCV infection. This correlation, however, is weak; in addition, serum ALT levels are poor predictors of liver disease. Among hemodialysis patients, for example, serum ALT levels are elevated in [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1048/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      4 to 67 percent patients with anti-HCV",
"     </li>",
"     <li>",
"      12 to 31 percent of patients with HCV RNA",
"     </li>",
"     <li>",
"      One-third of patients with biopsy-proven hepatitis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similarly, biochemical evidence of liver disease is present in only 42 to 52 percent of HCV RNA positive transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1048/abstract/35,41\">",
"     35,41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The discrepancy between serum ALT levels and the presence of anti-HCV is due to the following reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chronic HCV infection characteristically has a fluctuating course with multiple peaks and troughs in ALT levels [",
"      <a class=\"abstract\" href=\"UTD.htm?1/1/1048/abstract/7\">",
"       7",
"      </a>",
"      ]. Thus, patients with normal ALT levels may have severe histologic lesions.",
"     </li>",
"     <li>",
"      HCV infection is not always associated with chronic liver disease. In one report, only 69 percent of anti-HCV positive symptom-free blood donors who underwent liver biopsy had histologic evidence of chronic hepatitis.",
"     </li>",
"     <li>",
"      As discussed earlier, some anti-HCV-positive patients may have cleared the infection and anti-HCV may be the remnant of past infection.",
"     </li>",
"     <li>",
"      Baseline serum ALT levels are depressed in patients on dialysis [",
"      <a class=\"abstract\" href=\"UTD.htm?1/1/1048/abstract/42\">",
"       42",
"      </a>",
"      ]. However, elevated serum ALT has been observed in 4 to 23 percent of anti-HCV negative dialysis patients [",
"      <a class=\"abstract\" href=\"UTD.htm?1/1/1048/abstract/28,29\">",
"       28,29",
"      </a>",
"      ]. These patients could be carriers of HCV infection in whom anti-HCV production is absent, or the liver disease might be due to a non-A, non-B virus other than HCV, or to non-viral causes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Liver biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of these limitations, liver biopsy remains the",
"    <strong>",
"     only",
"    </strong>",
"    reliable method of confirming the presence and assessing the severity of liver disease in patients with HCV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1048/abstract/43\">",
"     43",
"    </a>",
"    ]. Liver histology at the time of initial presentation has been shown to be a good predictor of intermediate and long term outcome in renal transplant recipients with liver disease [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1048/abstract/44\">",
"     44",
"    </a>",
"    ]. Over a mean follow-up of six years, progression to liver failure and death was rare in transplant recipients with mild histologic abnormalities such as fat metamorphosis or chronic persistent hepatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1048/abstract/44\">",
"     44",
"    </a>",
"    ]. In contrast, 35 percent of recipients with early chronic active hepatitis and 60 percent of recipients with advanced chronic active hepatitis progressed to liver failure and death.",
"   </p>",
"   <p>",
"    At present, we perform a liver biopsy in patients in whom serum ALT levels are persistently elevated [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1048/abstract/45\">",
"     45",
"    </a>",
"    ]. Patients with normal ALT levels are biopsied only if they are being considered for transplantation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/30/15847?source=see_link\">",
"     \"Approach to patients with chronic hepatitis C virus infection and normal serum aminotransferases\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1441974061\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The gold standard for the identification of current HCV infection is the detection of HCV RNA by reverse transcriptase polymerase chain reaction (PCR). High levels of circulating HCV RNA can be detected by PCR within one week of exposure and prior to the appearance of HCV antibodies or elevations in ALT levels. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Tests for HCV RNA'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Both qualitative and quantitative PCR assays are available. The qualitative PCR assays report results as the presence or absence of HCV RNA. These assays are considered the most sensitive tests for the diagnosis of HCV infection but reliability is limited by false positive and negative results. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Tests for HCV RNA'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Quantification of HCV RNA titers can be done with the use of quantitative reverse transcriptase PCR (RT-PCR) assays or branched-chain DNA (bDNA) assays. The quantitative RT-PCR assay is more sensitive than the bDNA assay but is labor-intensive, lacks standardization, and has wide variations in sensitivity and specificity. By comparison, the bDNA assays are automated, simpler to perform, and more reproducible. Quantitative tests for HCV RNA should not serve as an initial diagnostic tool for HCV infection, but should be reserved for pretreatment evaluation and monitoring patient response to anti-viral treatments. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Tests for HCV RNA'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Tests for antibodies to HCV (anti-HCV) are the mainstay of the clinical diagnosis of HCV infection. Enzyme linked immunosorbent assays (ELISA) and recombinant immunoblot assays (RIBA) detect non-neutralizing antibodies. ELISAs are generally used as screening tests and RIBAs are considered confirmatory tests because of their increased specificity. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41849?source=see_link\">",
"       \"Screening for and diagnosis of chronic hepatitis C virus infection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      HCV antigenemia may be detected using a monoclonal antibody to the HCV core antigen (HCVcAg). Assays for HCVcAg have shown excellent correlation with tests for HCV RNA and allow for the detection of HCV infection prior to HCV seroconversion, confirm HCV seropositive status, assess patient infectivity, depict those patients who are most likely to be viremic, and monitor the dynamics of the infection as well as the therapeutic response in individuals receiving anti-viral treatments. The HCVcAg assays detect HCV infection between 40 and 50 days earlier than the current third generation anti-HCV tests. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Tests for hepatitis C core antigen'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Some patients may be anti-HCV negative and HCV RNA positive. Possible explanations for this include lack of sensitivity of the anti-HCV test or immunosuppression. Additionally the patient may be in the \"window\" period between infection and anti-HCV seroconversion or the antibody may have disappeared despite the persistence of HCV RNA. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'The anti-HCV negative and HCV RNA positive patient'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Liver biopsy remains the",
"      <strong>",
"       only",
"      </strong>",
"      reliable method of confirming the presence and assessing the severity of liver disease in patients with HCV infection. At present, we perform a liver biopsy in patients in whom serum ALT levels are persistently elevated. Patients with normal ALT levels are biopsied only if they are being considered for transplantation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/30/15847?source=see_link\">",
"       \"Approach to patients with chronic hepatitis C virus infection and normal serum aminotransferases\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H15\">",
"       'Clinical course of HCV infection'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1048/abstract/1\">",
"      Choo QL, Kuo G, Weiner AJ, et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989; 244:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1048/abstract/2\">",
"      Kuo G, Choo QL, Alter HJ, et al. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 1989; 244:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1048/abstract/3\">",
"      Fehr T, Amb&uuml;hl PM. Chronic hepatitis virus infections in patients on renal replacement therapy. Nephrol Dial Transplant 2004; 19:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1048/abstract/4\">",
"      Houghton M, Weiner A, Han J, et al. Molecular biology of the hepatitis C viruses: implications for diagnosis, development and control of viral disease. Hepatology 1991; 14:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1048/abstract/5\">",
"      Simmonds P, Alberti A, Alter HJ, et al. A proposed system for the nomenclature of hepatitis C viral genotypes. Hepatology 1994; 19:1321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1048/abstract/6\">",
"      Fabrizi F, Poordad FF, Martin P. Diagnostic workup of hepatitis C and the patient on maintenance dialysis. Int J Artif Organs 2001; 24:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1048/abstract/7\">",
"      Farci P, Alter HJ, Wong D, et al. A long-term study of hepatitis C virus replication in non-A, non-B hepatitis. N Engl J Med 1991; 325:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1048/abstract/8\">",
"      Weiner AJ, Kuo G, Bradley DW, et al. Detection of hepatitis C viral sequences in non-A, non-B hepatitis. Lancet 1990; 335:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1048/abstract/9\">",
"      Podzorski RP. Molecular testing in the diagnosis and management of hepatitis C virus infection. Arch Pathol Lab Med 2002; 126:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1048/abstract/10\">",
"      Busch MP, Wilber JC, Johnson P, et al. Impact of specimen handling and storage on detection of hepatitis C virus RNA. Transfusion 1992; 32:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1048/abstract/11\">",
"      Grant PR, Kitchen A, Barbara JA, et al. Effects of handling and storage of blood on the stability of hepatitis C virus RNA: implications for NAT testing in transfusion practice. Vox Sang 2000; 78:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1048/abstract/12\">",
"      Lau JY, Davis GL, Orito E, et al. Significance of antibody to the host cellular gene derived epitope GOR in chronic hepatitis C virus infection. J Hepatol 1993; 17:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1048/abstract/13\">",
"      Hofg&auml;rtner WT, Kant JA, Weck KE. Hepatitis C virus quantitation: optimization of strategies for detecting low-level viremia. J Clin Microbiol 2000; 38:888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1048/abstract/14\">",
"      Kwok S, Higuchi R. Avoiding false positives with PCR. Nature 1989; 339:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1048/abstract/15\">",
"      Fabrizi F, Martin P, Quan S, et al. Serotyping strip immunoblot assay for assessing hepatitis C virus strains in dialysis patients. Am J Kidney Dis 2000; 35:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1048/abstract/16\">",
"      Saab S, Brezina M, Gitnick G, et al. Hepatitis C screening strategies in hemodialysis patients. Am J Kidney Dis 2001; 38:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1048/abstract/17\">",
"      Aach RD, Stevens CE, Hollinger FB, et al. Hepatitis C virus infection in post-transfusion hepatitis. An analysis with first- and second-generation assays. N Engl J Med 1991; 325:1325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1048/abstract/18\">",
"      Soffredini R, Rumi M, Lampertico P, et al. Increased detection of antibody to hepatitis C virus in renal transplant patients by third-generation assays. Am J Kidney Dis 1996; 28:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1048/abstract/19\">",
"      Fabrizi F, Lunghi G, Raffaele L, et al. Serologic survey for control of hepatitis C in haemodialysis patients: third-generation assays and analysis of costs. Nephrol Dial Transplant 1997; 12:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1048/abstract/20\">",
"      Busch MP, Korelitz JJ, Kleinman SH, et al. Declining value of alanine aminotransferase in screening of blood donors to prevent posttransfusion hepatitis B and C virus infection. The Retrovirus Epidemiology Donor Study. Transfusion 1995; 35:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1048/abstract/21\">",
"      KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int 2008; 73(Suppl 109):S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1048/abstract/22\">",
"      Tanaka T, Lau JY, Mizokami M, et al. Simple fluorescent enzyme immunoassay for detection and quantification of hepatitis C viremia. J Hepatol 1995; 23:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1048/abstract/23\">",
"      Tanaka E, Ohue C, Aoyagi K, et al. Evaluation of a new enzyme immunoassay for hepatitis C virus (HCV) core antigen with clinical sensitivity approximating that of genomic amplification of HCV RNA. Hepatology 2000; 32:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1048/abstract/24\">",
"      Aoyagi K, Ohue C, Iida K, et al. Development of a simple and highly sensitive enzyme immunoassay for hepatitis C virus core antigen. J Clin Microbiol 1999; 37:1802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1048/abstract/25\">",
"      Kurtz JB, Boxall E, Qusir N, et al. The diagnostic significance of an assay for 'total' hepatitis C core antigen. J Virol Methods 2001; 96:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1048/abstract/26\">",
"      Seme K, Poljak M, Babic DZ, et al. The role of core antigen detection in management of hepatitis C: a critical review. J Clin Virol 2005; 32:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1048/abstract/27\">",
"      Dentico P, Sacco R, Buongiorno R, et al. Hepatitis C virus-RNA, immunoglobulin M anti-HCV and risk factors in haemodialysis patients. Microbios 1999; 99:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1048/abstract/28\">",
"      Natov SN, Pereira BJ. Hepatitis C in dialysis patients. Adv Ren Replace Ther 1996; 3:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1048/abstract/29\">",
"      Pereira BJ, Levey AS. Hepatitis C virus infection in dialysis and renal transplantation. Kidney Int 1997; 51:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1048/abstract/30\">",
"      Gal&aacute;n F, P&eacute;rez-Gracia MT, Lozano A, et al. A 3-year follow-up of HCV-RNA viraemia in haemodialysis patients. Nephrol Dial Transplant 1998; 13:1211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1048/abstract/31\">",
"      Barril G, Castillo I, Arenas MD, et al. Occult hepatitis C virus infection among hemodialysis patients. J Am Soc Nephrol 2008; 19:2288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1048/abstract/32\">",
"      Umlauft F, Gruenewald K, Weiss G, et al. Patterns of hepatitis C viremia in patients receiving hemodialysis. Am J Gastroenterol 1997; 92:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1048/abstract/33\">",
"      Alter MJ, Margolis HS, Krawczynski K, et al. The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team. N Engl J Med 1992; 327:1899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1048/abstract/34\">",
"      al Meshari K, al Ahdal M, Alfurayh O, et al. New insights into hepatitis C virus infection of hemodialysis patients: the implications. Am J Kidney Dis 1995; 25:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1048/abstract/35\">",
"      Pereira BJ, Milford EL, Kirkman RL, et al. Prevalence of hepatitis C virus RNA in organ donors positive for hepatitis C antibody and in the recipients of their organs. N Engl J Med 1992; 327:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1048/abstract/36\">",
"      Kalantar-Zadeh K, Miller LG, Daar ES. Diagnostic discordance for hepatitis C virus infection in hemodialysis patients. Am J Kidney Dis 2005; 46:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1048/abstract/37\">",
"      Martin P, Fabrizi F. Treatment of chronic hepatitis C infection in patients with renal failure. Clin Gastroenterol Hepatol 2005; 3:S113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1048/abstract/38\">",
"      Espinosa M, Martin-Malo A, Alvarez de Lara MA, et al. Natural history of acute HCV infection in hemodialysis patients. Clin Nephrol 2002; 58:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1048/abstract/39\">",
"      Kiyosawa K, Sodeyama T, Tanaka E, et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology 1990; 12:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1048/abstract/40\">",
"      Tong MJ, el-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995; 332:1463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1048/abstract/41\">",
"      Aeder MI, Shield CF, Tegtmeier GE, et al. Incidence and clinical impact of hepatitis C virus-positive donors in cadaveric transplantation. Transplant Proc 1993; 25:1469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1048/abstract/42\">",
"      Wolf PL, Williams D, Coplon N, Coulson AS. Low aspartate transaminase activity in serum of patients undergoing chronic hemodialysis. Clin Chem 1972; 18:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1048/abstract/43\">",
"      Terrault NA, Adey DB. The kidney transplant recipient with hepatitis C infection: pre- and posttransplantation treatment. Clin J Am Soc Nephrol 2007; 2:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1048/abstract/44\">",
"      Rao KV, Anderson WR, Kasiske BL, Dahl DC. Value of liver biopsy in the evaluation and management of chronic liver disease in renal transplant recipients. Am J Med 1993; 94:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1048/abstract/45\">",
"      Meyers CM, Seeff LB, Stehman-Breen CO, Hoofnagle JH. Hepatitis C and renal disease: an update. Am J Kidney Dis 2003; 42:631.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1871 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-61.234.146.186-8377BC303A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_1_1048=[""].join("\n");
var outline_f1_1_1048=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1441974061\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      STRUCTURE OF HCV GENOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TESTS FOR HCV RNA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Qualitative polymerase chain reaction assay",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - False negatives",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - False positives",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Quantitative assays for HCV RNA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Tests for genotypes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      TESTS FOR ANTIBODY TO HCV",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      TESTS FOR HEPATITIS C CORE ANTIGEN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DIFFICULTIES IN INTERPRETING HCV TESTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      The anti-HCV positive and HCV RNA negative patient",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      The anti-HCV negative and HCV RNA positive patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      KDIGO GUIDELINES FOR HCV TESTING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      CLINICAL COURSE OF HCV INFECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Relationship among serum ALT, HCV infection, and liver disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Liver biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1441974061\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/30/15847?source=related_link\">",
"      Approach to patients with chronic hepatitis C virus infection and normal serum aminotransferases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/5/29780?source=related_link\">",
"      Characteristics of the hepatitis C virus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/38/25194?source=related_link\">",
"      Epidemiology and etiologic associations of hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31289?source=related_link\">",
"      Hepatitis C virus infection and renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/24/31114?source=related_link\">",
"      Hepatitis C virus infection in patients on maintenance dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41849?source=related_link\">",
"      Screening for and diagnosis of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_1_1049="Prevention of pressure ulcers";
var content_f1_1_1049=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Prevention of pressure ulcers",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/1/1049/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/1/1049/contributors\">",
"     Dan Berlowitz, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/1/1049/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/1/1049/contributors\">",
"     Kenneth E Schmader, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/1/1049/contributors\">",
"     Hilary Sanfey, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/1/1049/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/1/1049/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/1/1049/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 1, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pressure ulcers are a significant problem in elderly and critically ill patients, causing pain, decreasing quality of life, and leading to significant morbidity and prolonged hospital stays. Pressure ulcers are among the most common conditions encountered in hospitalized patients or those requiring long-term institutional care. Critically ill patients admitted to intensive care units are at particularly high risk of developing pressure ulcers [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1049/abstract/1\">",
"     1",
"    </a>",
"    ]. Ulcer prevention and treatment are cost-effective approaches to improving health status [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1049/abstract/2-6\">",
"     2-6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As of October 2008, new Center for Medicare and Medicaid Services (CMS) guidelines in the United States state that hospitals will no longer receive additional payments when patients develop stage 3 or 4 pressure ulcers (",
"    <a class=\"graphic graphic_table graphicRef62903 \" href=\"UTD.htm?20/62/21483\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1049/abstract/7\">",
"     7",
"    </a>",
"    ]. In addition, failure to provide appropriate pressure ulcer care may expose providers to significant liability [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1049/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Knowledge of factors contributing to the pathogenesis of pressure ulcers allows the identification of patients at risk for ulcer development. Preventive measures may then be targeted to those specific patients.",
"   </p>",
"   <p>",
"    The prevention of pressure ulcers will be reviewed here. The treatment, epidemiology, pathogenesis, clinical manifestations, and staging are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/20/34120?source=see_link\">",
"     \"Pressure ulcers: Epidemiology, pathogenesis, clinical manifestations, and staging\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/12/37064?source=see_link\">",
"     \"Treatment of pressure ulcers\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RISK IDENTIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Identifying patients at risk, to target appropriate interventions, is central to preventing pressure ulcers. A comprehensive history and physical examination can identify potentially correctable predisposing factors. Specific interventions may then be initiated depending upon the measured level of risk [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1049/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pressure ulcer prevention is an ongoing task; regular follow-up is required to identify changes in clinical status, and daily skin inspections should be performed to detect early evidence of pressure-induced skin damage and alter the care plan as needed [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1049/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two general approaches have been used when developing prediction rules that allow the identification of patients at high risk for pressure ulcers. The first approach involves use of clinical judgment to determine patient characteristics and their relative importance. More recently, empirical studies combined with multivariate statistical techniques have been employed.",
"   </p>",
"   <p>",
"    Assessment of risk for pressure ulcer development is not a one-time activity. Patients should be reassessed periodically, particularly when there is a change in health status.",
"   </p>",
"   <p>",
"    Once at-risk individuals are identified, preventive measures should be implemented that address each risk factor. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Pressure relief'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H11\">",
"     'Supportive interventions'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Risk prediction tools and guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guidelines from the Agency for Healthcare Research and Quality (AHRQ) in the United States have strongly prompted the use of prediction tools to identify at-risk individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1049/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. While these guidelines are longstanding, their recommendations are still considered relevant to pressure ulcer prevention [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1049/abstract/12\">",
"     12",
"    </a>",
"    ]. The National Pressure Ulcer Advisory Panel and European Pressure Ulcer Advisory Panel (EPUAP) have also published similar guidelines for the prevention of pressure ulcers.",
"   </p>",
"   <p>",
"    The AHRQ Publications Clearinghouse, and the NPUAP and EPUAP guidelines are available on the internet [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1049/abstract/13-15\">",
"     13-15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Norton and Braden scales",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most commonly used prediction tools are the Norton and Braden scales (",
"    <a class=\"graphic graphic_table graphicRef68532 \" href=\"UTD.htm?10/60/11214\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef59158 \" href=\"UTD.htm?1/25/1436\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Norton scale uses a 1 to 4 scoring system in rating patients in each of five subscales: physical condition; mental condition; activity; mobility; and incontinence (",
"      <a class=\"graphic graphic_table graphicRef59158 \" href=\"UTD.htm?1/25/1436\">",
"       table 3",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?1/1/1049/abstract/16\">",
"       16",
"      </a>",
"      ]. A score less than 14 indicates a high risk of pressure ulcer development.",
"     </li>",
"     <li>",
"      The Braden scale rates patients in six subscales: sensory perception; moisture; activity; mobility; nutrition; and friction and shear using scores ranging from 1 to 3 or 4 (",
"      <a class=\"graphic graphic_table graphicRef68532 \" href=\"UTD.htm?10/60/11214\">",
"       table 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?1/1/1049/abstract/17\">",
"       17",
"      </a>",
"      ]. The maximal total score is 23; a score of 18 or less indicates high risk (",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?39/36/40513?source=see_link\">",
"       calculator 1",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The Norton scale generally identifies more patients at high risk than the Braden scale [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1049/abstract/18\">",
"     18",
"    </a>",
"    ]. The performance of these scales has been evaluated in a variety of settings; sensitivity typically ranges from 70 to 90 percent and specificity from 60 to 80 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1049/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A limitation of these systems is that interrater reliability is low unless performed by trained staff [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1049/abstract/17\">",
"     17",
"    </a>",
"    ]. In addition, it is unclear whether they perform better than clinical judgment of risk [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1049/abstract/18,20,21\">",
"     18,20,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nevertheless, both the Norton and Braden scales have withstood the test of time and have been shown to be useful in clinical practice to predict patients at risk of pressure ulcer development. While these scales have been validated [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1049/abstract/22\">",
"     22",
"    </a>",
"    ], concerns about their positive predictive value have been raised [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1049/abstract/21,23\">",
"     21,23",
"    </a>",
"    ]. Two studies have used empirical data to validate the Norton scale and found that the activity and mobility subscales are sufficient to express the risk for pressure ulcers among hospitalized patients [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1049/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. Inclusion of the physical condition, mental condition, and incontinence subscales resulted in worse performance in identifying patients at risk for pressure ulcer compared with activity and mobility alone in the larger of these two studies, which included over 2000 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1049/abstract/23\">",
"     23",
"    </a>",
"    ]. Similar analyses evaluating subscales of the Braden scale have not been performed, and verification of the other scales in prospective trials is needed.",
"   </p>",
"   <p>",
"    In addition, despite the widespread use of risk assessment tools, there are no randomized trials that evaluate their effect on pressure ulcer incidence [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1049/abstract/25\">",
"     25",
"    </a>",
"    ]. Risk assessment tools are best used as an adjunct to clinical judgment [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1049/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Empirical studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first empirical study that attempted to identify factors that could be used for predicting the risk of pressure ulcer development identified three predictors among bed- and chair-bound hospital patients: low serum albumin; fecal incontinence; and a recent fracture [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1049/abstract/27\">",
"     27",
"    </a>",
"    ]. However, factors associated with the presence of a pressure ulcer do not necessarily predict their development. Thus, subsequent studies used a prospective design.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study at a chronic care hospital, three risk factors among 301 admissions were identified: being bed or chair-bound, a history of a cerebrovascular accident, and impaired nutritional intake [",
"      <a class=\"abstract\" href=\"UTD.htm?1/1/1049/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a prospective report of hospitalized patients (n = 286) with activity limitations, the presence of a stage 1 ulcer, lymphopenia, immobility, dry sacral skin, and decreased body weight were each associated with the development of a stage 2 or larger pressure ulcer [",
"      <a class=\"abstract\" href=\"UTD.htm?1/1/1049/abstract/29\">",
"       29",
"      </a>",
"      ]. When three or more of these factors were present, over 13 percent of patients developed an ulcer.",
"     </li>",
"     <li>",
"      In a large (n = 1192) multicenter prospective study designed to compare products for ulcer prevention in hospitalized patients, the following factors were associated with increased risk for ulcer development: admission for an acute condition, medical rather than vascular or orthopedic admission, nonblanching erythema or skin trauma at baseline, older age, low hemoglobin level, and diabetes [",
"      <a class=\"abstract\" href=\"UTD.htm?1/1/1049/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study of 3233 patients, independent risk factors for the development of pressure ulcers in the first two days following admission included older age, male gender, dry skin over a bony prominence, incontinence, difficulty turning in bed, residing in a nursing home, prior hospitalization in the past six months, and poor nutritional status [",
"      <a class=\"abstract\" href=\"UTD.htm?1/1/1049/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Databases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Large databases have also been used to derive prediction rules. One study, for example, used a database with over 30,000 long-term care patients to identify eleven characteristics associated with pressure ulcer development [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1049/abstract/32\">",
"     32",
"    </a>",
"    ]. The Minimum Data Set has been used to develop a predictive model for nursing homes that considers 17 patient characteristics [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1049/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. An expected probability of ulcer development can then be calculated for each patient. It remains to be established whether this methodology will be clinically useful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PRESSURE RELIEF",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pressure relief is the most important factor in preventing pressure ulcers and may be accomplished in two ways: proper patient positioning and appropriate use of pressure-reducing devices and surfaces.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Patient positioning",
"    </span>",
"    &nbsp;&mdash;&nbsp;Proper positioning of bed-bound individuals is recommended, including a regular turning and repositioning schedule, with particular attention to vulnerable tissue covering bony prominences such as the sacrum [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1049/abstract/35\">",
"     35",
"    </a>",
"    ]. Typically, a two-hour interval is recommended although this is based upon expert opinion in the absence of randomized trials [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1049/abstract/35-39\">",
"     35-39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A randomized controlled trial of repositioning, conducted in 16 elder care nursing homes, compared repositioning with alternating time intervals (two hours in a lateral position and four hours supine) with repositioning every four hours [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1049/abstract/36\">",
"     36",
"    </a>",
"    ]. There was no statistically significant difference in ulcer incidence, severity, or location between the two groups.",
"   </p>",
"   <p>",
"    Despite the paucity of randomized controlled trials, it has been demonstrated that skin erythema can occur in healthy adults in less than two hours on a standard mattress [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1049/abstract/40\">",
"     40",
"    </a>",
"    ]. Skin and soft tissues with borderline perfusion at baseline will often develop irreversible changes even with shorter intervals of pressure.",
"   </p>",
"   <p>",
"    Prevention of progression of a stage 1 pressure ulcer may require more frequent repositioning [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1049/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Turning should be performed successively from the back, to one side, and then to the other side. The aim of repositioning is to reduce interface pressure and maintain microcirculation to areas at risk for pressure ulcers [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1049/abstract/35\">",
"     35",
"    </a>",
"    ]. It is important that repositioning be done gently and properly, with the assist of devices as necessary to avoid friction and shear forces. Timing and positioning should be documented [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1049/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to regular turning, the position of bed-bound patients is likely to be important. It is recommended that:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients should be placed at a 30 degree angle when lying on their side to avoid direct pressure over the greater trochanter or other bony prominences.",
"     </li>",
"     <li>",
"      Pillows or foam wedges should be placed between the ankles and knees to avoid pressure at these sites when patients have no mobility at these areas.",
"     </li>",
"     <li>",
"      The heels require particular attention; pillows may be placed under the lower legs to elevate the heels, or special heel protectors can be used.",
"     </li>",
"     <li>",
"      The head of the bed should not be elevated more that 30 degrees to prevent sliding and friction injury.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Chair-bound patients may generate considerable pressures over the ischial tuberosities; they should be repositioned at least every hour with wheelchair pushups or with tilting of the seat to reduce contact between the patient's buttocks and the seat [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1049/abstract/42\">",
"     42",
"    </a>",
"    ]. Patients who are cognitively intact and are able to use their upper extremities can be trained to shift weight even more frequently, using monitoring devices as a reminder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Continuous rotation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Continuous lateral rotation was originally developed to enhance respiratory function in hospitalized patients, but has been advocated for the prevention and management of pressure ulcers. Continuous lateral rotation is achieved with a mechanized bed that continuously rotates around its longitudinal axis. Observational studies indicate modest improvements in healing rates when continuous lateral rotation is added to an advanced therapy surface [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1049/abstract/43\">",
"     43",
"    </a>",
"    ]. Conceptually, the advantage gained by this automated approach to pressure reduction could be offset by the presence of continuous shearing forces. Technical parameters such as bed rotation frequency and bed tilt angle need to be better defined. Continuous rotation therapy is not likely to replace the need to reposition the patient every two hours, but clearly further study is warranted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Support surfaces",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many pressure-reducing support surfaces and products are available [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1049/abstract/44\">",
"     44",
"    </a>",
"    ]. These products are classified as non-powered, overlays, or powered as defined by the National Pressure Ulcer Advisory Panel Support Surface Standards Initiative (",
"    <a class=\"graphic graphic_table graphicRef61798 \" href=\"UTD.htm?23/23/23932\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1049/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Non-powered (static) support surfaces do not require electricity and consist of mattresses that are made of gel, foam, air, or water, or a combination of these. They work by distributing local pressure over a wider body surface area.",
"     </li>",
"     <li>",
"      Overlays are support surfaces designed to be placed on top of another surface. Foam, air, or water overlays may be used for patients who are able to assume a variety of positions without bearing weight on the ulcer.",
"     </li>",
"     <li>",
"      Powered or dynamic support surfaces use electricity to generate currents that redistribute pressure against the body. Examples include alternating pressure mattresses, low air loss beds, and air-fluidized mattresses.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The selection of device for pressure ulcer prevention is balanced by a variety of considerations including the risk of ulcer development, ease of use, other patient characteristics, and cost (special beds may cost up to several hundred dollars per day to rent) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1049/abstract/46\">",
"     46",
"    </a>",
"    ]. Inexpensive static devices or overlays are acceptable in most situations, whereas dynamic support surfaces may be more appropriate in patients who are at high risk. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Risk identification'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    There is reasonably good evidence to suggest that mattress overlays on operating tables and hospital beds reduce the incidence of pressure ulcers compared with no overlay [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1049/abstract/26,35,47,48\">",
"     26,35,47,48",
"    </a>",
"    ]. In the operating room, the use of a micro-pulse overlay system reduced the incidence of pressure ulcers by 80 percent in a metaanalysis of two trials (relative risk 0.21, 95% CI 0.06, 0.70) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1049/abstract/48\">",
"     48",
"    </a>",
"    ]. Australian Medical Sheepskin, when placed over a mattress, is also beneficial in preventing pressure ulcers [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1049/abstract/48,49\">",
"     48,49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is less clear how different classes of support surfaces, or different products within a class of support surfaces compare. Systematic reviews and metaanalyses of randomized trials have not consistently demonstrated superiority of one product class over another [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1049/abstract/35,48\">",
"     35,48",
"    </a>",
"    ]. Standard mattresses without an overlay should probably not be used, but alternative foam mattresses may provide a singular solution. A metaanalysis of five trials found a significantly reduced incidence of pressure ulcers in patients using alternative foam mattresses (risk ratio 0.40 95% CI 0.21, 0.74) compared with standard foam mattresses [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1049/abstract/48\">",
"     48",
"    </a>",
"    ]. Unfortunately, there are no trials comparing standard mattresses plus overlay with alternative foam mattresses.",
"   </p>",
"   <p>",
"    Trials comparing static surfaces and overlays with dynamic surfaces are inconsistent, with some but not all trials demonstrating better outcomes for the more expensive dynamic devices [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1049/abstract/35,50\">",
"     35,50",
"    </a>",
"    ]. One particularly well-designed trial involving 1972 patients (PRESSURE trial) compared two dynamic devices, alternating pressure mattresses and alternating pressure overlays, and found no differences in the number of ulcers, or the median time for development of pressure ulcers; patient satisfaction was higher for the mattress [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1049/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Dynamic support devices in high-risk patients may be cost effective. A trial that randomly assigned 100 intensive care unit patients to an air-suspension bed or standard bed, found a significantly lower risk of developing a pressure ulcer in those using the air-suspension bed (odds ratio 0.18, 95% CI 0.08-0.41 ) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1049/abstract/2\">",
"     2",
"    </a>",
"    ]. The cost of dynamic support surfaces may be offset by reduced length of hospitalization related to pressure ulcers, and ulcer care that includes nursing time and wound care supplies, and possibly surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1049/abstract/51\">",
"     51",
"    </a>",
"    ]. One study of air suspension beds in an intensive care unit found that this intervention resulted in a cost savings of over $700 per patient [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1049/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For chair-bound patients, full-seat wheelchair cushions are recommended. Donut cushions should",
"    <strong>",
"     not",
"    </strong>",
"    be used because they increase edema and venous congestion and concentrate the pressure to surrounding tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1049/abstract/10\">",
"     10",
"    </a>",
"    ]. Selection of customized chair cushions requires the services of a qualified seating specialist. The three main types of seat cushions include gel and foam seat cushions, non-powered adjustable cushions and powered adjustable seat cushions. Adjustable seat cushions contain a honeycomb of air cells that are first fully inflated, placed under the patient and then partially deflated via a release valve to better conform to the patient's body; the patient essentially floats on a cushion of air while sitting in the chair. Powered seat cushions include a motorized blower to circulate the air within the cushion.",
"   </p>",
"   <p>",
"    In a study of 232 wheelchair-bound nursing home residents, significantly fewer pressure ulcers developed in those randomly assigned to use a skin protection cushion (air, viscous fluid and foam, or gel and foam cushion) (10.6 versus 17.6 percent) compared with a standard segmented foam cushion [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1049/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUPPORTIVE INTERVENTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to positioning and pressure support devices, other interventions to prevent pressure ulcers may be helpful, and are indicated on the basis of individual patient assessment. There is minimal evidence from randomized trials to support many of these interventions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Minimize immobility",
"    </span>",
"    &nbsp;&mdash;&nbsp;Encouraging patient mobility is key to the prevention of pressure ulcers. Several approaches may be helpful to minimize immobility, including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Immobilized patients may benefit from physical therapy.",
"     </li>",
"     <li>",
"      Severe spasticity may be relieved with muscle relaxant drugs or a nerve block. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/48/37642?source=see_link\">",
"       \"Chronic complications of spinal cord injury\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Medications contributing to immobility, such as sedatives, should be stopped.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Manage incontinence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Excess moisture can promote breakdown of the skin, and it is necessary to protect patients who are incontinent from being exposed to urine or feces. Both urine and feces can irritate the skin and make it more susceptible to breakdown [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1049/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Practices for managing urinary incontinence have been described in a Clinical Practice Guideline from the AHRQ and are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/4/32842?source=see_link\">",
"     \"Treatment of urinary incontinence\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In general, underpads or adult briefs, combined with consistent skin cleansing are adequate for managing incontinence. The tabs can be left open at the sides of the incontinence briefs to allow air circulation. An alternative method is to place absorptive pads under the patient without a diaper so that any incontinence episode can be readily detected and addressed. An indwelling or condom catheter is sometimes needed when treating an ulcer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Nutrition assessment and support",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nutritional goals should address any documented nutritional compromise. Formal nutritional assessment should be carried out and a plan of support instituted to address any deficiencies. If dietary intake of protein or calories is inadequate, the factors compromising intake should be addressed as part of total patient care. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/32/13831?source=see_link\">",
"     \"Nutrition support in critically ill patients: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is generally felt that adequate nutrition may both prevent ulcer formation and promote healing of early stage ulcers [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1049/abstract/10,41\">",
"     10,41",
"    </a>",
"    ]. Unless there is a contraindication, individuals at risk of developing pressure ulcers should have a protein intake of approximately 1.2 to 1.5",
"    <span class=\"nowrap\">",
"     gm/kg",
"    </span>",
"    body weight daily [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1049/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies evaluating nutritional supplements or enteral feeding have demonstrated mixed results on rates of pressure ulcer development [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1049/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. The effectiveness of specific nutritional interventions, such as tube feedings or dietary supplements, will depend on the baseline nutritional status of participants [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1049/abstract/10,55\">",
"     10,55",
"    </a>",
"    ]. One study in critically ill elderly patients did find that patients who were given a standard diet, compared to oral nutritional supplementation plus standard diet, had an increased risk for developing pressure ulcers, although questions have been raised about methodological aspects of this study [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1049/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Skin care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skin condition should be inspected and documented daily.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Skin assessment should include skin temperature, color, turgor, moisture status, and integrity [",
"      <a class=\"abstract\" href=\"UTD.htm?1/1/1049/abstract/57\">",
"       57",
"      </a>",
"      ]. Any changes should be recorded as soon as they are observed [",
"      <a class=\"abstract\" href=\"UTD.htm?1/1/1049/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Keeping the skin clean and dry, while avoiding excess dryness and scaling is the primary goal.",
"     </li>",
"     <li>",
"      Skin cleansing should be done with mild cleansing agents that minimize irritation.",
"     </li>",
"     <li>",
"      Hot water should be avoided.",
"     </li>",
"     <li>",
"      Vigorous massage over bony prominences should be avoided.",
"     </li>",
"     <li>",
"      Cleansings should be done at regular intervals to minimize exposure to excess moisture due to incontinence, perspiration, or wound drainage [",
"      <a class=\"abstract\" href=\"UTD.htm?1/1/1049/abstract/11,26\">",
"       11,26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Dry sacral skin is a risk factor for the development of pressure ulcers [",
"      <a class=\"abstract\" href=\"UTD.htm?1/1/1049/abstract/29\">",
"       29",
"      </a>",
"      ]. Lotions containing fatty acids may protect against friction and pressure as well as reduce hyperproliferative skin growth [",
"      <a class=\"abstract\" href=\"UTD.htm?1/1/1049/abstract/58\">",
"       58",
"      </a>",
"      ]. One study of 331 patients comparing hyperoxygenated fatty acid compound versus placebo in acute care and long-term care patients found that the fatty acid preparation significantly reduced the incidence of ulcers (7.3 percent in the intervention group versus 17.3 percent in the placebo group) [",
"      <a class=\"abstract\" href=\"UTD.htm?1/1/1049/abstract/58\">",
"       58",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Education and quality initiatives",
"    </span>",
"    &nbsp;&mdash;&nbsp;Education of clinical staff, patients, and families is important in pressure ulcer prevention, and should include information regarding the causes of pressure ulcers and how they may be prevented. In one study of hospitalized patients, the incidence of new pressure sores decreased from 15 to 5 percent after introduction of a staff educational program [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1049/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    No single individual involved in patient care is able to prevent pressure ulcers. Rather, the coordinated effort of multiple disciplines is critical for pressure ulcer prevention. Several team-related interventions may be helpful:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One member of the nursing unit should be designated as a skin care resource, and additional expertise should be readily available through consultations.",
"     </li>",
"     <li>",
"      Barriers to obtaining necessary supplies such as special mattresses and overlays should be minimized.",
"     </li>",
"     <li>",
"      Prompting methods for turning patients at regular intervals should be instituted.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A toolkit that helps organize preventive efforts has been disseminated by the Agency for Healthcare Research and Quality (AHRQ) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1049/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     EFFICACY OF PREVENTION EFFORTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Implementation of preventive practices can decrease the rate of pressure ulcer development. It is uncertain, however, whether all pressure ulcers are avoidable even when best practices are implemented, or whether some patients may be at such a high risk that pressure ulcer development is unavoidable. One survey of pressure ulcer experts indicated that 62 percent disagreed with the statement \"all pressure ulcers are preventable\" [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1049/abstract/61\">",
"     61",
"    </a>",
"    ]. Ulcers are likely to be unavoidable among patients with poor skin perfusion (eg, peripheral artery disease, hypotension, terminal care) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1049/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sufficient staffing levels are necessary for effective pressure ulcer prevention and it is easy to understand why some failures will inevitably occur given that a single bed-bound patient must be repositioned over 4000 times per year [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1049/abstract/63\">",
"     63",
"    </a>",
"    ]. Adequate staffing and the availability of resources in nursing facilities may depend upon the business model (for-profit versus not-for-profit) of the facility. A systematic review and meta-analysis of randomized trials and observational studies found a significantly lower risk of developing a pressure ulcer (odds ratio 0.91, 95% CI 0.83-0.98) for not-for-profit facilities compared with for-profit facilities [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1049/abstract/64\">",
"     64",
"    </a>",
"    ]. The results were consistent with two other analyses [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1049/abstract/65,66\">",
"     65,66",
"    </a>",
"    ]. For-profit facilities have strong incentives to minimize expenditures and, although the average effect supported not-for-profit facilities, the authors noted variability in the quality of nursing home care due to a variety of factors including managerial styles, business motivations, and organizational behavior. In an observational study of 12,473 certified nursing facilities in the United States evaluating over 2 million residents, the quality of nursing care was the primary factor contributing to an increased prevalence of pressure ulcers at facilities with a high concentration of minority patients (mostly black) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1049/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies evaluating the implementation of educational programs and continuous quality improvement (QI) practices in nursing homes have shown a reduction in the rate of pressure ulcers, although such efforts need ongoing maintenance to sustain results [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1049/abstract/68-73\">",
"     68-73",
"    </a>",
"    ]. Failures are less common when effective systems for staff education are in place [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1049/abstract/68\">",
"     68",
"    </a>",
"    ]. When an ulcer does occur, problems contributing to its development should be identified and methods for solving these problems implemented.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H186016118\">",
"    <span class=\"h1\">",
"     COST EFFECTIVENESS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cost effectiveness of preventive strategies has received a limited amount of attention. Based upon cost modeling, several studies have found the use of pressure redistribution surfaces to be cost-effective or even cost-saving.",
"   </p>",
"   <p>",
"    One study simulated admissions to an acute care hospital and compared enhanced prevention practices versus standard care [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1049/abstract/3\">",
"     3",
"    </a>",
"    ]. Preventive measures resulted in greater quality-adjusted life-years (QALY) and saved money. This conclusion mirrors results from a randomized clinical trial of specialized beds in an intensive care unit which found fewer pressure ulcers and lower costs associated with preventive intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1049/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The cost-effectiveness of using support surfaces on emergency department (ED) stretchers and beds as an early measure to prevent pressure ulcers in elderly patients admitted through the ED was also studied [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1049/abstract/4\">",
"     4",
"    </a>",
"    ]. The model projected an incidence of emergency department-acquired pressure ulcers of 1.9 percent with current practice and 1.5 percent with early preventive strategies, which corresponded to a number needed-to-treat of 238 patients. Early prevention of pressure ulcers was found to be more effective and less costly than standard practice even for short emergency department stays (ie, one hour), with a mean cost-saving of $32 per patient.",
"   </p>",
"   <p>",
"    Another study modelled the cost-effectiveness of viscoelastic overlays in patients requiring surgical procedures lasting longer than 90 minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1049/abstract/5\">",
"     5",
"    </a>",
"    ]. An intraoperative prevention strategy that decreased the incidence of pressure ulcers by 0.51 percent corresponded to a number-needed-to-treat of 196 patients. The average cost of using the operating table overlay was calculated to be $1.66 per patient. For the projected decrease in the incidence of pressure ulcers, the cost savings averaged $46 per patient.",
"   </p>",
"   <p>",
"    An evaluation of preventive strategies used in long-term nursing home care also found that support surfaces are cost effective [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1049/abstract/6\">",
"     6",
"    </a>",
"    ]. Multiple strategies were evaluated including pressure redistribution surfaces, oral nutritional supplements for high-risk residents with recent weight loss, skin emollients for high-risk residents with dry skin, and skin cleansing for high-risk residents requiring incontinence care. Preventive strategies cost, on average, $11.66 per resident per week. The lifetime risk of developing a pressure ulcer was reduced with the use of preventive strategies and the number needed-to-treat was calculated to be 45 for pressure redistribution surfaces, 63 for skin cleansing, 158 for skin emollients, and 333 for nutritional supplementation. Pressure redistribution surfaces and skin cleansing reduced the mean lifetime cost by $115 and $179 per resident, respectively. The cost per Quality Adjusted Life Year (QALY) gained was less than $50,000 for support surfaces and skin cleansing but exceeded $50,000 for nutritional supplements and skin emollients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?38/53/39761?source=see_link\">",
"       \"Patient information: Pressure sores (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pressure ulcers are among the most common conditions encountered in hospitalized patients or those requiring long-term institutional care. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest using risk prediction tools to identify patients at risk for the development of pressure ulcers (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Risk prediction tools and guidelines'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pressure relief is the most important factor in preventing pressure ulcers. We suggest that bed-bound patients be repositioned at least every two hours to relieve tissue pressure (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Proper positioning and turning techniques should be used to minimize friction and shear forces. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Patient positioning'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend the use of pressure-reducing products for patients at increased risk (identified by clinical assessment or risk scales) for developing pressure ulcers (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). The choice of product, including overlays, foam, gel supports, or dynamic devices, will depend upon patient risk factors and the availability of resources. Dynamic supports, such as air fluidized beds, may be cost-effective in high-risk patients. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Support surfaces'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other measures that may be helpful for pressure ulcer prevention in selected patients include limiting immobility (with physical therapy and decreased use of sedatives), nutritional supplementation, and meticulous skin care. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Supportive interventions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Education of clinical staff, patients, and families along with a team staff approach and supporting policies are essential to reduce the development of pressure sores. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Education and quality initiatives'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1049/abstract/1\">",
"      de Laat EH, Pickkers P, Schoonhoven L, et al. Guideline implementation results in a decrease of pressure ulcer incidence in critically ill patients. Crit Care Med 2007; 35:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1049/abstract/2\">",
"      Inman KJ, Sibbald WJ, Rutledge FS, Clark BJ. Clinical utility and cost-effectiveness of an air suspension bed in the prevention of pressure ulcers. JAMA 1993; 269:1139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1049/abstract/3\">",
"      Padula WV, Mishra MK, Makic MB, Sullivan PW. Improving the quality of pressure ulcer care with prevention: a cost-effectiveness analysis. Med Care 2011; 49:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1049/abstract/4\">",
"      Pham B, Teague L, Mahoney J, et al. Early prevention of pressure ulcers among elderly patients admitted through emergency departments: a cost-effectiveness analysis. Ann Emerg Med 2011; 58:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1049/abstract/5\">",
"      Pham B, Teague L, Mahoney J, et al. Support surfaces for intraoperative prevention of pressure ulcers in patients undergoing surgery: a cost-effectiveness analysis. Surgery 2011; 150:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1049/abstract/6\">",
"      Pham B, Stern A, Chen W, et al. Preventing pressure ulcers in long-term care: a cost-effectiveness analysis. Arch Intern Med 2011; 171:1839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1049/abstract/7\">",
"      Pronovost PJ, Goeschel CA, Wachter RM. The wisdom and justice of not paying for \"preventable complications\". JAMA 2008; 299:2197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1049/abstract/8\">",
"      Soloway DN. Civil claims relating to pressure ulcers: a claimants' lawyer's perspective. Ostomy Wound Manage 1998; 44:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1049/abstract/9\">",
"      Bennett RG, O'Sullivan J, DeVito EM, Remsburg R. The increasing medical malpractice risk related to pressure ulcers in the United States. J Am Geriatr Soc 2000; 48:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1049/abstract/10\">",
"      Stechmiller JK, Cowan L, Whitney JD, et al. Guidelines for the prevention of pressure ulcers. Wound Repair Regen 2008; 16:151.",
"     </a>",
"    </li>",
"    <li>",
"     Pressure ulcers in adults: Prediction and prevention. Clinical Practice Guideline Number 3, AHCPR Publication no. 92-0047, May 1992.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1049/abstract/12\">",
"      Shekelle PG, Ortiz E, Rhodes S, et al. Validity of the Agency for Healthcare Research and Quality clinical practice guidelines: how quickly do guidelines become outdated? JAMA 2001; 286:1461.",
"     </a>",
"    </li>",
"    <li>",
"     file://ahrq.gov (Accessed on August 25, 2011).",
"    </li>",
"    <li>",
"     file://npuap.org/ (Accessed on August 25, 2011).",
"    </li>",
"    <li>",
"     file://epuap.org.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1049/abstract/16\">",
"      Pressure ulcers prevalence, cost and risk assessment: consensus development conference statement--The National Pressure Ulcer Advisory Panel. Decubitus 1989; 2:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1049/abstract/17\">",
"      Bergstrom N, Braden BJ, Laguzza A, Holman V. The Braden Scale for Predicting Pressure Sore Risk. Nurs Res 1987; 36:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1049/abstract/18\">",
"      Xakellis GC, Frantz RA, Arteaga M, et al. A comparison of patient risk for pressure ulcer development with nursing use of preventive interventions. J Am Geriatr Soc 1992; 40:1250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1049/abstract/19\">",
"      Smith DM, Winsemius DK, Besdine RW. Pressure sores in the elderly: can this outcome be improved? J Gen Intern Med 1991; 6:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1049/abstract/20\">",
"      Salvadalena GD, Snyder ML, Brogdon KE. Clinical trial of the Braden Scale on an acute care medical unit. J ET Nurs 1992; 19:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1049/abstract/21\">",
"      Schoonhoven L, Haalboom JR, Bousema MT, et al. Prospective cohort study of routine use of risk assessment scales for prediction of pressure ulcers. BMJ 2002; 325:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1049/abstract/22\">",
"      Bergstrom N, Demuth PJ, Braden BJ. A clinical trial of the Braden Scale for Predicting Pressure Sore Risk. Nurs Clin North Am 1987; 22:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1049/abstract/23\">",
"      Perneger TV, Gaspoz JM, Ra&euml; AC, et al. Contribution of individual items to the performance of the Norton pressure ulcer prediction scale. J Am Geriatr Soc 1998; 46:1282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1049/abstract/24\">",
"      Goldstone LA, Roberts BV. A preliminary discriminant function analysis of elderly orthopaedic patients who will or will not contract a pressure sore. Int J Nurs Stud 1980; 17:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1049/abstract/25\">",
"      Moore ZE, Cowman S. Risk assessment tools for the prevention of pressure ulcers. Cochrane Database Syst Rev 2008; :CD006471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1049/abstract/26\">",
"      European Pressure Ulcer Advisory Panel (EPUAP). Guidelines on treatment of pressure ulcers. EPUAP Review 1999; 1:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1049/abstract/27\">",
"      Allman RM, Laprade CA, Noel LB, et al. Pressure sores among hospitalized patients. Ann Intern Med 1986; 105:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1049/abstract/28\">",
"      Berlowitz DR, Wilking SV. Risk factors for pressure sores. A comparison of cross-sectional and cohort-derived data. J Am Geriatr Soc 1989; 37:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1049/abstract/29\">",
"      Allman RM, Goode PS, Patrick MM, et al. Pressure ulcer risk factors among hospitalized patients with activity limitation. JAMA 1995; 273:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1049/abstract/30\">",
"      Nixon J, Cranny G, Iglesias C, et al. Randomised, controlled trial of alternating pressure mattresses compared with alternating pressure overlays for the prevention of pressure ulcers: PRESSURE (pressure relieving support surfaces) trial. BMJ 2006; 332:1413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1049/abstract/31\">",
"      Baumgarten M, Margolis DJ, Localio AR, et al. Pressure ulcers among elderly patients early in the hospital stay. J Gerontol A Biol Sci Med Sci 2006; 61:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1049/abstract/32\">",
"      Berlowitz DR, Ash AS, Brandeis GH, et al. Rating long-term care facilities on pressure ulcer development: importance of case-mix adjustment. Ann Intern Med 1996; 124:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1049/abstract/33\">",
"      Berlowitz DR, Brandeis GH, Morris JN, et al. Deriving a risk-adjustment model for pressure ulcer development using the Minimum Data Set. J Am Geriatr Soc 2001; 49:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1049/abstract/34\">",
"      Berlowitz DR, Brandeis GH, Anderson JJ, et al. Evaluation of a risk-adjustment model for pressure ulcer development using the Minimum Data Set. J Am Geriatr Soc 2001; 49:872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1049/abstract/35\">",
"      Reddy M, Gill SS, Rochon PA. Preventing pressure ulcers: a systematic review. JAMA 2006; 296:974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1049/abstract/36\">",
"      Vanderwee K, Grypdonck MH, De Bacquer D, Defloor T. Effectiveness of turning with unequal time intervals on the incidence of pressure ulcer lesions. J Adv Nurs 2007; 57:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1049/abstract/37\">",
"      Defloor T, De Bacquer D, Grypdonck MH. The effect of various combinations of turning and pressure reducing devices on the incidence of pressure ulcers. Int J Nurs Stud 2005; 42:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1049/abstract/38\">",
"      Young T. The 30 degree tilt position vs the 90 degree lateral and supine positions in reducing the incidence of non-blanching erythema in a hospital inpatient population: a randomised controlled trial. J Tissue Viability 2004; 14:88, 90, 92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1049/abstract/39\">",
"      Moore ZE, Cowman S. Repositioning for treating pressure ulcers. Cochrane Database Syst Rev 2009; :CD006898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1049/abstract/40\">",
"      Knox DM, Anderson TM, Anderson PS. Effects of different turn intervals on skin of healthy older adults. Adv Wound Care 1994; 7:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1049/abstract/41\">",
"      Thomas DR. The new F-tag 314: prevention and management of pressure ulcers. J Am Med Dir Assoc 2006; 7:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1049/abstract/42\">",
"      Makhsous M, Priebe M, Bankard J, et al. Measuring tissue perfusion during pressure relief maneuvers: insights into preventing pressure ulcers. J Spinal Cord Med 2007; 30:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1049/abstract/43\">",
"      Anderson C, Rappl L. Lateral rotation mattresses for wound healing. Ostomy Wound Manage 2004; 50:50.",
"     </a>",
"    </li>",
"    <li>",
"     Thomas, DR. Pressure Ulcers. In: Geriatric Medicine, CK, Cassel (Ed), Springer, New York 1997.",
"    </li>",
"    <li>",
"     National Pressure Ulcer Advisory Panel Support Surface Standards Initiative. Terms and definitions related to support surfaces. www.npuap.org/NPUAP_S3I_TD.pdf (Accessed on December 11, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1049/abstract/46\">",
"      Jay R. Other considerations in selecting a support surface. Adv Wound Care 1997; 10:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1049/abstract/47\">",
"      Nixon J, McElvenny D, Mason S, et al. A sequential randomised controlled trial comparing a dry visco-elastic polymer pad and standard operating table mattress in the prevention of post-operative pressure sores. Int J Nurs Stud 1998; 35:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1049/abstract/48\">",
"      McInnes E, Jammali-Blasi A, Bell-Syer SE, et al. Support surfaces for pressure ulcer prevention. Cochrane Database Syst Rev 2011; :CD001735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1049/abstract/49\">",
"      Mistiaen P, Achterberg W, Ament A, et al. The effectiveness of the Australian Medical Sheepskin for the prevention of pressure ulcers in somatic nursing home patients: a prospective multicenter randomized-controlled trial (ISRCTN17553857). Wound Repair Regen 2010; 18:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1049/abstract/50\">",
"      Rich SE, Shardell M, Hawkes WG, et al. Pressure-redistributing support surface use and pressure ulcer incidence in elderly hip fracture patients. J Am Geriatr Soc 2011; 59:1052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1049/abstract/51\">",
"      Iglesias C, Nixon J, Cranny G, et al. Pressure relieving support surfaces (PRESSURE) trial: cost effectiveness analysis. BMJ 2006; 332:1416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1049/abstract/52\">",
"      Brienza D, Kelsey S, Karg P, et al. A randomized clinical trial on preventing pressure ulcers with wheelchair seat cushions. J Am Geriatr Soc 2010; 58:2308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1049/abstract/53\">",
"      Thomas DR. Issues and dilemmas in the prevention and treatment of pressure ulcers: a review. J Gerontol A Biol Sci Med Sci 2001; 56:M328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1049/abstract/54\">",
"      Langer G, Schloemer G, Knerr A, et al. Nutritional interventions for preventing and treating pressure ulcers. Cochrane Database Syst Rev 2003; :CD003216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1049/abstract/55\">",
"      Finucane TE. Malnutrition, tube feeding and pressure sores: data are incomplete. J Am Geriatr Soc 1995; 43:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1049/abstract/56\">",
"      Bourdel-Marchasson I, Barateau M, Rondeau V, et al. A multi-center trial of the effects of oral nutritional supplementation in critically ill older inpatients. GAGE Group. Groupe Aquitain Geriatrique d'Evaluation. Nutrition 2000; 16:1.",
"     </a>",
"    </li>",
"    <li>",
"     Lyder, CH, Ayello, EA. Chapter 12. Pressure ulcers: a patient safety issue. www.ahrq.gov/qual/nurseshdbk/docs/LyderC_PUPSI.pdf (Accessed on April 01, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1049/abstract/58\">",
"      Torra i Bou JE, Segovia G&oacute;mez T, Verd&uacute; Soriano J, et al. The effectiveness of a hyperoxygenated fatty acid compound in preventing pressure ulcers. J Wound Care 2005; 14:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1049/abstract/59\">",
"      Moody BL, Fanale JE, Thompson M, et al. Impact of staff education on pressure sore development in elderly hospitalized patients. Arch Intern Med 1988; 148:2241.",
"     </a>",
"    </li>",
"    <li>",
"     Berlowitz D, VanDeusen Lukas C, Parker V, et al. Preventing pressure ulcers in hospitals: A toolkit for improving quality of care. Agency for Healthcare Quality and Research; 2011. file://ahrq.gov/research/ltc/pressureulcertoolkit (Accessed on August 29, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1049/abstract/61\">",
"      Brandeis GH, Berlowitz DR, Katz P. Are pressure ulcers preventable? A survey of experts. Adv Skin Wound Care 2001; 14:244, 245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1049/abstract/62\">",
"      Sibbald RG, Krasner DL, Lutz J. SCALE: Skin Changes at Life's End: Final Consensus Statement: October 1, 2009. Adv Skin Wound Care 2010; 23:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1049/abstract/63\">",
"      Horn SD, Buerhaus P, Bergstrom N, Smout RJ. RN staffing time and outcomes of long-stay nursing home residents: pressure ulcers and other adverse outcomes are less likely as RNs spend more time on direct patient care. Am J Nurs 2005; 105:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1049/abstract/64\">",
"      Comondore VR, Devereaux PJ, Zhou Q, et al. Quality of care in for-profit and not-for-profit nursing homes: systematic review and meta-analysis. BMJ 2009; 339:b2732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1049/abstract/65\">",
"      Davis MA. On nursing home quality: a review and analysis. Med Care Rev 1991; 48:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1049/abstract/66\">",
"      Hillmer MP, Wodchis WP, Gill SS, et al. Nursing home profit status and quality of care: is there any evidence of an association? Med Care Res Rev 2005; 62:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1049/abstract/67\">",
"      Li Y, Yin J, Cai X, et al. Association of race and sites of care with pressure ulcers in high-risk nursing home residents. JAMA 2011; 306:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1049/abstract/68\">",
"      Rosen J, Mittal V, Degenholtz H, et al. Ability, incentives, and management feedback: organizational change to reduce pressure ulcers in a nursing home. J Am Med Dir Assoc 2006; 7:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1049/abstract/69\">",
"      Zinn JS, Brannon D, Weech R. Quality improvement in nursing care facilities: extent, impetus, and impact. Am J Med Qual 1997; 12:51.",
"     </a>",
"    </li>",
"    <li>",
"     McKenna, MJ, Moyers, J, Feuerberg, M. Review of Non-regulatory Quality Improvement Interventions. Pp.339-384 in HCFA Report to Congress: Study of Private Accreditation (Deeming) Nursing Homes, Regulatory Incentives and Non-regulatory Initiatives, and Effectiveness of the Survey and Certification System, Vol II, HCFA, Washington, DC 1998.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1049/abstract/71\">",
"      Baier RR, Gifford DR, Lyder CH, et al. Quality improvement for pressure ulcer care in the nursing home setting: the Northeast Pressure Ulcer Project. J Am Med Dir Assoc 2003; 4:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1049/abstract/72\">",
"      Berlowitz DR, Young GJ, Hickey EC, et al. Quality improvement implementation in the nursing home. Health Serv Res 2003; 38:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1049/abstract/73\">",
"      Rosen J, Mittal V, Degenholtz H, et al. Pressure ulcer prevention in black and white nursing home residents: A QI initiative of enhanced ability, incentives, and management feedback. Adv Skin Wound Care 2006; 19:262.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2885 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-2.133.93.82-ACA0B7D5D4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_1_1049=[""].join("\n");
var outline_f1_1_1049=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RISK IDENTIFICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Risk prediction tools and guidelines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Norton and Braden scales",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Empirical studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Databases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PRESSURE RELIEF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Patient positioning",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Continuous rotation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Support surfaces",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUPPORTIVE INTERVENTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Minimize immobility",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Manage incontinence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Nutrition assessment and support",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Skin care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Education and quality initiatives",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      EFFICACY OF PREVENTION EFFORTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H186016118\">",
"      COST EFFECTIVENESS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/2885\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/2885|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/62/21483\" title=\"table 1\">",
"      Staging of pressure ulcers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/60/11214\" title=\"table 2\">",
"      Braden scale for predicting pressure sore risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/25/1436\" title=\"table 3\">",
"      Norton scale for predicting pressure sore risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/23/23932\" title=\"table 4\">",
"      Characteristics of support surfaces",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?39/36/40513?source=related_link\" title=\"calculator 1\">",
"      Calculator: Pressure ulcer risk stratification (Braden score)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/48/37642?source=related_link\">",
"      Chronic complications of spinal cord injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/32/13831?source=related_link\">",
"      Nutrition support in critically ill patients: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?38/53/39761?source=related_link\">",
"      Patient information: Pressure sores (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/20/34120?source=related_link\">",
"      Pressure ulcers: Epidemiology, pathogenesis, clinical manifestations, and staging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/12/37064?source=related_link\">",
"      Treatment of pressure ulcers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/4/32842?source=related_link\">",
"      Treatment of urinary incontinence",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_1_1050="Pericardial disease associated with malignancy";
var content_f1_1_1050=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pericardial disease associated with malignancy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/1/1050/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/1/1050/contributors\">",
"     Barry A Borlaug, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/1/1050/contributors\">",
"     Malcolm M DeCamp, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/1/1050/contributors\">",
"     Sidhu P Gangadharan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/1/1050/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/1/1050/contributors\">",
"     Martin M LeWinter, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/1/1050/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/1/1050/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/1/1050/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/1/1050/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 25, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malignant involvement of the pericardium is detected in 1 to 20 percent of cancer cases in autopsy studies [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1050/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Direct involvement of the myocardium is much less frequent, either by metastatic or primary tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1050/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. In two large autopsy series [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1050/abstract/2,5\">",
"     2,5",
"    </a>",
"    ], the incidence of any cardiac involvement was 11 and 12 percent, respectively. Of these, 76 percent had pericardial involvement, and 34 percent had an effusion [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1050/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most common metastatic tumor involving the pericardium is lung cancer; others include breast and esophageal cancer, melanoma, lymphoma, and leukemia. Although AIDS-related Kaposi's sarcoma (KS) has been an important cause of neoplastic pericardial disease, the incidence of KS has declined dramatically since the advent of potent antiretroviral therapy. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Etiology and pathogenesis'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/40/25226?source=see_link&amp;anchor=H4#H4\">",
"     \"Cardiac involvement in HIV-infected patients\", section on 'Pericarditis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/52/12103?source=see_link&amp;anchor=H2#H2\">",
"     \"AIDS-related Kaposi sarcoma: Clinical manifestations and diagnosis\", section on 'Epidemiology and risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Here we will discuss the presentation and management of pericardial disease associated with malignancy. An overview of the etiology of pericardial disease, and the clinical presentation, diagnosis and management of",
"    <span class=\"nowrap\">",
"     constrictive/restrictive",
"    </span>",
"    pericardial disease related to cancer or its treatment is presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/43/30392?source=see_link\">",
"     \"Etiology of pericardial disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/12/12490?source=see_link\">",
"     \"Constrictive pericarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL SYNDROMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malignant involvement of the pericardium can be manifested as pericarditis, pericardial effusion, cardiac tamponade, or pericardial constriction (constrictive pericarditis).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Pericarditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pericarditis is an acute inflammatory process characterized clinically by chest pain, pericardial friction rub, and widespread saddle-shaped or concave up ST segment elevation on the electrocardiogram (ECG) (",
"    <a class=\"graphic graphic_waveform graphicRef77572 \" href=\"UTD.htm?42/53/43866\">",
"     waveform 1",
"    </a>",
"    ). At least two of these features, with or without an accompanying pericardial effusion, should be present to make the diagnosis. The chest pain is characteristically pleuritic, radiates to the trapezius ridge, and is worse in the supine position. These factors help to differentiate it from pain due to myocardial ischemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/47/37625?source=see_link\">",
"     \"Clinical presentation and diagnostic evaluation of acute pericarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Approximately 4 to 7 percent of patients presenting with pericarditis without a known malignancy will have a neoplastic effusion. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Pericardial disease as the first manifestation of cancer'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Pericardial effusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pericardial effusion is an accumulation of fluid in the pericardial space, with or without associated pericarditis. While an effusion may present with recognizable clinical findings, the most common method of detection is by echocardiography. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/59/4025?source=see_link\">",
"     \"Diagnosis and treatment of pericardial effusion\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In different case series of patients with pericardial effusion, malignancy accounted for 13 to 23 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1050/abstract/1,6\">",
"     1,6",
"    </a>",
"    ]. In areas where tuberculosis is not highly prevalent, malignancy may be the most common cause of a hemorrhagic effusion [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1050/abstract/1,7\">",
"     1,7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/43/30392?source=see_link&amp;anchor=H4#H4\">",
"     \"Etiology of pericardial disease\", section on 'Pericardial effusion'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Malignancy may also be a more common cause of large symptomatic pericardial effusions. In some cases, the effusion may be the initial clinical manifestation of the malignancy. This was suggested in a review of 173 consecutive patients undergoing pericardiocentesis for symptomatic pericardial effusion [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1050/abstract/6\">",
"     6",
"    </a>",
"    ]. Symptomatic effusions were defined as those with cardiorespiratory symptoms (eg, dyspnea), signs (eg, tachycardia), echocardiographic features of right heart compromise, or if pericardiocentesis was deemed therapeutic by the clinician. A cause for the effusion was found in all but 13 patients. The most common cause was malignancy, which was found in 58 patients (33 percent), 45 of whom had known malignant disease. After exclusion of pericardial effusions in which the etiology was apparent from the history, physical examination, and simple laboratory tests (eg, trauma, uremia, postpericardiotomy, rheumatic disease, known malignancy), newly found cancer was responsible for 18 percent of the remaining 74 cases.",
"   </p>",
"   <p>",
"    A pericardial effusion that arises in a patient with a known malignancy usually represents metastatic spread of the malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1050/abstract/1\">",
"     1",
"    </a>",
"    ]. However, other etiologies for the pericardial effusion should be considered. Patients with a history of thoracic radiation treatment can develop a radiation-induced pericarditis with a pericardial effusion. In addition, patients who are immunocompromised due to treatment of an underlying malignancy can develop infectious or autoimmune pericardial effusions [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1050/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/43/30392?source=see_link&amp;anchor=H4#H4\">",
"     \"Etiology of pericardial disease\", section on 'Pericardial effusion'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/59/4025?source=see_link\">",
"     \"Diagnosis and treatment of pericardial effusion\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/21/34137?source=see_link&amp;anchor=H19#H19\">",
"     \"Cardiotoxicity of radiation therapy for malignancy\", section on 'Pericarditis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Cardiac tamponade",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac tamponade refers to a situation in which the pressure from an accumulating pericardial effusion approaches and then equalizes with intracardiac pressures, leading to impaired filling of one, or usually both, ventricles and decreased cardiac output. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/52/19273?source=see_link\">",
"     \"Cardiac tamponade\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The rigid pericardium normally does not significantly affect diastolic ventricular compliance, but when fluid accumulates rapidly",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    in large volume, the \"effective\" compliance of all four chambers is that of the rigid pericardial sac and markedly decreased. The clinical features of tamponade usually depend upon whether the onset of fluid accumulation is acute or subacute; tamponade is usually subacute in the setting of malignancy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute cardiac tamponade is generally sudden in onset, may be associated with chest pain and dyspnea, and is life-threatening if not promptly treated. With rapid introduction of even a small amount of fluid into the pericardial space, the parietal pericardium cannot \"stretch\" to accommodate the increase in volume. This results in an acute rise in pericardial pressure, which is transmitted to all cardiac chambers and limits diastolic filling. The jugular venous pressure is usually elevated (except with volume depletion), and hypotension is common due to the decline in cardiac output. The heart rate is increased in the absence of beta blockade, and heart sounds are often muted.",
"     </li>",
"     <li>",
"      Subacute cardiac tamponade is a less dramatic process. Patients may be asymptomatic or complain of dyspnea, chest discomfort or fullness,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      easy fatigability. The physical examination may reveal hypotension with a narrow pulse pressure, reflecting the limited stroke volume. The jugular venous pressure is typically elevated, and peripheral edema may be seen.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Pulsus paradoxus, defined as an abnormally large decrease in systolic blood pressure (&gt;10 mmHg) on inspiration, is a common finding in moderate to severe tamponade, whether acute or subacute. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/57/11158?source=see_link\">",
"     \"Pulsus paradoxus in pericardial disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Constrictive pericarditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Constrictive pericarditis, sometimes referred to as pericardial constriction, results from scarring and fibrosis of the visceral",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    parietal pericardium, which progressively restricts diastolic filling of the ventricles. Similar to cardiac tamponade, constrictive pericarditis leads to moderately elevated cardiac filling pressures with reduced preload and stroke volumes. The clinical features overlap, but there are important differences, and the management and prognosis are different. In effusive-constrictive pericarditis, there is both pericardial scarring and a hemodynamically significant effusion. Drainage of pericardial fluid may unmask findings typical of constrictive physiology [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1050/abstract/8\">",
"     8",
"    </a>",
"    ]. This subject is discussed in greater detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/12/12490?source=see_link\">",
"     \"Constrictive pericarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     ETIOLOGY AND PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common primary tumor involving the pericardium is lung cancer; others include breast and esophageal cancer, melanoma, lymphoma, and leukemia [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1050/abstract/2,5,9-13\">",
"     2,5,9-13",
"    </a>",
"    ]. Although AIDS-related Kaposi's sarcoma (KS) has been an important cause of neoplastic pericardial disease [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1050/abstract/14,15\">",
"     14,15",
"    </a>",
"    ], the incidence of KS has declined dramatically in the era of highly active antiretroviral therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/40/25226?source=see_link&amp;anchor=H4#H4\">",
"     \"Cardiac involvement in HIV-infected patients\", section on 'Pericarditis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/52/12103?source=see_link&amp;anchor=H2#H2\">",
"     \"AIDS-related Kaposi sarcoma: Clinical manifestations and diagnosis\", section on 'Epidemiology and risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Malignant tumors can involve the pericardium by direct local invasion or through metastatic spread via the lymphatics or bloodstream. In addition, primary tumors can arise in the pericardium, although these are much less frequent than secondary involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1050/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Miscellaneous pericardial lesions'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/32/17930?source=see_link\">",
"     \"Cardiac tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pericardial disease in patients with known malignancy may have a benign etiology, but the majority of cases will be due to malignant involvement. In several single-center series of pericardiocentesis, a malignant etiology for pericardial disease was identified in up to 60 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1050/abstract/1,9,10,16\">",
"     1,9,10,16",
"    </a>",
"    ]. In the remainder, idiopathic pericarditis was most common, while prior radiation therapy was thought to be contributory in 10 to 20 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1050/abstract/17-19\">",
"     17-19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/43/30392?source=see_link\">",
"     \"Etiology of pericardial disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/21/34137?source=see_link\">",
"     \"Cardiotoxicity of radiation therapy for malignancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with a known malignancy, the development of a symptomatic pericardial effusion is usually associated with a short median survival (two to four months from the time of detection). However, prognosis may be better in certain subsets of patients, such as those with an absence of malignant cells in the pericardium using cytologic or histologic techniques, hematologic rather than solid tumors, and breast cancer rather than lung cancer. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Prognosis and status of the underlying malignancy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Pericardial disease as the first manifestation of cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients presenting with pericarditis or a small pericardial effusion without known malignancy, the likelihood of finding previously undiagnosed cancer is between 4 to 7 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1050/abstract/20-23\">",
"     20-23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As an example, a prospective study evaluated 231 consecutive patients presenting with acute pericarditis or tamponade without apparent cause [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1050/abstract/21\">",
"     21",
"    </a>",
"    ]. All received an empiric trial of antiinflammatory therapy, and nonresponders went on to pericardiocentesis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pericardial biopsy. A specific diagnosis was established in 32 (14 percent), only 13 of whom had cancer (6 percent of the total).",
"   </p>",
"   <p>",
"    Patients presenting with constrictive pericarditis also have a low likelihood of harboring an undiagnosed malignancy. In three large case series of patients with constriction, malignancy was identified in fewer than 3 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1050/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. However, radiation therapy, mostly for previously diagnosed Hodgkin's disease or breast cancer, was thought to be causative in 9 to 31 percent of patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/12/12490?source=see_link\">",
"     \"Constrictive pericarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast, the likelihood of finding malignancy is higher in patients who present with a large pericardial effusion or tamponade:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a series of 57 patients with a new large effusion, a specific diagnosis was established by pericardial biopsy",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      fluid cytology in 93 percent; thirteen (23 percent) had a previously undiagnosed malignancy [",
"      <a class=\"abstract\" href=\"UTD.htm?1/1/1050/abstract/27\">",
"       27",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/59/4025?source=see_link\">",
"       \"Diagnosis and treatment of pericardial effusion\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In a report of 450 patients with acute pericardial disease, 33 (7.3 percent) had a neoplastic cause [",
"      <a class=\"abstract\" href=\"UTD.htm?1/1/1050/abstract/20\">",
"       20",
"      </a>",
"      ]. Other than a prior history of malignancy, the major clinical characteristics associated with a neoplastic cause were cardiac tamponade at presentation (odds ratio [OR] 7.0, 95% CI 1.3 to 38.2), lack of response to nonsteroidal antiinflammatory drugs, and recurrent or persistent pericarditis (OR 10.0, 95% CI 3.6 to 27.1). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/52/19273?source=see_link\">",
"       \"Cardiac tamponade\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, a detailed evaluation to search for occult malignancy should generally be reserved for patients who have persistent pericarditis that is unresponsive to antiinflammatory therapy, and those who present with a new large pericardial effusion or cardiac tamponade [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1050/abstract/20,27,28\">",
"     20,27,28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/52/19273?source=see_link\">",
"     \"Cardiac tamponade\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/59/4025?source=see_link&amp;anchor=H23112237#H23112237\">",
"     \"Diagnosis and treatment of pericardial effusion\", section on 'Quantification of the pericardial effusion'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnostic approach to suspected pericardial disease may include any or all of the following: electrocardiography (ECG), radiologic imaging studies, pericardial biopsy or pericardiocentesis to obtain material for",
"    <span class=\"nowrap\">",
"     histologic/cytologic",
"    </span>",
"    analysis, and cardiac catheterization.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Electrocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients with suspected pericardial disease should have an ECG. In patients with pericarditis, characteristic findings include ST segment elevation that is concave upward and PR segment depression (",
"    <a class=\"graphic graphic_waveform graphicRef77572 \" href=\"UTD.htm?42/53/43866\">",
"     waveform 1",
"    </a>",
"    ). PR segment elevation is often seen in lead aVR. With pericardial effusion, especially if tamponade is present, QRS voltage may be decreased, and occasionally electrical alternans is seen (",
"    <a class=\"graphic graphic_waveform graphicRef72525 \" href=\"UTD.htm?42/27/43450\">",
"     waveform 2",
"    </a>",
"    ). This abnormality is characterized by a cyclic beat-to-beat shift in the QRS axis associated with mechanical swinging of the heart to-and-fro, usually in a large pericardial effusion. Atrial fibrillation may be seen in patients with pericardial disease, especially constrictive pericarditis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/7/23669?source=see_link\">",
"     \"Electrocardiogram in pericarditis and pericardial effusion\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Imaging studies",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22120562\">",
"    <span class=\"h3\">",
"     Chest radiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chest x-ray is insensitive for the detection of pericardial disease and is typically normal in acute pericarditis. In patients with subacute tamponade, typical findings can include an enlarged cardiac silhouette with clear lung fields. Pericardial calcifications in the presence of typical symptoms are strongly suggestive of constrictive pericarditis, although calcification is infrequently seen.",
"   </p>",
"   <p>",
"    A chest x-ray is useful for detecting a concomitant pleural effusion. In a surgical series of 47 patients treated for symptomatic pericardial effusion, 41 (87 percent) had a concomitant pleural effusion, and 20 (42 percent) of these were cytologically-positive for malignancy (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef54772 \" href=\"UTD.htm?2/9/2195\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1050/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Echocardiography is the primary imaging tool used to establish the presence and quantity of a pericardial effusion and to evaluate its hemodynamic impact, particularly the presence of tamponade or constrictive physiology. For patients not requiring immediate therapeutic intervention, echocardiography is also the primary means to monitor changes in hemodynamic status or effusion size. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/59/4025?source=see_link&amp;anchor=H5#H5\">",
"     \"Diagnosis and treatment of pericardial effusion\", section on 'Diagnostic approach'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/12/12490?source=see_link\">",
"     \"Constrictive pericarditis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/52/19273?source=see_link\">",
"     \"Cardiac tamponade\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     CT and MRI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Computed tomography (CT) and magnetic resonance imaging (MRI) are useful adjuncts in the diagnostic workup, although they are seldom selected as the initial imaging procedure (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef61127 \" href=\"UTD.htm?19/46/20192\">",
"     image 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef81292 \" href=\"UTD.htm?41/17/42257\">",
"     image 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1050/abstract/30\">",
"     30",
"    </a>",
"    ]. However, given the ubiquity of CT scanning for the evaluation of patients with malignancy, asymptomatic pericardial effusions should not be overlooked. Both abdominal and chest CT can provide information about the pericardial space.",
"   </p>",
"   <p>",
"    Although large tumor masses within the pericardial sac can be recognized by all of these imaging modalities, CT and MRI are both superior to echocardiography for providing information about whether an effusion is hemorrhagic or loculated [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1050/abstract/31\">",
"     31",
"    </a>",
"    ]. These modalities also have the advantage of providing information about the remainder of the chest as well (eg, detecting the presence of a primary tumor or metastatic foci within lung parenchyma). In some cases (particularly in the setting of trauma), a hematoma may be mistaken for a neoplasm. CT and MRI are also especially useful in the evaluation of constrictive pericarditis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/3/34874?source=see_link&amp;anchor=H8#H8\">",
"     \"Clinical utility of cardiovascular magnetic resonance imaging\", section on 'Pericardial disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Cytology, flow cytometry, and pericardial biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pericardiocentesis with cytologic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    flow cytometric examination of the pericardial fluid should be performed in patients with a pericardial effusion whenever there is a reason to suspect malignancy. Cytologic evaluation is especially important if the effusion is hemorrhagic, and there is no history of antecedent trauma; such effusions are more likely to be malignant than nonhemorrhagic effusions [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1050/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/36/25159?source=see_link\">",
"     \"Technique of pericardiocentesis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/59/4025?source=see_link\">",
"     \"Diagnosis and treatment of pericardial effusion\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The sensitivity of cytology for the diagnosis of a malignant effusion is between 67 and 92 percent, and is lowest for mesothelioma and lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1050/abstract/9,16,32,33\">",
"     9,16,32,33",
"    </a>",
"    ]. Immunohistochemical staining may help in the distinction between malignant cells and atypical mesothelial cells, as well as provide information as to the likely tissue of origin if malignant cells are present [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1050/abstract/34-36\">",
"     34-36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Negative cytology should not be used to exclude the diagnosis of malignancy, particularly if the index of suspicion is high [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1050/abstract/37\">",
"     37",
"    </a>",
"    ]. A pericardial biopsy may be required, and can be performed via a subxiphoid or transthoracic pericardiostomy (window) or by pericardioscopy. Pericardioscopy allows direct visualization of the pericardial space; the reported sensitivity for the diagnosis of malignancy is as high as 97 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1050/abstract/16,38,39\">",
"     16,38,39",
"    </a>",
"    ]. In contrast, the sensitivity for blind pericardial biopsy is lower (56 to 65 percent), presumably because of sampling error [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1050/abstract/9,16,32,33\">",
"     9,16,32,33",
"    </a>",
"    ]. The therapeutic drainage \"window\" created by a subxiphoid or transthoracic approach yields a four square centimeter piece of tissue which can be useful to confirm the diagnosis.",
"   </p>",
"   <p>",
"    A positive cytology may be predictive of a poorer outcome in patients with neoplastic pericardial disease. In a multivariate analysis of patients with malignancy-related pericardial effusion, a positive cytology was an independent predictor of shortened survival (median survival seven versus 30 weeks in the setting of normal cytology) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1050/abstract/10\">",
"     10",
"    </a>",
"    ]. Patients with positive cytology were also more likely to require repeat pericardiocentesis or surgical intervention.",
"   </p>",
"   <p>",
"    Flow cytometry is an important adjunct to cytology, particularly for lymphomas [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1050/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. In one report of 115 consecutive serous cavity effusions in patients with a variety of malignant diagnoses, the provisional cytopathologic diagnosis was altered by the results of flow cytometry in 18 cases (16 percent of the total), from",
"    <span class=\"nowrap\">",
"     atypical/suspicious",
"    </span>",
"    to benign in 8 cases, and from benign or",
"    <span class=\"nowrap\">",
"     atypical/suspicious",
"    </span>",
"    to malignant in 10 cases [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1050/abstract/41\">",
"     41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27610?source=see_link&amp;anchor=H31#H31\">",
"     \"Clinical presentation and diagnosis of non-Hodgkin lymphoma\", section on 'Evaluation of other tissues'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Cardiac catheterization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemodynamic assessment with simultaneous right and left heart catheterization is useful diagnostically and can also characterize the impact of pericardial disease upon cardiac filling and performance, particularly if echocardiographic findings are inconclusive or equivocal. Constrictive pericarditis is often indistinguishable from restrictive cardiomyopathy based upon clinical and echo criteria alone, and invasive hemodynamic assessment, particularly the examination of respirophasic changes in pressures, can be vital in the diagnostic algorithm [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1050/abstract/42\">",
"     42",
"    </a>",
"    ]. Indeed, both entities may coexist, particularly in the setting of radiation-induced pericardial disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/12/12490?source=see_link\">",
"     \"Constrictive pericarditis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/3/29752?source=see_link&amp;anchor=H15#H15\">",
"     \"Differentiating constrictive pericarditis and restrictive cardiomyopathy\", section on 'Cardiac catheterization'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of neoplastic pericardial disease needs to be individualized and requires a detailed consideration of the cardiovascular and medical status of the patient, as well as the prognosis of the underlying malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1050/abstract/43-45\">",
"     43-45",
"    </a>",
"    ]. Components of management may include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Removal of fluid to improve hemodynamic status",
"     </li>",
"     <li>",
"      Prevention of effusion reaccumulation",
"     </li>",
"     <li>",
"      Management of pericardial constriction",
"     </li>",
"     <li>",
"      Treatment of the underlying malignancy",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Acute management of the effusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Asymptomatic or minimally symptomatic pericardial effusions can be managed conservatively with careful monitoring, avoidance of volume depletion, and appropriate antineoplastic therapy, if possible (see below). Some patients will never develop symptoms or require treatment. As an example, in one series of 20 women with breast cancer and an incidentally found pericardial effusion, only one subsequently became symptomatic [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1050/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The development of symptoms such as fatigue, dyspnea, or chest heaviness should prompt repeat echocardiography and consideration of therapeutic intervention. For highly symptomatic patients or those with evidence of hemodynamic compromise, urgent fluid removal is needed to alleviate symptoms and prevent hemodynamic collapse. This generally results in rapid and dramatic improvement in symptoms and hemodynamics, even if clinical or echocardiographic signs of tamponade persist. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/52/19273?source=see_link\">",
"     \"Cardiac tamponade\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fluid is typically removed either by pericardiocentesis under echocardiographic guidance or at the time of surgical creation of a pericardial window. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Surgical decompression of the pericardium'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/36/25159?source=see_link&amp;anchor=H2#H2\">",
"     \"Technique of pericardiocentesis\", section on 'Choice of percutaneous pericardiocentesis or surgical drainage'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Prevention of effusion reaccumulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although pericardiocentesis effectively relieves symptoms and improves hemodynamics, fluid reaccumulates in as many as 60 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1050/abstract/43,46\">",
"     43,46",
"    </a>",
"    ]. Recurrence rates are higher following simple pericardiocentesis (ie, without prolonged drainage) and with large effusion size [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1050/abstract/46\">",
"     46",
"    </a>",
"    ]. Thus, initial management of an effusion is usually combined with measures to prevent recurrence.",
"   </p>",
"   <p>",
"    Among the approaches to prevent reaccumulation are prolonged catheter drainage, obliteration of the pericardial space, and the creation of a permanent pericardial \"window\" allowing drainage of fluid into the pleural or peritoneal cavity. There is no single approach that is applicable to all patients, and the therapeutic choice should be guided by the patient's overall medical status, prognosis of the underlying malignancy, and the availability of medical and surgical resources.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Prolonged catheter drainage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prolonged catheter drainage effectively prevents fluid reaccumulation, although the mechanism by which this occurs is unclear. In multiple series, this approach was successful in 70 to 88 percent of cases, although the duration of effusion control was not always reported [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1050/abstract/46-49\">",
"     46-49",
"    </a>",
"    ]. As an example, one series reported recurrence in 30 percent of cases at a median average time of 39 days [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1050/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Catheter drainage may be required for several days. The catheter should not be removed until drainage is less than 20 to 30",
"    <span class=\"nowrap\">",
"     ml/24",
"    </span>",
"    hours.",
"   </p>",
"   <p>",
"    The reported incidence of complications from prolonged catheter drainage ranges from 7 to 17 percent, and includes pericarditic chest pain, catheter occlusion, infection, fever, pneumothorax, ventricular puncture, and cardiac arrest [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1050/abstract/46,48,50\">",
"     46,48,50",
"    </a>",
"    ]. Intermittent rather than continuous drainage may help to maintain catheter patency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Pericardial sclerosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intrapericardial instillation of sclerosing agents is thought to produce inflammation and scarring of the pericardial surfaces, thereby eliminating the potential space for fluid reaccumulation. A number of sclerosing agents have been used, generally in conjunction with prolonged catheter drainage. These include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1050/abstract/51\">",
"     51",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/10/3240?source=see_link\">",
"     minocycline",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1050/abstract/52-54\">",
"     52-54",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1050/abstract/51,55-58\">",
"     51,55-58",
"    </a>",
"    ], and talc [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1050/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    No treatment has shown a clear advantage to prolonged catheter drainage alone. Retrospective series suggest similar rates of effusion reaccumulation from percutaneous catheter drainage with or without the addition of a sclerosing agent [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1050/abstract/47\">",
"     47",
"    </a>",
"    ]. The only prospective randomized trial that compared intrapericardial",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    to prolonged catheter drainage alone showed a modest benefit that was not statistically significant [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1050/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, the potential toxicity with sclerosing therapy has limited their role. Instillation of most of these agents is accompanied by severe pain. Furthermore, there are case reports of sclerosis ultimately leading to constrictive pericarditis, effectively trading one pericardial disease for another [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1050/abstract/60\">",
"     60",
"    </a>",
"    ]. However, given the typically short life expectancy for most patients with malignant pericardial disease, this is less often observed, and sclerotherapy is generally associated with low morbidity [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1050/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nevertheless, pericardial sclerosis to prevent reaccumulation has fallen out of general use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Surgical decompression of the pericardium",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical decompression of the pericardium is also known as pericardiotomy, pericardiostomy, and \"window\" pericardiectomy. Surgical creation of a pericardial \"window\" can be accomplished using various surgical techniques (eg, open surgery, video assisted thoracoscopy [VATS]). While no randomized trials have been done comparing surgical and percutaneous drainage of pericardial effusions, retrospective studies demonstrated immediate hemodynamic benefit in almost all patients with minimal surgical morbidity and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1050/abstract/47,48,61-66\">",
"     47,48,61-66",
"    </a>",
"    ]. While recurrence rates vary slightly according to surgical technique, recurrence of a large or symptomatic pericardial effusion following transthoracic (thoracotomy or VATS) pericardiostomy was seen in only 5 to 10 percent of patients, compared to approximately a 20 percent rate following pericardiocentesis alone. Recurrence rates are slightly higher when a subxiphoid approach is used because these \"windows\" do not drain to an absorptive mesothelial surface [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1050/abstract/66\">",
"     66",
"    </a>",
"    ]. Moreover, approximately one-third of patients with malignant pericardial disease have coexisting pleural pathology which may need to be addressed concurrently.",
"   </p>",
"   <p>",
"    A hemodynamically-significant pericardial effusion is often best treated with pericardiocentesis prior to surgery, in order to avoid further instability or cardiovascular collapse during induction of general anesthesia for a surgical approach [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1050/abstract/66\">",
"     66",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/52/19273?source=see_link\">",
"     \"Cardiac tamponade\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Balloon pericardiotomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Balloon pericardiotomy is an alternative to surgical creation of a pericardial window [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1050/abstract/67-71\">",
"     67-71",
"    </a>",
"    ]. This procedure may be performed either immediately following initial pericardiocentesis or after pericardial effusion recurrence. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/59/4025?source=see_link&amp;anchor=H15#H15\">",
"     \"Diagnosis and treatment of pericardial effusion\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Management of pericardial constriction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with constrictive pericarditis may require surgical removal of the pericardium, provided that the prognosis from the malignancy justifies surgery. The reported operative mortality for pericardiectomy for pericardial constriction is 6 to 12 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1050/abstract/21,25,26,72\">",
"     21,25,26,72",
"    </a>",
"    ]. Although the majority of patients have relief of symptoms after pericardiectomy, some do not. Pericardiectomy may not benefit patients with mild constriction or those patients with very advanced disease. Constriction in patients whose only abnormality is a mild to moderate increase in central venous pressure with little or no edema can be followed clinically. Patients with \"end-stage\" constrictive pericarditis manifest by cachexia, atrial fibrillation, low cardiac output at rest, and depressed serum albumin level due to protein losing enteropathy show little or no benefit and the operative risk is inordinately high. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/12/12490?source=see_link\">",
"     \"Constrictive pericarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H971723\">",
"    <span class=\"h3\">",
"     Intrapericardial chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intrapericardial treatment of confirmed malignant pericardial effusions has been attempted with a variety of chemotherapeutic agents. This approach allows for relatively high doses of chemotherapy to be administered locally with minimal systemic side effects and palliation of symptoms from a hemodynamically significant effusion [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1050/abstract/73-81\">",
"     73-81",
"    </a>",
"    ]. In small series using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    for intrapericardial treatment, 93 percent and 83 percent of patients were free of recurrent hemodynamically significant pericardial effusion at three and six months, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1050/abstract/1,78\">",
"     1,78",
"    </a>",
"    ]. However, few of these patients have disease that is restricted to the pericardium; almost all have disseminated stage IV disease. Similarly effective and less expensive methods of controlling a hemodynamically significant pericardial effusion are available, and intrapericardial chemotherapy is generally not used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Prognosis and status of the underlying malignancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, most patients with a symptomatic malignant pericardial effusion have a short life expectancy, (median two to four months) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1050/abstract/29,46,48,52,61-63,65,70,82-84\">",
"     29,46,48,52,61-63,65,70,82-84",
"    </a>",
"    ]. However, prognosis may be better in certain subsets of patients, such as those without malignant cells in the pericardium [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1050/abstract/85,86\">",
"     85,86",
"    </a>",
"    ], hematologic rather than solid tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1050/abstract/83\">",
"     83",
"    </a>",
"    ], breast cancer rather than lung cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1050/abstract/83,87,88\">",
"     83,87,88",
"    </a>",
"    ], and in patients whose malignancy is otherwise well controlled [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1050/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As an example, in one series, patients with breast cancer or hematologic malignancies had a better median survival (9 and 17 months, respectively) than those with lung cancer (three months) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/1/1050/abstract/62\">",
"     62",
"    </a>",
"    ]. The potential for prolonged survival should be considered when choosing the therapeutic intervention for an individual patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     MISCELLANEOUS PERICARDIAL LESIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although a number of primary tumors may arise in the pericardium, they are extremely rare. These include lesions such as mesotheliomas, teratomas, and paragangliomas. In addition, benign lesions such as pericardial cysts and lipomas should be included in the differential diagnosis. These issues are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/32/17930?source=see_link\">",
"     \"Cardiac tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/40/32392?source=see_link&amp;anchor=H19#H19\">",
"     \"Anterior mediastinal mass lesions\", section on 'Pericardial cysts'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?11/53/12115?source=see_link\">",
"       \"Patient information: Pericarditis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H971738\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Malignant involvement of the pericardium is detected in up to 20 percent of cancer patients in autopsy studies. While the most common primary tumor involving the pericardium is lung, tumors of the breast and esophagus, melanoma, lymphoma, and leukemia also frequently spread to the pericardium. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Etiology and pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Malignant involvement of the pericardium can be manifested as pericarditis, pericardial effusion, cardiac tamponade, or constrictive pericarditis. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical syndromes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients without a history of malignancy who present with pericarditis or a small pericardial effusion, malignancy is uncommon, accounting for between 4 and 7 percent of cases. In contrast, the likelihood of finding malignancy is higher in patients who present with a large symptomatic pleural effusion. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Pericardial disease as the first manifestation of cancer'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/43/30392?source=see_link&amp;anchor=H4#H4\">",
"       \"Etiology of pericardial disease\", section on 'Pericardial effusion'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Among patients known to have an underlying malignancy who present with pericardial effusion requiring drainage, between 50 and 60 percent will have a malignant effusion. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Etiology and pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Echocardiography is the primary imaging tool used to establish the presence, location, quality, and quantity of a pericardial effusion and evaluate its hemodynamic impact, particularly the presence of tamponade or constrictive physiology. Echocardiography is also useful for serial evaluation of pericardial effusions which do not require urgent treatment. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Echocardiography'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/59/4025?source=see_link&amp;anchor=H15#H15\">",
"       \"Diagnosis and treatment of pericardial effusion\", section on 'Treatment'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/52/19273?source=see_link\">",
"       \"Cardiac tamponade\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cytologic examination of the pericardial fluid with or without flow cytometric evaluation should be performed in patients with a pericardial effusion whenever there is a reason to suspect malignancy. A positive cytology may be predictive of a shorter survival in patients with neoplastic pericardial disease. Negative cytology does not exclude the diagnosis of malignancy, particularly if there is a high index of suspicion. In this situation, a pericardial biopsy should be considered to confirm or exclude pericardial malignancy. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Cytology, flow cytometry, and pericardial biopsy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For symptomatic patients or those with evidence of hemodynamic compromise, we recommend urgent drainage of pericardial fluid by pericardiocentesis or pericardiotomy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Acute management of the effusion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Several interventions (eg, prolonged catheter drainage, pericardial sclerosis, pericardiotomy &ldquo;window&rdquo;) can prevent recurrent symptomatic or hemodynamically significant pericardial effusions. The approach to prevention of recurrent pericardial effusions should be considered on a case by case basis, depending on the patient&rsquo;s overall medical condition and life expectancy. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Prevention of effusion reaccumulation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1050/abstract/1\">",
"      Maisch B, Ristic A, Pankuweit S. Evaluation and management of pericardial effusion in patients with neoplastic disease. Prog Cardiovasc Dis 2010; 53:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1050/abstract/2\">",
"      Klatt EC, Heitz DR. Cardiac metastases. Cancer 1990; 65:1456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1050/abstract/3\">",
"      Lam KY, Dickens P, Chan AC. Tumors of the heart. A 20-year experience with a review of 12,485 consecutive autopsies. Arch Pathol Lab Med 1993; 117:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1050/abstract/4\">",
"      MacGee W. Metastatic and invasive tumours involving the heart in a geriatric population: a necropsy study. Virchows Arch A Pathol Anat Histopathol 1991; 419:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1050/abstract/5\">",
"      Abraham KP, Reddy V, Gattuso P. Neoplasms metastatic to the heart: review of 3314 consecutive autopsies. Am J Cardiovasc Pathol 1990; 3:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1050/abstract/6\">",
"      Ben-Horin S, Bank I, Guetta V, Livneh A. Large symptomatic pericardial effusion as the presentation of unrecognized cancer: a study in 173 consecutive patients undergoing pericardiocentesis. Medicine (Baltimore) 2006; 85:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1050/abstract/7\">",
"      Atar S, Chiu J, Forrester JS, Siegel RJ. Bloody pericardial effusion in patients with cardiac tamponade: is the cause cancerous, tuberculous, or iatrogenic in the 1990s? Chest 1999; 116:1564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1050/abstract/8\">",
"      Mann T, Brodie BR, Grossman W, McLaurin L. Effusive-constrictive hemodynamic pattern due to neoplastic involvement of the pericardium. Am J Cardiol 1978; 41:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1050/abstract/9\">",
"      Wilkes JD, Fidias P, Vaickus L, Perez RP. Malignancy-related pericardial effusion. 127 cases from the Roswell Park Cancer Institute. Cancer 1995; 76:1377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1050/abstract/10\">",
"      Gornik HL, Gerhard-Herman M, Beckman JA. Abnormal cytology predicts poor prognosis in cancer patients with pericardial effusion. J Clin Oncol 2005; 23:5211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1050/abstract/11\">",
"      Sampat K, Rossi A, Garcia-Gutierrez V, et al. Characteristics of pericardial effusions in patients with leukemia. Cancer 2010; 116:2366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1050/abstract/12\">",
"      Barbaric D, Holley D, Lau KC, McCowage G. It is ALL in the heart: a patient with acute lymphoblastic leukemia and cardiac infiltration at time of diagnosis. Leuk Lymphoma 2002; 43:2417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1050/abstract/13\">",
"      Savoia P, Fierro MT, Zaccagna A, Bernengo MG. Metastatic melanoma of the heart. J Surg Oncol 2000; 75:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1050/abstract/14\">",
"      Chen Y, Brennessel D, Walters J, et al. Human immunodeficiency virus-associated pericardial effusion: report of 40 cases and review of the literature. Am Heart J 1999; 137:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1050/abstract/15\">",
"      Gouny P, Lancelin C, Girard PM, et al. Pericardial effusion and AIDS: benefits of surgical drainage. Eur J Cardiothorac Surg 1998; 13:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1050/abstract/16\">",
"      Porte HL, Janecki-Delebecq TJ, Finzi L, et al. Pericardoscopy for primary management of pericardial effusion in cancer patients. Eur J Cardiothorac Surg 1999; 16:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1050/abstract/17\">",
"      Posner MR, Cohen GI, Skarin AT. Pericardial disease in patients with cancer. The differentiation of malignant from idiopathic and radiation-induced pericarditis. Am J Med 1981; 71:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1050/abstract/18\">",
"      Buck M, Ingle JN, Giuliani ER, et al. Pericardial effusion in women with breast cancer. Cancer 1987; 60:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1050/abstract/19\">",
"      Edoute Y, Kuten A, Ben-Haim SA, et al. Symptomatic pericardial effusion in breast cancer patients: the role of fluid cytology. J Surg Oncol 1990; 45:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1050/abstract/20\">",
"      Imazio M, Demichelis B, Parrini I, et al. Relation of acute pericardial disease to malignancy. Am J Cardiol 2005; 95:1393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1050/abstract/21\">",
"      Permanyer-Miralda G, Sagrist&aacute;-Sauleda J, Soler-Soler J. Primary acute pericardial disease: a prospective series of 231 consecutive patients. Am J Cardiol 1985; 56:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1050/abstract/22\">",
"      Zayas R, Anguita M, Torres F, et al. Incidence of specific etiology and role of methods for specific etiologic diagnosis of primary acute pericarditis. Am J Cardiol 1995; 75:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1050/abstract/23\">",
"      Imazio M, Cecchi E, Demichelis B, et al. Indicators of poor prognosis of acute pericarditis. Circulation 2007; 115:2739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1050/abstract/24\">",
"      Cameron J, Oesterle SN, Baldwin JC, Hancock EW. The etiologic spectrum of constrictive pericarditis. Am Heart J 1987; 113:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1050/abstract/25\">",
"      Ling LH, Oh JK, Schaff HV, et al. Constrictive pericarditis in the modern era: evolving clinical spectrum and impact on outcome after pericardiectomy. Circulation 1999; 100:1380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1050/abstract/26\">",
"      Bertog SC, Thambidorai SK, Parakh K, et al. Constrictive pericarditis: etiology and cause-specific survival after pericardiectomy. J Am Coll Cardiol 2004; 43:1445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1050/abstract/27\">",
"      Corey GR, Campbell PT, Van Trigt P, et al. Etiology of large pericardial effusions. Am J Med 1993; 95:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1050/abstract/28\">",
"      Sagrist&agrave;-Sauleda J, Merc&eacute; J, Permanyer-Miralda G, Soler-Soler J. Clinical clues to the causes of large pericardial effusions. Am J Med 2000; 109:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1050/abstract/29\">",
"      Gross JL, Younes RN, Deheinzelin D, et al. Surgical management of symptomatic pericardial effusion in patients with solid malignancies. Ann Surg Oncol 2006; 13:1732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1050/abstract/30\">",
"      Wang ZJ, Reddy GP, Gotway MB, et al. CT and MR imaging of pericardial disease. Radiographics 2003; 23 Spec No:S167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1050/abstract/31\">",
"      Bellon RJ, Wright WH, Unger EC. CT-guided pericardial drainage catheter placement with subsequent pericardial sclerosis. J Comput Assist Tomogr 1995; 19:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1050/abstract/32\">",
"      Wiener HG, Kristensen IB, Haubek A, et al. The diagnostic value of pericardial cytology. An analysis of 95 cases. Acta Cytol 1991; 35:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1050/abstract/33\">",
"      Meyers DG, Meyers RE, Prendergast TW. The usefulness of diagnostic tests on pericardial fluid. Chest 1997; 111:1213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1050/abstract/34\">",
"      Zoppi JA, Pellicer EM, Sundblad AS. Diagnostic value of p53 protein in the study of serous effusions. Acta Cytol 1995; 39:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1050/abstract/35\">",
"      Gong Y, Sun X, Michael CW, et al. Immunocytochemistry of serous effusion specimens: a comparison of ThinPrep vs cell block. Diagn Cytopathol 2003; 28:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1050/abstract/36\">",
"      Mayall F, Heryet A, Manga D, Kriegeskotten A. p53 immunostaining is a highly specific and moderately sensitive marker of malignancy in serous fluid cytology. Cytopathology 1997; 8:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1050/abstract/37\">",
"      Bardales RH, Stanley MW, Schaefer RF, et al. Secondary pericardial malignancies: a critical appraisal of the role of cytology, pericardial biopsy, and DNA ploidy analysis. Am J Clin Pathol 1996; 106:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1050/abstract/38\">",
"      Maisch B, Pankuweit S, Brilla C, et al. Intrapericardial treatment of inflammatory and neoplastic pericarditis guided by pericardioscopy and epicardial biopsy--results from a pilot study. Clin Cardiol 1999; 22:I17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1050/abstract/39\">",
"      Nugue O, Millaire A, Porte H, et al. Pericardioscopy in the etiologic diagnosis of pericardial effusion in 141 consecutive patients. Circulation 1996; 94:1635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1050/abstract/40\">",
"      Iqbal J, Liu T, Mapow B, et al. Importance of flow cytometric analysis of serous effusions in the diagnosis of hematopoietic neoplasms in patients with prior hematopoietic malignancies. Anal Quant Cytol Histol 2010; 32:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1050/abstract/41\">",
"      Czader M, Ali SZ. Flow cytometry as an adjunct to cytomorphologic analysis of serous effusions. Diagn Cytopathol 2003; 29:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1050/abstract/42\">",
"      Hurrell DG, Nishimura RA, Higano ST, et al. Value of dynamic respiratory changes in left and right ventricular pressures for the diagnosis of constrictive pericarditis. Circulation 1996; 93:2007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1050/abstract/43\">",
"      Laham RJ, Cohen DJ, Kuntz RE, et al. Pericardial effusion in patients with cancer: outcome with contemporary management strategies. Heart 1996; 75:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1050/abstract/44\">",
"      Spodick DH. Acute cardiac tamponade. N Engl J Med 2003; 349:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1050/abstract/45\">",
"      Vaitkus PT, Herrmann HC, LeWinter MM. Treatment of malignant pericardial effusion. JAMA 1994; 272:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1050/abstract/46\">",
"      Tsang TS, Seward JB, Barnes ME, et al. Outcomes of primary and secondary treatment of pericardial effusion in patients with malignancy. Mayo Clin Proc 2000; 75:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1050/abstract/47\">",
"      McDonald JM, Meyers BF, Guthrie TJ, et al. Comparison of open subxiphoid pericardial drainage with percutaneous catheter drainage for symptomatic pericardial effusion. Ann Thorac Surg 2003; 76:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1050/abstract/48\">",
"      Allen KB, Faber LP, Warren WH, Shaar CJ. Pericardial effusion: subxiphoid pericardiostomy versus percutaneous catheter drainage. Ann Thorac Surg 1999; 67:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1050/abstract/49\">",
"      Kopecky SL, Callahan JA, Tajik AJ, Seward JB. Percutaneous pericardial catheter drainage: report of 42 consecutive cases. Am J Cardiol 1986; 58:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1050/abstract/50\">",
"      Celermajer DS, Boyer MJ, Bailey BP, Tattersall MH. Pericardiocentesis for symptomatic malignant pericardial effusion: a study of 36 patients. Med J Aust 1991; 154:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1050/abstract/51\">",
"      Liu G, Crump M, Goss PE, et al. Prospective comparison of the sclerosing agents doxycycline and bleomycin for the primary management of malignant pericardial effusion and cardiac tamponade. J Clin Oncol 1996; 14:3141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1050/abstract/52\">",
"      Maher EA, Shepherd FA, Todd TJ. Pericardial sclerosis as the primary management of malignant pericardial effusion and cardiac tamponade. J Thorac Cardiovasc Surg 1996; 112:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1050/abstract/53\">",
"      Davis S, Rambotti P, Grignani F. Intrapericardial tetracycline sclerosis in the treatment of malignant pericardial effusion: an analysis of thirty-three cases. J Clin Oncol 1984; 2:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1050/abstract/54\">",
"      Lashevsky I, Ben Yosef R, Rinkevich D, et al. Intrapericardial minocycline sclerosis for malignant pericardial effusion. Chest 1996; 109:1452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1050/abstract/55\">",
"      Patz EF Jr, McAdams HP, Erasmus JJ, et al. Sclerotherapy for malignant pleural effusions: a prospective randomized trial of bleomycin vs doxycycline with small-bore catheter drainage. Chest 1998; 113:1305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1050/abstract/56\">",
"      Maruyama R, Yokoyama H, Seto T, et al. Catheter drainage followed by the instillation of bleomycin to manage malignant pericardial effusion in non-small cell lung cancer: a multi-institutional phase II trial. J Thorac Oncol 2007; 2:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1050/abstract/57\">",
"      Kunitoh H, Tamura T, Shibata T, et al. A randomised trial of intrapericardial bleomycin for malignant pericardial effusion with lung cancer (JCOG9811). Br J Cancer 2009; 100:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1050/abstract/58\">",
"      van Belle SJ, Volckaert A, Taeymans Y, et al. Treatment of malignant pericardial tamponade with sclerosis induced by instillation of bleomycin. Int J Cardiol 1987; 16:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1050/abstract/59\">",
"      Buchanan CL, Sullivan VV, Lampman R, Kulkarni MG. Pericardiocentesis with extended catheter drainage: an effective therapy. Ann Thorac Surg 2003; 76:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1050/abstract/60\">",
"      Lin MT, Yang PC, Luh KT. Constrictive pericarditis after sclerosing therapy with mitomycin C for malignant pericardial effusion: report of a case. J Formos Med Assoc 1994; 93:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1050/abstract/61\">",
"      Moores DW, Allen KB, Faber LP, et al. Subxiphoid pericardial drainage for pericardial tamponade. J Thorac Cardiovasc Surg 1995; 109:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1050/abstract/62\">",
"      Cullinane CA, Paz IB, Smith D, et al. Prognostic factors in the surgical management of pericardial effusion in the patient with concurrent malignancy. Chest 2004; 125:1328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1050/abstract/63\">",
"      Park JS, Rentschler R, Wilbur D. Surgical management of pericardial effusion in patients with malignancies. Comparison of subxiphoid window versus pericardiectomy. Cancer 1991; 67:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1050/abstract/64\">",
"      Olson JE, Ryan MB, Blumenstock DA. Eleven years' experience with pericardial-peritoneal window in the management of malignant and benign pericardial effusions. Ann Surg Oncol 1995; 2:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1050/abstract/65\">",
"      Hankins JR, Satterfield JR, Aisner J, et al. Pericardial window for malignant pericardial effusion. Ann Thorac Surg 1980; 30:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1050/abstract/66\">",
"      DeCamp MM Jr, Mentzer SJ, Swanson SJ, Sugarbaker DJ. Malignant effusive disease of the pleura and pericardium. Chest 1997; 112:291S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1050/abstract/67\">",
"      Wang HJ, Hsu KL, Chiang FT, et al. Technical and prognostic outcomes of double-balloon pericardiotomy for large malignancy-related pericardial effusions. Chest 2002; 122:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1050/abstract/68\">",
"      Galli M, Politi A, Pedretti F, et al. Percutaneous balloon pericardiotomy for malignant pericardial tamponade. Chest 1995; 108:1499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1050/abstract/69\">",
"      Jalisi FM, Morise AP, Haque R, Jain AC. Primary percutaneous balloon pericardiotomy. W V Med J 2004; 100:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1050/abstract/70\">",
"      Ziskind AA, Pearce AC, Lemmon CC, et al. Percutaneous balloon pericardiotomy for the treatment of cardiac tamponade and large pericardial effusions: description of technique and report of the first 50 cases. J Am Coll Cardiol 1993; 21:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1050/abstract/71\">",
"      Swanson N, Mirza I, Wijesinghe N, Devlin G. Primary percutaneous balloon pericardiotomy for malignant pericardial effusion. Catheter Cardiovasc Interv 2008; 71:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1050/abstract/72\">",
"      DeValeria PA, Baumgartner WA, Casale AS, et al. Current indications, risks, and outcome after pericardiectomy. Ann Thorac Surg 1991; 52:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1050/abstract/73\">",
"      Bishiniotis TS, Antoniadou S, Katseas G, et al. Malignant cardiac tamponade in women with breast cancer treated by pericardiocentesis and intrapericardial administration of triethylenethiophosphoramide (thiotepa). Am J Cardiol 2000; 86:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1050/abstract/74\">",
"      Colleoni M, Martinelli G, Beretta F, et al. Intracavitary chemotherapy with thiotepa in malignant pericardial effusions: an active and well-tolerated regimen. J Clin Oncol 1998; 16:2371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1050/abstract/75\">",
"      Martinoni A, Cipolla CM, Cardinale D, et al. Long-term results of intrapericardial chemotherapeutic treatment of malignant pericardial effusions with thiotepa. Chest 2004; 126:1412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1050/abstract/76\">",
"      Moriya T, Takiguchi Y, Tabeta H, et al. Controlling malignant pericardial effusion by intrapericardial carboplatin administration in patients with primary non-small-cell lung cancer. Br J Cancer 2000; 83:858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1050/abstract/77\">",
"      Tomkowski WZ, Wi��niewska J, Szturmowicz M, et al. Evaluation of intrapericardial cisplatin administration in cases with recurrent malignant pericardial effusion and cardiac tamponade. Support Care Cancer 2004; 12:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1050/abstract/78\">",
"      Maisch B, Risti�� AD, Pankuweit S, et al. Neoplastic pericardial effusion. Efficacy and safety of intrapericardial treatment with cisplatin. Eur Heart J 2002; 23:1625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1050/abstract/79\">",
"      Musch E, Gremmler B, Nitsch J, et al. Intrapericardial instillation of mitoxantrone in palliative therapy of malignant pericardial effusion. Onkologie 2003; 26:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1050/abstract/80\">",
"      Norum J, Lunde P, Aaseb&oslash; U, Himmelmann A. Mitoxantrone in malignant pericardial effusion. J Chemother 1998; 10:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1050/abstract/81\">",
"      Kawashima O, Kurihara T, Kamiyoshihara M, et al. Management of malignant pericardial effusion resulting from recurrent cancer with local instillation of aclarubicin hydrochloride. Am J Clin Oncol 1999; 22:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1050/abstract/82\">",
"      Dequanter D, Lothaire P, Berghmans T, Sculier JP. Severe pericardial effusion in patients with concurrent malignancy: a retrospective analysis of prognostic factors influencing survival. Ann Surg Oncol 2008; 15:3268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1050/abstract/83\">",
"      Dosios T, Theakos N, Angouras D, Asimacopoulos P. Risk factors affecting the survival of patients with pericardial effusion submitted to subxiphoid pericardiostomy. Chest 2003; 124:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1050/abstract/84\">",
"      Piehler JM, Pluth JR, Schaff HV, et al. Surgical management of effusive pericardial disease. Influence of extent of pericardial resection on clinical course. J Thorac Cardiovasc Surg 1985; 90:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1050/abstract/85\">",
"      Neragi-Miandoab S, Linden PA, Ducko CT, et al. VATS pericardiotomy for patients with known malignancy and pericardial effusion: survival and prognosis of positive cytology and metastatic involvement of the pericardium: a case control study. Int J Surg 2008; 6:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1050/abstract/86\">",
"      Wang PC, Yang KY, Chao JY, et al. Prognostic role of pericardial fluid cytology in cardiac tamponade associated with non-small cell lung cancer. Chest 2000; 118:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1050/abstract/87\">",
"      Girardi LN, Ginsberg RJ, Burt ME. Pericardiocentesis and intrapericardial sclerosis: effective therapy for malignant pericardial effusions. Ann Thorac Surg 1997; 64:1422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/1/1050/abstract/88\">",
"      Garc&iacute;a-Riego A, Cui&ntilde;as C, Vilanova JJ. Malignant pericardial effusion. Acta Cytol 2001; 45:561.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4954 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-118.195.65.248-F33F7FC12B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_1_1050=[""].join("\n");
var outline_f1_1_1050=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H971738\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL SYNDROMES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Pericarditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Pericardial effusion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Cardiac tamponade",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Constrictive pericarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      ETIOLOGY AND PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Pericardial disease as the first manifestation of cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      DIAGNOSTIC EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Electrocardiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Imaging studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22120562\">",
"      - Chest radiography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Echocardiography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - CT and MRI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Cytology, flow cytometry, and pericardial biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Cardiac catheterization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Acute management of the effusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Prevention of effusion reaccumulation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Prolonged catheter drainage",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Pericardial sclerosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Surgical decompression of the pericardium",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Balloon pericardiotomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Management of pericardial constriction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H971723\">",
"      - Intrapericardial chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Prognosis and status of the underlying malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      MISCELLANEOUS PERICARDIAL LESIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H971738\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/4954\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/4954|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?2/9/2195\" title=\"diagnostic image 1\">",
"      CXR and chest CT scan showing pericardial and pleural effusions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?19/46/20192\" title=\"diagnostic image 2\">",
"      CT scan thickened pericardium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?41/17/42257\" title=\"diagnostic image 3\">",
"      CT and MRI showing pericardial thickening",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/4954|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?42/53/43866\" title=\"waveform 1\">",
"      ECG in pericarditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?42/27/43450\" title=\"waveform 2\">",
"      ECG in electrical alternans",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/52/12103?source=related_link\">",
"      AIDS-related Kaposi sarcoma: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/40/32392?source=related_link\">",
"      Anterior mediastinal mass lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/40/25226?source=related_link\">",
"      Cardiac involvement in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/52/19273?source=related_link\">",
"      Cardiac tamponade",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/32/17930?source=related_link\">",
"      Cardiac tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/21/34137?source=related_link\">",
"      Cardiotoxicity of radiation therapy for malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27610?source=related_link\">",
"      Clinical presentation and diagnosis of non-Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/47/37625?source=related_link\">",
"      Clinical presentation and diagnostic evaluation of acute pericarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/3/34874?source=related_link\">",
"      Clinical utility of cardiovascular magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/12/12490?source=related_link\">",
"      Constrictive pericarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/59/4025?source=related_link\">",
"      Diagnosis and treatment of pericardial effusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/3/29752?source=related_link\">",
"      Differentiating constrictive pericarditis and restrictive cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/7/23669?source=related_link\">",
"      Electrocardiogram in pericarditis and pericardial effusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/43/30392?source=related_link\">",
"      Etiology of pericardial disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?11/53/12115?source=related_link\">",
"      Patient information: Pericarditis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/57/11158?source=related_link\">",
"      Pulsus paradoxus in pericardial disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/36/25159?source=related_link\">",
"      Technique of pericardiocentesis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_1_1051="Contraindications laparosc hyst";
var content_f1_1_1051=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F75465&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=12\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F75465&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=12\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Relative contraindications to laparoscopic hysterectomy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Medical condition that does not allow a pneumoperitoneum",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Medical condition that does not allow proper ventilation during anesthesia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Uterine size precluding access to the uterine arteries",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Extensive pelvic-abdominal adhesions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pelvic organ prolapse amenable to a vaginal approach",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_1_1051=[""].join("\n");
var outline_f1_1_1051=null;
var title_f1_1_1052="WHO MEC for Depressive disorders";
var content_f1_1_1052=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F61848&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F61848&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    World Health Organization medical eligibility for contraceptive use: Depressive disorders",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Condition",
"       </td>",
"       <td class=\"subtitle1\">",
"        COC",
"       </td>",
"       <td class=\"subtitle1\">",
"        CIC",
"       </td>",
"       <td class=\"subtitle1\">",
"        P/R",
"       </td>",
"       <td class=\"subtitle1\">",
"        POP",
"       </td>",
"       <td class=\"subtitle1\">",
"        <p>",
"         DMPA",
"        </p>",
"        <p>",
"         NET-EN",
"        </p>",
"       </td>",
"       <td class=\"subtitle1\">",
"        <p>",
"         LNG/ETG",
"        </p>",
"        <p>",
"         Implants",
"        </p>",
"       </td>",
"       <td class=\"subtitle1\">",
"        Cu-IUD",
"       </td>",
"       <td class=\"subtitle1\">",
"        LNG-IUD",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Depressive disorders",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     1: A condition for which there is no restriction for the use of the contraceptive method.",
"     <br>",
"      2: A condition where the advantages of using the method generally outweigh the theoretical or proven risks.",
"      <br>",
"       3: A condition where the theoretical or proven risks usually outweigh the advantages of using the method.",
"       <br>",
"        4: A condition which represents an unacceptable health risk if the contraceptive method is used.",
"        <br>",
"         COC: low-dose combined oral contraceptive; CIC: combined injectable contraceptives; P: combined patch; R: combined vaginal ring; POP: progestogen-only pill; DMPA: depot medroxyprogesterone acetate; NET-EN: norethisterone enantate; LNG: levonorgestrel; ETG: etonogestrel; ECP: emergency contraceptive pill; Cu-IUD: copper intrauterine device; LNG-IUD: levonorgestrel-releasing IUDs; E-IUD: copper-IUD for emergency contraception; BARR: barrier methods; FAB: fertility awareness-based methods; LAM: lactational amenorrhoea method; CI: coitus interruptus; STER: female and male sterilization.",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: file://www.who.int/reproductive-health/publications/mec/summary.html. Copyright &copy; 2006 World Health Organization.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_1_1052=[""].join("\n");
var outline_f1_1_1052=null;
var title_f1_1_1053="Dyspnea signs";
var content_f1_1_1053=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F76513&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F76513&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Dyspnea signs",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Physical examination finding",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical significance",
"       </td>",
"       <td class=\"subtitle1\">",
"        Possible diagnosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Absent/diminished breath sounds",
"       </td>",
"       <td>",
"        Decreased air movement",
"       </td>",
"       <td>",
"        <p>",
"         COPD",
"        </p>",
"        <p>",
"         Severe asthma",
"        </p>",
"        <p>",
"         Pneumothorax",
"        </p>",
"        <p>",
"         Tension pneumothorax",
"        </p>",
"        <p>",
"         Hemothorax",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Accessory muscle use",
"       </td>",
"       <td>",
"        Muscle weakness, fatigue",
"       </td>",
"       <td>",
"        <p>",
"         Respiratory failure",
"        </p>",
"        <p>",
"         Severe COPD",
"        </p>",
"        <p>",
"         Severe asthma",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Expiratory/mixed stridor",
"       </td>",
"       <td>",
"        Air flow obstruction below vocal cords",
"       </td>",
"       <td>",
"        <p>",
"         Croup",
"        </p>",
"        <p>",
"         Foreign body",
"        </p>",
"        <p>",
"         Bacterial tracheitis",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inspiratory stridor",
"       </td>",
"       <td>",
"        Air flow obstruction above vocal cords",
"       </td>",
"       <td>",
"        <p>",
"         Foreign body",
"        </p>",
"        <p>",
"         Epiglottitis",
"        </p>",
"        <p>",
"         Angioedema",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hyperventilation",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        <p>",
"         Acidosis",
"        </p>",
"        <p>",
"         Sepsis",
"        </p>",
"        <p>",
"         Salicylate poisoning",
"        </p>",
"        <p>",
"         Anxiety",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        JVD with clear lungs",
"       </td>",
"       <td>",
"        Right heart failure",
"       </td>",
"       <td>",
"        <p>",
"         Cardiac tamponade",
"        </p>",
"        <p>",
"         Pulmonary embolism",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        JVD with crackles",
"       </td>",
"       <td>",
"        Right and left heart failure",
"       </td>",
"       <td>",
"        <p>",
"         ADHF",
"        </p>",
"        <p>",
"         ARDS",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Heart murmur",
"       </td>",
"       <td>",
"        Valvular disease",
"       </td>",
"       <td>",
"        Valvular dysfunction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hepatojugular reflux",
"       </td>",
"       <td>",
"        Right heart failure",
"       </td>",
"       <td>",
"        ADHF",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pulsus paradoxus",
"       </td>",
"       <td>",
"        Poor right heart filling",
"       </td>",
"       <td>",
"        <p>",
"         Right heart failure",
"        </p>",
"        <p>",
"         Pulmonary embolism",
"        </p>",
"        <p>",
"         Cardiogenic shock",
"        </p>",
"        <p>",
"         Pericardial tamponade",
"        </p>",
"        <p>",
"         Asthma exacerbation",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Crackles (Rales)",
"       </td>",
"       <td>",
"        Interalveolar fluid",
"       </td>",
"       <td>",
"        <p>",
"         ADHF",
"        </p>",
"        <p>",
"         ARDS",
"        </p>",
"        <p>",
"         Pneumonia",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Wheezes",
"       </td>",
"       <td>",
"        Obstruction below trachea",
"       </td>",
"       <td>",
"        <p>",
"         Asthma exacerbation",
"        </p>",
"        <p>",
"         Foreign body",
"        </p>",
"        <p>",
"         ADHF",
"        </p>",
"        <p>",
"         COPD",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    ADHF: Acute decompensated heart failure; ARDS: Acute respiratory distress syndrome; COPD: Chronic obstructive pulmonary disease; JVD: Jugular venous distension;",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_1_1053=[""].join("\n");
var outline_f1_1_1053=null;
var title_f1_1_1054="Ipodate versus PTU hyperthyroidism";
var content_f1_1_1054=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F54848&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F54848&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Efficacy of ipodate and PTU in hyperthyroidism",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 447px; height: 242px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Percent change from baseline in serum concentrations of T4 (left panel) and T3 (right panel) in patients with hyperthyroidism who were treated with ipodate (1 g/day) or propylthiouracil (200 mg TID). Ipodate produced more rapid correction of the hyperthyroidism.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Wu SY, Shyh TP, Chopra IJ, et al. Comparison sodium ipodate (oragrafin) and propylthiouracil in early treatment of hyperthyroidism. J Clin Endocrinol Metab 1982; 54:630.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_1_1054=[""].join("\n");
var outline_f1_1_1054=null;
var title_f1_1_1055="Gram stain urine 1";
var content_f1_1_1055=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F80918&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F80918&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Gram stain urine 1",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 366px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_1_1055=[""].join("\n");
var outline_f1_1_1055=null;
